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Abstract 
The work described in this dissertation is focused on two major areas: the biological 
effects of ultrasound and ultrasound contrast agents, and nutritional interventions to 
inhibit the development of atherosclerosis. 
Ultrasound is a highly flexible and affordable imaging modality that has proven 
clinically useful in many diagnostic situations ranging from pregnancy to cardiovascular 
disease and cancer. Ultrasound imaging can be performed with concomitant 
intravenous administration of microbubble contrast agents to improve image clarity. 
While useful for imaging of the cardiovascular system, concerns have been raised 
regarding the safety of ultrasound contrast agents, and further research is needed to 
determine their biological effects. This work investigates interactions between 
ultrasound, microbubbles, and the vascular endothelium, the inner cellular lining of 
blood vessels. The goal of this research is to help define the specific conditions under 
which contrast ultrasound is safe so that this knowledge can be applied to clinical 
patient care and diagnosis. A series of four studies were conducted to evaluate the 
effects of ultrasound and ultrasound contrast agents (Chapters 3-6). First, ultrasound 
imaging was performed on rabbit arteries, and histological and biochemical analyses 
were used to determine any effects on the tissue being imaged. As part of this project, 
an assay was developed and validated for measurement of one of the biomarkers, von 
Willebrand Factor (Chapter 2). Effects of contrast ultrasound on von Willebrand Factor 
and atheroma thickness were observed. Next, another rabbit study was performed to 
assess the effect of contrast ultrasound on Hsp70, a cellular stress protein. The 
ultrasound procedure was hypothesized to elevate Hsp70 protein levels. Hsp70 protein 
levels were measured in aorta tissue at the site of ultrasound exposure by Western blot. 
Ultrasound with contrast agent did not affect Hsp70 levels (Chapter 4). In addition to 
rabbits, work with ApoE-/- mice and rats will be described. We did not observe any 
adverse effects of ultrasound in these models (Chapters 5 and 6). 
We also studied the effects of tomato and soy germ on atherosclerosis in ApoE-/- 
mice (Chapter 7). We did not find that tomato and soy germ decreased atherosclerosis, 
but soy germ consumption favorably affected plasma and tissue lipid accumulation. 
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CHAPTER 1: Literature review 
Introduction 
Cardiovascular Disease (CVD) is the leading cause of death in the United States. It 
progresses silently throughout life and manifests itself in old age, reducing life 
expectancy and prematurely killing over 2000 Americans each day1. The economic 
burden is also staggering, with direct costs alone totaling $300 billion each year1. CVD 
is an umbrella term that broadly refers to several related conditions, including heart 
attack (myocardial infarction), strokes, peripheral arterial disease, hypertension, and 
heart failure. The vast majority of heart attacks, strokes, and deaths are caused by 
atherosclerosis. Atherosclerosis is, in large part, a disorder of lipoprotein metabolism. 
This review will thus begin with an overview of cholesterol and lipoprotein metabolism, 
and will then apply this information to an explanation of atherosclerosis. Risk factors 
and imaging modalities used in human clinical management of cardiovascular disease 
will be covered. After a description of the effects of diet on atherosclerosis and CVD, the 
final sections will discuss animal models and methods used in atherosclerosis research.  
Cholesterol and lipoprotein metabolism 
Transport of lipophilic compounds through the aqueous systemic circulation is 
facilitated by their inclusion in lipoproteins. Lipoproteins contain triglycerides, cholesterol 
esters, and other fat-soluble compounds enclosed within a phospholipid monolayer. 
Integral membrane proteins called apolipoproteins mediate functions related to 
enzymatic activity and receptor recognition. After consumption of a lipid-containing 
meal, triglycerides from food are hydrolyzed to free fatty acids and glycerol. These, and 
other lipophilic digestion products including cholesterol and fat-soluble vitamins A, D, E 
and K, are mixed with bile acids in the intestinal lumen to form micelles, which are then 
absorbed into enterocytes, the epithelial cells of the intestine. Sterol absorption is also 
actively regulated by transporters including ATP-binding cassette transporter (ABC) G 
isoforms and Niemann-Pick C1-like 12-5. Production of these transporters is regulated 
transcriptionally by the liver X receptor (LXR)5. The enterocyte packages lipophilic 
compounds into lipoprotein particles called chylomicrons for export into the 
circulation6,7. Chylomicrons contain predominantly triglyceride enclosed within a 
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phospholipid monolayer, along with a small amount of cholesterol8. At this stage, 
chylomicrons contain one major apolipoprotein, ApoB48, which is a truncated form of 
ApoB100 produced by editing of the ApoB mRNA by Apobec-19-11. ApoB48 is loaded 
onto the chylomicron with the assistance of the chaperone microsomal triglyceride 
transfer protein (MTTP)6,7. 
Chylomicrons are then absorbed from the enterocyte into the lymphatic system, and 
not the blood, primarily because they are too large to move past capillary endothelial 
cells12. A major purpose of the chylomicron is to deliver fatty acids to extrahepatic 
tissues such as heart and skeletal muscle. Transport through the lymph, which empties 
into the subclavian vein, allows chylomicrons to be distributed throughout the general 
circulation and metabolized before being managed by the liver. In addition to their initial 
ApoB48, chylomicrons also receive ApoA, C, and E lipoproteins in the circulation, 
usually donated from HDL. After removal of triglyceride in the circulation, primarily 
through the action of capillary endothelial lipoprotein lipase (LPL)13, the particle is 
referred to as a chylomicron remnant. Remnant lipoproteins are cleared from the 
circulation through the action of the LDL receptor-related protein (LRP)14.  
In addition to the intestine, the liver is the second major site of lipoprotein production. 
Fats from the diet or circulation are taken up, processed, and incorporated into VLDL 
particles in the liver. In the fed state, particularly after a carbohydrate-rich meal, insulin 
suppresses ApoB production and VLDL formation15,16. Fatty acids are esterified through 
a series of enzymatic reactions, finishing with the formation of triglycerides by 
diacylglycerol acyl transferase  (DGAT)17, and the triglycerides are stored in cytosolic 
lipid droplets at this stage. When the suppression by insulin is relieved, ApoB and 
triglyceride can be incorporated into VLDL particles, with the activity of MTTP being 
particularly important again, and the particles are then exported to the circulation. In 
addition to ApoB100, human VLDL may contain ApoA518, multiple ApoC isoforms, and 
ApoE19.  As with chylomicrons, VLDL particles primarily serve to distribute triglycerides 
to extrahepatic tissues. Metabolism by LPL produces the VLDL remnant. 
LDL can be produced either by removal of ApoE from the VLDL remnant, or by de 
novo synthesis in the liver. LDL contains mostly cholesterol, and carries a single 
lipoprotein, ApoB100. Although almost all cells can synthesize cholesterol20, LDL 
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assists by delivering cholesterol to extrahepatic tissues, especially steroidogenic tissues 
such as the adrenals and gonads21. The majority of LDL particles are cleared from the 
circulation through the use of the hepatic LDLR in a process known as receptor-
mediated endocytosis22-25. Receptor-mediated endocytosis was discovered through 
studies of the LDLR, and is now recognized as a general cellular strategy for 
internalization of large particles and their cargo26. This process begins with recognition 
of ApoB100 by LDLRs located in clathrin-coated extracellular pits. Binding of LDL to 
LDLRs triggers formation of vesicles that are rapidly internalized and fuse with 
lysosomes. Once LDL enters the lysosome, its protein components are digested to 
amino acids, and its cholesterol is subject to the actions of two Niemann-Pick C (NPC) 
proteins, NPC1 and NPC2. Recent studies support the existence of a cooperative 
handoff mechanism whereby NPC2 binds cholesterol, with cholesterol’s hydrophobic 
iso-octyl side chain buried in NPC2’s binding pocket, forms a closed channel with 
NPC1, and hands off the cholesterol molecule27. NPC1 may then be able to move 
cholesterol through the membrane for exit from the lysosome and transport to the 
endoplasmic reticulum (ER), but this step is not fully understood. 
Internalization of cholesterol results in three cellular regulatory responses: 
suppression of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-
limiting step in cholesterol biosynthesis; activation of acyl-coenzyme A:cholesterol 
acyltransferase (ACAT) for cholesterol esterification and intracellular storage; and 
reduction in synthesis of LDLR, preventing excess cholesterol accumulation. In addition 
to the three classical regulatory mechanisms, further layers of regulation are achieved 
through the sterol response element binding protein (SREBP) pathway and through the 
use of microRNAs (miRNAs). SREBPs are master transcriptional regulators of 
cholesterol and lipid synthesis28,29. When cellular cholesterol levels are high, cholesterol 
binds directly to SREBP cleavage activating protein (Scap), triggering binding of Scap to 
insulin-induced gene (INSIG), a protein that promotes retention of Scap and SREBP at 
the ER. When cellular cholesterol concentrations decrease, Scap is released from 
INSIG. The six amino acid MELADL sequence in Scap interacts with CopII coat proteins 
to generate membrane vesicles that enclose Scap and SREBP for transport to the Golgi 
apparatus, where Site-1 and Site-2 proteases sequentially cleave SREBP to release the 
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mature basic helix-loop-helix transcription factor. SREBP regulates the transcription of 
target genes including those encoding HMG-CoA reductase and the LDL receptor. 
MiRNAs provide another layer of regulation. The canonical function of miRNAs is to 
bind complementary sequences on mRNAs to trigger their degradation30,31. Recent 
studies have uncovered miRNAs located within intronic regions of the SREBP genes. 
These miRNAs, miR-33 in mice and miR-33a and b in humans, are co-transcribed with 
SREBPs in times of low cellular cholesterol and inhibit translation of ABCA1 mRNA, 
decreasing cholesterol efflux32-36. SREBP-2 also regulates transcription of miR-96, 182, 
and 183, which in turn regulate levels of other proteins in the SREBP pathway37. These 
homeostatic feedback mechanisms allow close regulation of cholesterol levels within 
the cell. 
HDL is another type of lipoprotein with unique functions and benefits. In contrast with 
other lipoproteins, its primary component by weight is protein. ApoA1 from the liver or 
intestine combines with phospholipid and cholesterol to form pre-β HDL. HDL can also 
be formed in plasma from chylomicron and VLDL remnants. ApoA1 is the sole 
apolipoprotein on pre-β and discoidal HDL; mature HDL particles may pick up other 
ApoA, C, D and E isoforms. ApoA1 on HDL activates lecithin:cholesterol acyltransferase 
(LCAT). This key enzyme esterifies cholesterol to move it from the surface to the center 
of the lipoprotein, allowing for continued cholesterol uptake. The production of ApoA1 is 
controlled transcriptionally by the retinoid orphan receptor α (RORα), which binds 
cholesterol as a ligand38. HDL particles are highly heterogeneous, and can be 
categorized based on their shape (spherical or discoidal), density (HDL2 and 3), 
electrophoretic mobility (pre-β vs. α), and apolipoproteins39. HDL has anti-inflammatory, 
antioxidant, anti-thrombotic, and vasodilatory functions, and has a central role in the 
process of reverse cholesterol transport40. 
Reverse cholesterol transport is the process of returning cholesterol from peripheral 
tissues to the liver for disposal41. Arterial tissue is a particularly important peripheral 
location in which this occurs. Cholesterol can accumulate in the arterial intima, leading 
to formation of atherosclerotic lesions, as will be discussed in the following section. 
Macrophages ingest this cholesterol in an attempt to remove it from the arterial tissue, 
and donate it to HDL via ABCA1 and ABCG1. The ApoA1 on HDL activates LCAT, 
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esterifying cholesterol to move it toward the core of the particle. Circulating HDL can 
then deliver cholesterol to the liver either directly, through scavenger receptor B1, or 
indirectly, by exchanging cholesterol and lipids with VLDL or LDL through the actions of 
cholesterol ester transfer protein (CETP). The liver can excrete this cholesterol through 
the ABCG5 and G8 transporters into the bile, or by using it to synthesize bile acids, with 
cholesterol 7α hydroxylase (CYP7A1) as the rate-limiting enzyme. Cholesterol and bile 
can then be excreted in the feces.  
Nuclear receptors and miRNAs regulate reverse cholesterol transport. The nuclear 
receptor LXR coordinates the reverse cholesterol transport program throughout the 
body5,42,43. As a transcription factor, LXR upregulates expression of genes involved in 
cholesterol efflux, including ABCA1, G1, G5, and G8. This information previously led to 
the hypothesis that pharmacological LXR activation could reduce atherosclerosis by 
upregulating reverse cholesterol transport. Indeed, mice given LXR agonists display 
reduced atherosclerosis44. However, enthusiasm for this therapeutic strategy was 
rapidly curbed when studies of mice given LXR agonists revealed severe hepatic 
steatosis and hypertriglyceridemia as side effects, due to upregulation of SREBP-1c 
and suppression of ApoA55. Reverse cholesterol transport is also regulated by miRNAs. 
As mentioned, miR-33 regulates cellular cholesterol efflux by inhibiting translation of 
ABCA1 mRNA. In the context of the cardiovascular system, pharmacological inhibition 
of miR-33 promotes reverse cholesterol transport45, increases HDL46,47, and reduces 
atherosclerosis48.  
It is important to note that cholesterol is essential for life. It is a critical building block 
for steroid hormones and bile acids, and is a major constituent of cell membranes 
throughout the body. LDL delivers cholesterol to tissues where it can be used, and thus 
should not be considered categorically bad. Cholesterol also plays an important 
signaling role. It is a key component of the Hedgehog signaling pathway, and depletion 
of cholesterol during embryonic development leads to severe birth defects49-51.  
Although cholesterol is important for normal physiology, it can also be detrimental. 
Aberrant cholesterol metabolism is a major contributor to atherosclerosis, the underlying 
pathological process that causes heart attacks and strokes. Cholesterol metabolism can 
be pathologically altered in several major respects. First, cholesterol metabolism can be 
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affected at the level of intestinal absorption and processing. This is illustrated by studies 
of the ABCG5 and G8 transporters. ABCG5 and G8 are involved in cholesterol efflux, 
including excretion from the liver into bile and from the enterocyte back into the intestine 
for excretion5. Humans with mutations in these transporters exhibit sitosterolemia, 
characterized by increased absorption and decreased excretion of sterols, resulting in 
tissue accumulation and premature atherosclerosis52,53. Conversely, transgene-driven 
overexpression of ABCG5 and G8 has been shown to reduce plasma cholesterol levels 
and atherosclerosis in LDLR-/- mice by promoting cholesterol excretion54. Defects in the 
MTTP gene cause abetalipoproteinemia, which is characterized by lack of chylomicron 
and VLDL synthesis55. In terms of cholesterol synthesis, genetic polymorphisms in the 
HMG-CoA Reductase gene are present in hypercholesterolemic patients and affect 
responsiveness to inhibition by statins56,57. LDL uptake is another regulatory point that is 
frequently disturbed. Genetic mutations in the LDLR23 or autosomal recessive 
hypercholesterolemia (ARH)58-60 genes cause familial hypercholesterolemia, with 
homozygous forms being more severe than heterozygous forms. Familial 
hypercholesterolemia can be complicated by the actions of proprotein convertase 
subtilisin kexin 9 (PCSK9), an LDLR-interacting protein. PCSK9 binds to the LDLR and 
triggers its cellular internalization61,62. Defective intracellular cholesterol processing also 
causes Niemann-Pick diseases. In patients with these diseases, after LDL is 
internalized, the lysosomal processing of cholesterol is disrupted by genetic mutations 
in the NPC genes63. Mutations in ABCA1 result in defective cholesterol efflux and cause 
Tangier disease, which is characterized by an absence of HDL, cholesterol 
accumulation in tissues, and premature atherosclerosis64. Mutations in the LPL gene 
also cause premature atherosclerosis by preventing removal of fatty acids from 
chylomicrons, resulting in familial hyperchylomicronemia65.  
The discovery of the HMG-CoA reductase regulatory step led to the development of 
statin drugs as a solution to the problem of dysregulated cholesterol metabolism66. The 
canonical mode of action of statins is to inhibit HMG-CoA reductase, which decreases 
cellular cholesterol synthesis. The reduction of cholesterol synthesis affects the entire 
system of cellular cholesterol homeostasis, resulting in a compensatory increase in 
LDLR production. Importantly, statins also have pleiotropic effects that contribute to 
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their efficacy, including decreased inflammation, plaque stabilization, and reversal of 
endothelial dysfunction67,68. As concrete evidence of these pleiotropic effects, statins 
have been shown to reverse atherosclerosis in human patients69-73. 
Although statins have been highly successful in reducing cardiovascular events, they 
are not adequate in all circumstances. Patients with homozygous familial 
hypercholesterolemia do not enjoy the full benefits of statins because they produce 
defective LDLR, or none at all, in response to the suppression of cellular cholesterol 
synthesis. Statins also increase the production of PCSK9, which may reduce their 
efficacy74. Therapies targeting PCSK9 have recently met this need. Antibodies against 
PCSK9 have successfully lowered circulating cholesterol levels in familial 
hypercholesterolemia patients75-77, but only in patients that produce functional LDLR. 
Patients who lack functional LDLR have not benefitted from PCSK9 antibody therapy78. 
Many other therapies are currently under consideration67,79,80. 
Aberrant cholesterol metabolism is important in the pathogenesis of other diseases 
as well, including cancers and Alzheimer’s disease. Recent evidence demonstrates 
accumulation of cholesterol esters in prostate cancer cells, prolonging activation of 
SREBP for lipogenesis and cell proliferation81. Statins display potential as anticancer 
therapeutics, due in large part to their ability to reduce protein prenylation82. The role of 
cholesterol metabolism in Alzheimer’s disease is apparent from the effects of ApoE 
polymorphisms on disease risk83. ApoE affects amyloid β aggregation and other 
aspects of brain metabolism. In addition to ApoE, other aspects of lipid metabolism and 
signaling affect the progression of Alzheimer’s84. HMG-CoA reductase polymorphisms 
may also be important determinants of Alzheimer’s risk85,86. In summary, the evidence 
presented in this section highlights the central causal role of cholesterol and lipoproteins 
in cardiovascular disease, and illustrates the pervasive impact of cholesterol 
metabolism on physiology and pathology. 
Pathogenesis of atherosclerosis 
Atherosclerosis is a maladaptive immune response to ectopic lipoprotein deposits in 
the artery wall. This maladaptive immune response leads to the development of 
atherosclerotic plaques in the arterial system that cause heart attacks and strokes, and 
  8 
is therefore responsible for more deaths than any other disease. Atherosclerosis begins 
early in life. There is evidence that maternal hypercholesterolemia can promote the 
development of atherosclerosis in the fetus in utero87. Autopsy studies have 
demonstrated fatty streaks in children at two years of age, and advanced atherosclerotic 
lesions in teenagers88. It is not exclusively a disease of Western civilization, as recent 
work has demonstrated atherosclerosis in mummies from ancient Egypt and other 
societies89-95. Diet, lifestyle, genetics, and geographic location varied widely among 
these societies, suggesting a fundamental predisposition to the development of 
atheromatous plaques. Infection was also common and may have contributed. 
Our understanding of atherosclerosis has advanced tremendously over the last 50 
years. Although inflammation had been implicated in atherosclerosis as early as 185696, 
physicians typically regarded it as a “plumbing problem”: passive deposition of lipid in 
the artery wall would cause it to grow inward until it was too narrow for blood to flow 
through. However, after intensive study of the pathogenesis, we now understand it not 
simply as passive lipid accumulation, but as an active process of chronic inflammation 
incited by arterial lipoprotein retention97.  
The key event in initiation of atherosclerosis is the entry of ApoB-containing 
lipoproteins into the arterial tissue. This process is still incompletely understood, but 
current evidence points to several key mechanisms. First, arterial sites that experience 
disturbed blood flow seem to be predisposed to atherosclerosis, while sites with laminar 
blood flow are resistant. The altered shear stress in disturbed flow regions may affect 
the permeability of the vascular endothelium, the cellular monolayer lining the vessel 
lumen.  
Second, endothelial dysfunction may facilitate the development of atherosclerosis. 
Normally the vascular endothelium, the inner cellular lining of the blood vessels, 
regulates clotting, inflammation, vasodilation through production of nitric oxide (NO), 
and exchange of molecules between the blood and the blood vessel tissue. As blood 
vessels age, their inner endothelial cell lining fails to adequately perform its functions, 
which predisposes aged adults to CVD in a process known as endothelial dysfunction68. 
Endothelial dysfunction promotes a vasoconstrictive, inflammatory and thrombotic 
environment that results in progression of hypertension and atherosclerosis, leading to 
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its title as “the risk of the risk factors”98 (Figure 1.1). It was originally thought that 
endothelial damage was the primary initiating event99, but we now realize that 
endothelial dysfunction and inflammation, rather than physical damage, figure more 
prominently in the atherosclerotic process100. The vasoconstriction is a result of 
decreased NO bioavailability in the vasculature. Normally NO mediates vasodilation by 
diffusing from endothelial cells to vascular smooth muscle cells, causing them to relax 
and allow dilation of the blood vessel. In the presence of endothelial dysfunction, 
inactivation of NO by reactive oxygen species (ROS) leads to decreased vasodilatory 
ability101. Additionally, dysfunctional endothelial cells display adhesion molecules such 
as VCAM-1 that bind monocytes and permit them to enter the vascular tissue, where 
they initiate an inflammatory response. These are common mechanisms by which 
endothelial dysfunction can lead to a variety of cardiovascular disorders, including 
hypertension and atherosclerosis, which in turn lead to heart attacks and strokes. 
Abundant data demonstrate that oxidative stress in the vasculature, primarily through 
elevated ROS, leads to decreased NO bioavailability and gradual endothelial 
dysfunction102, a prelude to hypertension and atherosclerosis. The transcription factor 
nuclear factor erythroid-derived 2 related factor 2 (Nrf2) plays a central role in 
antioxidant defense by binding to the antioxidant response element in target genes and 
inducing expression of detoxifying and free radical scavenging enzymes103. Nrf2 is 
normally sequestered in the cytosol by an inhibitor protein until it is needed, when it is 
then liberated from the inhibitor protein and translocates into the nucleus103. However, in 
aging Nrf2 has a reduced capacity both to translocate into the nucleus and to bind to the 
antioxidant response element104, diminishing the cell’s capability to resist oxidative 
stress. There is a great deal of interplay between oxidative stress and inflammation in 
endothelial dysfunction. Nuclear factor κB (NF-κB), while typified as an inflammatory 
transcription factor, is also redox-sensitive, with oxidative stress triggering its 
activation105 and Nrf2-mediated resistance to oxidative stress inhibiting its activation106. 
Conversely, NF-κB can also evoke oxidative stress in the endothelium107. The end 
result of these processes is an endothelium that cannot perform its normal functions, 
and vascular health declines. 
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Recent studies have demonstrated the presence of dendritic cells at atherosclerosis-
prone sites of disturbed flow, and suggest their role in early arterial lipid 
accumulation108. Other risk factors like diabetes and smoking may also contribute to the 
dysfunctional vascular environment. It is likely that all the above mechanisms contribute 
Figure 1.1. Mechanisms of endothelial dysfunction. Aging leads to endothelial dysfunction, an 
underlying condition characterized by oxidative stress and inflammation that leads to hypertension and 
atherosclerosis, which result in cardiovascular events including myocardial infarction and stroke. In 
aging, increased activation of key receptors, including TNFR1 and AT1R, elicits oxidative stress and 
inflammation within the endothelial cell. The oxidative stress would normally trigger nuclear 
translocation of Nrf2, but in aging Nrf2 has a reduced ability to translocate and bind to the ARE to 
promote oxidative stress resistance. As a result, ROS within the endothelial cell inactivate NO, 
reducing the ability of the blood vessel to dilate properly and leading to hypertension. Receptor 
activation also triggers nuclear translocation of NF-κB, which increases transcription of inflammatory 
genes including TNF-α and VCAM-1. VCAM-1 is an endothelial cell surface receptor that binds 
monocytes and promotes their extravasation into the vascular tissue, where they perpetuate the 
inflammatory phenotype and contribute to hypertension and formation of atherosclerotic lesions. The 
impaired vasodilation and inflammatory phenotype are defining features of endothelial dysfunction. 
ARE; Antioxidant Response Element; AT1R, Angiotensin 1 Receptor; AT2, Angiotensin 2; NO, Nitric 
Oxide; ROS, Reactive Oxygen Species; TNFR1, TNF-α Receptor 1. 
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to varying degrees. The end result of these processes is the retention of ApoB-
containing lipoproteins in the artery wall, which prompts the immune system to mount 
an inflammatory response. 
Thus begins the chronic inflammatory state of atherosclerosis. Inflammation has 
been implicated in nearly every aspect of the atherosclerotic process. Mankind has 
been aware of inflammation since antiquity. The clinical signs, originally noted by 
Celsus in the first century AD, are rubor (redness), dolor (pain), calor (heat), and tumor 
(swelling). Inflammation occurs in a four-step process109. The first step involves 
inducers of inflammation, including bacterial infection or tissue damage and dysfunction, 
which lead to a loss of homeostasis. The “inducers” from the first step are detected in 
the second step by immune cells such as mast cells, dendritic cells, and macrophages. 
These “sensors” are both tissue-resident and circulating, and possess specialized 
membrane receptors, including Toll-Like Receptors (TLRs), which alert them to the 
problematic state. In the third step of this process, immune cells produce inflammatory 
mediators, such as interleukin-6 (IL-6). These molecules serve to target the immune 
response and appropriately prompt tissue repair and adaptation in the fourth and final 
stage of the immune response. Immune cells eliminate harmful bacteria and molecular 
debris to promote tissue healing.  
The overall goal of the inflammatory state is to promote adaptation and survival of 
the affected tissue. Thus, this response is beneficial when performed appropriately. 
However, if the pathogen cannot be eliminated or the tissue repaired, the inflammatory 
response becomes chronic. Although the tissue may survive, its homeostatic set point 
has been altered and the problematic state progresses further. These principles are 
exhibited in the atherosclerotic process110-113. Dysfunctional endothelial cells respond to 
the problematic condition of retained lipoprotein by expressing immune cell adhesion 
molecules such as vascular cell adhesion molecule 1 (VCAM-1) and chemotaxis-
stimulating molecules like monocyte chemoattractant protein 1 (MCP-1), inviting 
circulating monocytes to enter the arterial tissue for disposal of the retained lipoprotein. 
Monocytes respond by extravasating out of the blood and into the arterial tissue by 
squeezing between the endothelial cells, where they differentiate into macrophages and 
consume the excess cholesterol and lipid. After becoming engorged with lipid, 
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macrophages are referred to as foam cells based on their appearance. The condition 
continues with a dysregulated inflammatory response that allows for survival of the 
tissue but also leads to pathological alterations.  
Considering the central importance of the immune system in atherosclerosis, it is not 
surprising that lesions contain a diverse population of immune cells. Macrophages, 
which result from the differentiation of monocytes, are a major constituent of the 
immune cell community in atherosclerotic lesions. In mice, monocytes can be 
subdivided into two major populations based on their expression of the surface marker 
Ly-6C. Ly-6Chigh monocytes (comparable to CD16- CD14+ cells in humans) enter lesions 
and participate in atherosclerosis, while Ly-6Clow monocytes (comparable to CD16+ 
CD14dim cells in humans) roam the vasculature performing regulatory functions and 
typically do not enter lesions114,115. Lesion macrophages can be derived both from 
circulating Ly-6Chigh monocytes and from local macrophage proliferation, and the 
relative contribution of each source varies with the stage of the lesion116. Circulating 
monocytes may enter the arterial tissue from the artery lumen, or through the vasa 
vasorum, the blood supply to the artery tissue itself117. As previously mentioned, 
dendritic cells are also present and may be involved in the early stages of 
atherogenesis. Macrophages and dendritic cells are joined in the lesion by T cells, B 
cells, mast cells and innate lymphoid cells. T cells can be either pro-or anti-inflammatory 
depending on the type. T helper 1 cells are pro-inflammatory due to interferon-γ 
production, whereas regulatory T cells are considered anti-inflammatory because of IL-
10 and transforming growth factor β production118. The B cell population is not 
numerically prominent. It appears to generally exert a protective effect113,119, but may 
also accelerate atherosclerosis depending on the type of B cell120. Mast cells in the 
lesion produce proteases and inflammatory cytokines121,122. Natural helper cells also 
enter the arterial tissue and perform protective functions complementary to those of B 
cells123. 
Numerous other molecular mechanisms are involved in atherosclerosis. 
Inflammation is important at all stages. At the transcriptional level, inflammatory 
cytokines initiate signaling cascades that activate the NF-κB transcription factor, which 
coordinates expression of genes involved in inflammation, including VCAM-1124. 
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Interestingly, blockade of NF-κB in the mouse endothelium was recently shown to 
prevent vascular senescence and extend life span125. Recent studies have also focused 
on the role of the inflammasome, a large inflammatory protein complex. In addition to 
cholesterol contained within lipoproteins in the vessel wall, the formation of crystalline 
cholesterol deposits has been shown to promote inflammation through activation of the 
nucleotide-binding domain and leucine rich repeat containing family pyrin domain 
containing 3 (NLRP3) inflammasome, promoting plaque development in ApoE-/- mice 
and LDLR-/- mice126,127. However, another report showed that knockout of NLRP3 in 
ApoE-/- mice does not affect atherosclerosis128,129. More evidence is needed to delineate 
the role of the inflammasome in the atherosclerotic process. Oxidative stress was 
mentioned with regard to endothelial dysfunction. Another reported consequence of a 
pro-oxidative environment is the oxidation of lipoproteins, which may occur either in the 
circulation or arterial tissue130-132. Oxidative modification of ApoB100 and surface lipids 
prevents VLDL and LDL from being cleared by their normal receptor routes, and 
necessitates uptake by immune cell scavenger receptors133. While abundant 
experimental data implicate oxidized LDL in atherosclerosis, evidence for a role of 
oxidized LDL in human atherosclerosis is not currently compelling118. Nuclear receptors 
are also important in atherosclerosis. In addition to the functions of the nuclear 
receptors LXR and RORα mentioned in the section on lipoprotein metabolism, all 
isoforms of the peroxisome proliferator-activated receptors (PPARs)134, as well as 
isoforms of nuclear receptor subfamily 4A (NR4A)135, the peroxisome proliferator-
activated receptor γ coactivator 1α (PGC1α)136 and the corepressors silencing mediator 
of retinoid and thyroid hormones (SMRT) and nuclear receptor corepressor (NCoR)137 
play complex and important roles in the process, and their activation is generally 
beneficial and protective.  
Atherosclerosis is reversible in its early stages88, but if the risk factors and pathology 
are not corrected, lesions will continue to progress for decades in humans. Human 
plaque tissue has a slow turnover time138, making it physiologically challenging to 
reverse this progression. A key feature of lesion progression is the migration of smooth 
muscle cells from the vascular media to the intima96,118, where they proliferate and form 
a fibrous cap over the lesion, similar to a scab on the skin. Cells that appear foamy are 
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not only macrophages, but can also be smooth muscle cells that have migrated into the 
intima and adopted a foam cell phenotype139-141. Eventually, foam cells become 
overwhelmed by the accumulating lipid and die, contributing to the growing necrotic 
lesion core142. ER stress and the unfolded protein response are implicated in the 
process of macrophage cell death143. Many cellular proteins are cotranslationally 
translocated into the ER, where they fold into their three-dimensional conformations. 
During conditions of cellular stress, protein folding may be disrupted. The cell answers 
this dilemma by initiating an “unfolded protein response” which reduces protein 
synthesis, increases transcription of protein folding genes, and triggers apoptosis if 
homeostasis cannot be restored144. Excessive cholesterol accumulation in 
macrophages overwhelms the ER and triggers the apoptotic arm of the unfolded protein 
response145. In addition to smooth muscle cell proliferation and a necrotic core, 
advanced lesions may also become calcified. Calcification is performed by osteoblast-
like cells that arise from pericytes or smooth muscle cells in response to high circulating 
phosphate levels, dysregulated calcium metabolism, oxidative stress, and other 
factors146. Accumulation of calcium in the arterial tissue reflects the presence of 
atherosclerotic plaques and is a predictor of cardiovascular events147. 
Chronic lesion progression occurs asymptomatically until it results in clinical 
cardiovascular events. These cardiovascular events, including heart attacks and 
strokes, occur when atherosclerotic lesions rupture, exposing the coagulatory inner 
components to the blood and prompting formation of a clot that occludes the vessel148. 
Many factors affect plaque rupture. Lesions that rupture are not necessarily the most 
occlusive. The composition of the lesion and the thickness of the lesion cap may be 
more important. Matrix metalloproteinase enzymes secreted by immune cells may 
weaken the lesion’s fibrous cap. Calcification of the plaque may influence the likelihood 
of its rupture, but evidence is not clear whether it promotes or inhibits rupture. 
Identification of plaques vulnerable to rupture is a major clinical challenge149,150. After 
plaque rupture causes a cardiovascular event, the immune system is rapidly mobilized.  
A reserve population of Ly-6Chigh monocytes resides in the spleen and homes to the 
heart after ischemia151. Splenic monocytes are followed later by bone marrow-derived 
monocytes. Once they arrive and enter the cardiac tissue, monocytes are critical for 
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remodeling of the heart. Ly-6Chigh cells predominate during the initial inflammatory 
response and participate in removal of necrotic debris. Ly-6Clow monocytes repair and 
stabilize the cardiac tissue later. Prior myocardial infarction increases the risk of 
subsequent infarction. Until recently, reasons for this were not understood. Current 
evidence suggests that sympathetic nervous system activation stimulates increased 
production of immune cells by the bone marrow and spleen, which then enter 
atherosclerotic lesions and contribute to their progression114,152. 
Risk factors for cardiovascular disease 
The four conventional risk factors for CVD are hyperlipidemia, hypertension, 
diabetes, and smoking. Considering the central importance of lipoproteins in 
atherosclerosis, it is not surprising that they are some of the most well established 
cardiovascular biomarkers. Circulating cholesterol has been used as a biomarker in 
cardiovascular risk prediction for decades, and many studies have confirmed its 
predictive power for myocardial infarction, though interestingly not for stroke153. The 
most useful circulating lipid measurements have been total and HDL cholesterol, which 
can be reported separately or compared in a ratio. Although LDL is clearly a driver of 
atherosclerosis, measurement of LDL alone has not always proven effective. The utility 
of circulating triglycerides as a cardiovascular biomarker is also not clear154. While it is 
one of the key markers of metabolic syndrome, it has been difficult to establish elevated 
triglycerides as an independent risk factor because of its frequent co-occurrence with 
other risk factors. Other novel approaches to lipoprotein measurement have been 
considered, such as lipoprotein particle size. Evidence from animal155-157, clinical158,159, 
and epidemiological160 studies suggests that lipoprotein particles with a smaller 
diameter are more likely to enter the artery wall. This experimental evidence has not yet 
been translated into routine clinical practice. HDL is another lipoprotein fraction being 
re-examined. A recent study evaluated myocardial infarction risk in people with genetic 
variants associated with elevated HDL levels. Contrary to many headlines, this study 
does not disprove a protective effect for HDL in the cardiovascular system. The 
beneficial effects of HDL are numerous, and were summarized in the section on 
cholesterol and lipoprotein metabolism. This study simply suggests that having 
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genetically elevated HDL is not protective, and possibly that raising total HDL levels 
may not be an appropriate therapeutic strategy. Interest has shifted to other 
atheroprotective properties of HDL that could be potentially measured, particularly 
cholesterol efflux. A recent study demonstrated a strong inverse association between 
serum cholesterol efflux capacity and both carotid intima-media thickness and coronary 
atherosclerosis161,162. While interesting, the measurement methods appear complicated 
and would be challenging to perform in clinical practice. 
Blood pressure is another biomarker linearly and independently associated with 
cardiovascular risk. While many factors can affect blood pressure, clinical data have 
been remarkably consistent. Beginning at 115/75 mmHg, each increase of 20 mmHg in 
systolic blood pressure, or 10 mmHg diastolic, doubles mortality from myocardial 
infarction and stroke163. High blood pressure has traditionally been defined as 140/90 
mmHg. A previous revision of the blood pressure guidelines164 also recommended 
inclusion of a ‘prehypertensive’ category for those with blood pressure of 120-139/80-89 
for whom lifestyle changes are encouraged. The latest guidelines were recently 
released, and represent a more systematic and rigorous assessment of the evidence165-
168. Evidence strongly supports a recommendation to reduce blood pressure below 
150/90 with medication for those over 60 years old. Other blood pressure cutoff points 
are less clear, and usually require invoking expert clinical opinion. Surprisingly, the 
mechanisms causing hypertension are still not well understood, and basic research is 
needed169,170. 
Diabetic patients have a risk of myocardial infarction equivalent to non-diabetic 
patients who have already experienced a myocardial infarction171. The mechanisms by 
which diabetes accelerates CVD are being actively investigated, and may involve 
immune mechanisms143, altered metabolic signaling172 and formation of advanced 
glycation end-products173. Smoking is the single behavior choice most strongly 
associated with cardiovascular events, with most studies showing a 30-60% increased 
risk174. It accelerates atherosclerotic cardiovascular disease by pleiotropic mechanisms 
including oxidative stress and endothelial dysfunction175. In a meta-analysis, smoking 
cessation was associated with a 36% reduction in all-cause mortality in heart disease 
patients176. 
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As usual, biology is more complicated than was first realized, and shortcomings of 
biomarkers eventually become apparent. Conventional risk factors have been criticized 
because up to 50% of patients who experience cardiovascular events supposedly do 
not have conventional risk factors. This notion has been disproven, particularly by a set 
of papers published in JAMA in 2003177-180. These papers demonstrated the presence of 
conventional risk factors in nearly all patients who had cardiovascular events, and also 
questioned the value of adding novel biomarkers. A 2012 New England Journal of 
Medicine meta-analysis confirmed the predictive power of traditional risk factors on 
lifetime CVD risk181. No biomarker predicts disease with perfect accuracy, but traditional 
risk factors remain some of the best predictors of cardiovascular events. Additionally, 
what we consider “normal” cholesterol levels in our industrialized Western society may 
actually represent an elevation beyond what is physiologically necessary97,182. LDL 
<100 mg/dL has been considered optimal and <40 mg/dL nonpermissive88 for 
development of atherosclerosis. 
Traditional risk factors are usually aggregated into a scoring system183,184. There are 
several scoring systems available. The most widely used in the past has been the 
Framingham risk score185. This scoring system has proven valuable, but the 
Framingham cohort was not ethnically diverse, so the scoring system may not be valid 
for all population groups. The most recent scoring system and set of guidelines were 
released last year by the American Heart Association and American College of 
Cardiology186-189. This scoring system includes data from multiple cohorts in a dataset 
that is considered nationally representative. The updated guidelines suggest a move 
away from using target numbers and cutoff points as the determinants of treatment, and 
instead toward an approach in which all risk factors are considered holistically by the 
clinician, focusing on specific groups of high-risk patients. Contrary to headlines in the 
popular media, these guidelines are not designed to dramatically expand the population 
of patients treated with cholesterol-lowering statin drugs. The new guidelines are a more 
integrative and evidence-based approach to treatment. Instead of automatically 
prescribing a statin when a patient has risk factors above the target number, the 
clinician is instructed to carefully weigh the balance of the patient’s characteristics 
before making a decision. Workflows are provided to assist with this. 
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Other novel biomarkers have been sought because of the inability of lipoprotein risk 
factors to perfectly predict cardiovascular risk in all cases. Two such novel biomarkers, 
endothelial dysfunction and C-reactive protein (CRP) will be the focus. 
Endothelial dysfunction is an emerging risk factor that may also play a causal role in 
the pathogenesis of atherosclerosis. As mentioned previously, it is defined as an 
inability of vascular endothelial cells to properly mediate dilation and constriction of the 
blood vessels through reductions in nitric oxide bioavailability. In addition to propagating 
the development of major risk factors, endothelial dysfunction is an independent 
predictor of cardiovascular events including myocardial infarction, stroke and sudden 
cardiac death190-192. Endothelial dysfunction is usually determined through the use of 
brachial artery flow-mediated dilation, the compensatory response of the artery to 
restoration of blood flow after occlusion193,194. However, standardization of methods and 
stronger evidence for risk reclassification are needed, and the American Heart 
Association does not currently recommend its use in clinical risk prediction184.  
The critical role of inflammation in CVD has led to investigation of many cytokines 
and related molecules that are produced in response to this inflammation. One such 
molecule is C-Reactive Protein (CRP). This protein was first identified in 1930195 and its 
pentameric structure was subsequently determined196. CRP is produced by the liver197 
and represents the systemic acute phase response198. It has a half-life less than 24 
hours and a constant clearance rate, so an increase in serum levels indicates increased 
production199. Inflammatory mediators induce the production of acute phase proteins, 
and the acute phase protein CRP is produced in response to the inflammatory mediator 
IL-6. If there is a prevailing inflammatory state in the body, this could lead to 
development of atherosclerosis and incidence of resultant cardiovascular events. 
Clinical researchers thus became interested in measurement of CRP as a 
cardiovascular biomarker. A series of epidemiological studies and clinical trials, run 
mostly out of Harvard Medical School, have generated data in support of the use of 
CRP in clinical risk prediction. While CRP is clearly associated with cardiovascular 
events and has improved risk stratification in clinical trials200,201, it has not proven itself 
in routine clinical use. Of particular note is a large individual-participant meta-analysis, 
which showed, after obtaining individual patient data for over 160,000 participants in 
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various CRP trials, adjustment for traditional risk factors substantially weakened the 
association between CRP and CVD202. The Harvard investigators have also been 
criticized for having significant financial conflicts of interest. A re-analysis of the 
JUPITER trial revealed troubling biases in the data that may reflect the influence of 
corporate sponsors203. 
An interesting question has arisen from these investigations: is CRP simply a 
biomarker, or does it actively mediate the development of atherosclerosis? Interest in 
this area was generated by a report that CRP itself had direct proinflammatory effects 
on human endothelial cells in culture204. Another cell culture study demonstrated that 
CRP can attenuate endothelial progenitor cells205, a population of putative circulating 
stem cells that may contribute to vascular repair and angiogenesis. However, these 
effects were later shown to merely be an artifact of LPS and azide contaminants of the 
commercial CRP preparation206 and not properties of CRP itself.  
Animal studies have been equally inconclusive. One mouse study demonstrated 
acceleration of atherosclerosis in CRP transgenic ApoE-/- mice as compared with 
regular ApoE-/- mice207. Subsequent studies have shown no effect in mice208,209 and 
CRP transgenic rabbits210, and even a protective effect of CRP on atherosclerosis in 
mice211. Attempts to reconcile these results have led to further investigation of CRP’s 
molecular properties. After extensive investigation, one research group reported that the 
proatherogenic effects of CRP are dependent on a conformational rearrangement from 
its native pentameric structure to a monomer in endothelial cell culture212. A model213 
was proposed in which CRP binds to cell membranes (it can bind phosphocholine), 
undergoes dissociation of its subunits there, and proceeds to exert its proatherogenic 
effects. Monomeric CRP has recently been detected in human plaques but not in the 
circulation214 and monomeric CRP was also shown in that study to form on activated 
platelets. The activated platelets may tether to the vessel wall and attract monocytes, 
suggesting a possible mechanism of action for CRP. Furthermore, blocking the 
dissociation of CRP prevents its proinflammatory effects215. However, one mouse study 
demonstrated that native pentameric CRP increases atherosclerosis, but monomeric 
CRP is strongly protective against atherosclerosis216, findings which completely fly in 
the face of the proposed model of monomeric CRP’s involvement in atherosclerosis. 
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More research is needed before sound conclusions can be drawn. It is most likely that, 
if CRP is actually involved in atherosclerosis, there are other indirect mechanisms at 
work. It is probably more complex than CRP simply promoting, or protecting against, 
atherosclerosis.  
Numerous other biomarkers have been proposed, such as fibrinogen, Lipoprotein(a), 
and homocysteine. However, none of these biomarkers has been shown to substantially 
and consistently improve risk prediction179,185,217. Although these biomarkers may be 
associated with cardiovascular disease, they usually do not adequately meet the 
criterion of independent risk prediction, or reclassification of patients into different risk 
categories183. Genetics are involved in cardiovascular disease, but their role is unclear. 
In individuals without familial hypercholesterolemia or other monogenic disorders, the 
contribution of genetics to cardiovascular disease is highly complex218-221. Determination 
of family history is recommended184, but no specific genetic markers have proven 
clinically useful. Genome-wide association studies have identified dozens of loci 
associated with cardiovascular disease, and the biological functions of many of the 
genes are unclear at this time. Arterial calcium is emerging as a useful 
measurement147,222,223. Finally, age is a major risk factor, yet the mechanisms by which 
aging contributes to cardiovascular disease progression are not well understood. 
Evidence suggests that aging leads to a large number of changes in the cardiovascular 
system, including endothelial dysfunction, that create an atherogenic environment224-226. 
Cardiovascular aging will remain an important research area in the future. 
Imaging of cardiovascular disease  
In addition to measurement of biomarkers, imaging is the second major strategy for 
early detection of cardiovascular disease67,227. X-ray angiography has been the gold-
standard imaging modality for diagnosis of coronary and cerebral atherosclerosis. This 
procedure involves catheterization of the coronary artery, injection of a radio-opaque 
dye, and application of x-rays to the tissue. The invasiveness and use of ionizing 
radiation are obvious drawbacks, and it only provides a 2-dimensional extravascular 
image, which can limit its usefulness. Less invasive techniques have been developed, 
including computed tomography (CT), magnetic resonance imaging (MRI), and 
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ultrasound. CT scanning can be performed without invasive catheterization, but requires 
the use of ionizing radiation and contrast agents that may be toxic to the kidneys. MRI is 
emerging as a promising imaging modality. MRI utilizes non-ionizing radiation, and 
while it tends to deposit heat in biological tissues, its effects are generally considered 
less harmful than ionizing radiation. Data for multiple endpoints related to cardiac 
function and coronary artery stenosis can be gathered in a single imaging session, and 
contrast agents can be included for identification of cardiac scar tissue after myocardial 
infarction. It also has an emerging use in the measurement of endothelial function228. 
Ultrasound, sound waves above the 20 kHz threshold of human hearing, can be 
used in multiple ways for cardiovascular imaging229. Ultrasound transducers typically 
operate in the range of 1-40 MHz, and leverage the piezoelectric effect, the ability of 
quartz and related crystalline materials to interconvert electrical and sound energy. 
Pulses of electrical energy from the imaging system are received by the transducer, 
which then transduces that energy into sound waves. When the transducer is applied to 
biological tissue, sound waves are propagated through the tissue, reflected back to the 
transducer, and the transducer again uses the piezoelectric effect to transduce the 
sound waves back into electrical energy, which is returned to the imaging system for 
real-time processing. In terms of atherosclerosis, the key ultrasound imaging 
procedures are intravascular ultrasound and carotid intima-media thickness. 
Intravascular ultrasound imaging is another gold-standard technique that addresses 
some of the limitations of x-ray angiography. This invasive procedure requires insertion 
of an ultrasound probe into the artery230. The artery lumen is then imaged by slowly 
retracting the probe back through the artery, providing a view of the full circumference of 
the artery wall along the length of the artery. Measurement of carotid intima-media 
thickness (cIMT) is another ultrasound measurement that is simple and non-invasive. 
An ultrasound probe is placed on the neck, and the artery wall is visualized. The 
combined thickness of the intima and media is then computed, with the use of 
anatomical landmarks encouraged for repeatability and external validity231. cIMT 
improves cardiovascular risk prediction232, and is considered a reasonable test 
according to American Heart Association expert guidelines184. A third method is contrast 
ultrasound, which involves intravenous injection of gas-filled microbubbles during non-
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invasive ultrasound imaging. It is most useful in left-ventricular opacification for 
determination of cardiac function233,234, and some evidence suggests it may also be 
useful in assessing coronary artery stenosis235. 
Other than cIMT, none of the above imaging methods are recommended for 
screening of asymptomatic patients184. It should also be noted that these imaging 
modalities usually only provide information on stenosis and occlusion of blood vessels, 
and cannot determine plaque vulnerability or other important characteristics. In order to 
provide additional diagnostic information, novel molecular imaging technologies are in 
development and evaluation. While molecular imaging has primarily been used in 
research, it is beginning to prove its worth in clinical practice236. Molecular imaging of 
mechanistic targets is possible for nearly every aspect of the atherosclerotic process, 
including endothelial cell activation, inflammation, smooth muscle cell proliferation, 
apoptosis, angiogenesis, thrombosis, and tissue scarring227,237. MRI leads in this regard 
with the broadest assortment of molecular contrast agents. Macrophages are a key 
imaging target due to their pervasive influence in the atherosclerotic process. Iron oxide 
nanoparticles are phagocytosed by macrophages, and the macrophages can then be 
visualized by MRI238. Ultrasound can also be used for molecular imaging, and has found 
experimental success in imaging endothelial adhesion molecules239,240. Targeted 
microbubbles are created by conjugating an antibody to the shell of a gas-filled 
microbubble, typically through the use of streptavidin-biotin chemistry. These targeted 
microbubbles are injected intravenously, and the antibodies lead them to bind to 
endothelial cell surface markers, providing enhanced contrast that is detected with 
ultrasound. 
Challenges remain before the clinical use of molecular imaging is expanded241. Each 
new contrast agent must be FDA-approved, which requires millions of dollars and years 
of work. Also, the degree of expertise needed for molecular imaging typically restricts its 
use to specialists and research-oriented clinical centers. Imaging is also expensive, 
placing a burden on the Medicare system, and some argue that it should only be 
performed in patients at the highest risk for a cardiovascular event242. The feasibility of 
molecular imaging techniques remains to be determined. 
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Dietary acceleration of cardiovascular disease 
Ancel Keys concluded a 1952 Circulation article243 with “in summary then, we may 
remark that direct evidence on the effect of the diet on human atherosclerosis is very 
little and is likely to remain unsatisfactory for a long time.” Despite decades of research 
into the dietary causes of cardiovascular disease, questions remain. The literature on 
diet and cardiovascular disease is far from conclusive, but an attempt at a brief 
overview will be made. This first section will discuss dietary components with potentially 
deleterious effects on the cardiovascular system, with a focus on two types of dietary 
fat: trans and saturated fats.  
Of all the dietary factors hypothesized to be harmful to cardiovascular health, trans 
fats have received the greatest consensus. These fats both occur naturally, and are 
produced commercially by hydrogenation of vegetable oils for processed food products. 
Research on trans fats was summarized nicely in a review article by Mozaffarian et 
al244. Mechanisms including increased blood cholesterol, inflammation, and endothelial 
dysfunction lead to progression of atherosclerosis and diabetes, increasing risk of 
cardiovascular events. Prospective cohort studies have shown a 2% increase in energy 
intake from trans fats to be associated with a 23% increased risk of coronary heart 
disease. It is important to note that trans fats have never been shown to increase 
mortality in a randomized, controlled trial. However, the data from prospective cohort 
studies and short-term clinical trials with risk endpoints have been strong enough to 
mobilize our society against trans fats, and have prompted the widespread removal of 
trans fats from the food supply. It has also been argued that long-term trials of trans fats 
would be considered unethical given our current knowledge of their adverse health 
effects244. 
The role of saturated fats in cardiovascular disease remains a contentious topic. 
Evidence suggesting this link began with the work of Ancel Keys, whose Seven 
Countries study explored correlations between various aspects of diet and the 
occurrence of cardiovascular disease, and also provided early evidence linking 
circulating cholesterol levels with cardiovascular disease245. Findings from 
epidemiological studies were further explored with highly controlled “metabolic ward” 
studies. A 1997 quantitative meta-analysis of these studies246 demonstrated reductions 
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in blood total and LDL cholesterol levels when saturated fats were replaced with 
polyunsaturated fats or complex carbohydrates, but not monounsaturated fats, with an 
additional minor benefit to reductions in dietary cholesterol. Polyunsaturated and 
monounsaturated fats modestly increased HDL. The authors also derived equations to 
predict the response of circulating cholesterol levels to dietary fats and cholesterol. 
The influence of dietary fats on the development of CVD has been called into 
question many times. Early critics of the Seven Countries study explained that Keys 
actually had data for 22 countries, yet excluded 15 without good cause. One particular 
re-analysis of the study data247 is frequently cited248 as evidence that inclusion of all 22 
countries invalidates Keys’ conclusions from the study. However, the re-analysis 
supports, not refutes, the association between dietary fat and circulating cholesterol 
levels, with saturated fats of animal origin being particularly important in the association. 
Epidemiological studies, by nature, are prone to confounding variables, but Keys’ 
studies generated a wealth of data and hypotheses that have been used to create life-
saving treatments. A second, more recent example involves a highly publicized meta-
analysis disputing the link between saturated fats and CVD249. Controversy unfolded as 
corrections to the article had to be rapidly published, demonstrating numerous 
omissions and miscalculations250. Many confounding variables may have led to the 
misleading conclusions of the study. For example, grouping all sources of 
monounsaturated fats together ignores the differential effects of nuts and red meat on 
cardiovascular risk. It is surprising that the authors did not systematically address the 
effects of replacing saturated fats with other types of fat or carbohydrates, as the 
metabolic ward studies did. Additionally, a previous meta-analysis of prospective cohort 
studies showed that dietary polyunsaturated fats alone, as well as replacement of 
saturated with polyunsaturated fats, were inversely associated with coronary heart 
disease251. The Chowdhury study249 does not address the discrepancy between the two 
papers. This study is a poorly performed analysis taking the literature on fats and the 
heart off-course.   
Studies questioning the saturated fat-CVD link conveniently overlook a prodigious 
experimental literature on the detrimental effects of saturated fatty acids. In addition to 
consistently raising blood cholesterol levels in animal models, saturated fatty acids have 
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been shown to induce inflammation, insulin resistance, and impairment of endothelial 
function. Saturated fatty acids serve as ligands for TLR4252, inducing receptor 
dimerization and recruitment into cell membrane lipid rafts253. Receptor dimerization 
stimulates assembly of intracellular adapter proteins for activation of downstream 
signaling pathways. One of the most well characterized results of TLR4 pathway 
activation is nuclear translocation of NF-κB, the master inflammatory gene 
transcriptional regulator. The consequences of saturated fat-induced inflammation are 
numerous and vary depending on the tissue. In adipose tissue, TLR4 activation of NF-
κB by saturated fatty acids can lead to macrophage infiltration, production of 
inflammatory cytokines, and insulin resistance254-256. In the gastrointestinal tract, dietary 
saturated fatty acids facilitate expansion of microbial populations that stimulate 
inflammation and promote development of colitis257. In the vascular endothelium, NF-κB 
activation increases the expression of proatherogenic adhesion molecules, contributing 
to endothelial dysfunction (Figure 1.1), and recent evidence suggests endothelial NF-
κB signaling also contributes to insulin resistance125,258. A human clinical trial evaluated 
acute effects of either safflower oil, high in polyunsaturated fatty acids, or coconut oil, 
high in saturated fatty acids, on HDL and endothelial function259. In a crossover design, 
subjects consumed isocaloric meals containing either safflower or coconut oils, with the 
two meals separated by one month. Flow-mediated dilation, a marker of endothelial 
function, was measured in vivo, and HDL from the subjects was also isolated and used 
to treat human umbilical vein endothelial cells in culture. The authors found impaired 
flow-mediated dilation, and reduced anti-inflammatory capabilities of HDL, after coconut 
oil consumption. They attributed these detrimental effects to the fatty acid composition 
of the coconut oil, though it has also been argued that the differential vitamin E content 
of the two oils may have partially contributed260. The impairment of endothelial function 
and insulin action by saturated fatty acids may be prevented by concomitant 
consumption of omega-3 fatty acids261,262. 
The overly simplistic focus on single nutrients, such as saturated fats, belies the 
complexity of the human diet and has produced a confusing literature from which we 
can draw few conclusions. Studies also rarely account for the powerful effects of 
exercise, which may be a key mediator between diet and the cardiovascular system263. 
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To further complicate matters, levels of circulating, not dietary, saturated fatty acids may 
be most important. Limited evidence from small clinical trials suggests that low-
carbohydrate diets decrease circulating saturated fatty acids, which is associated with 
decreased circulating inflammatory markers264,265. Although it is difficult to draw 
conclusions from the collection of human studies, controlled experiments in cell and 
animal models have demonstrated consistently detrimental effects of saturated fatty 
acids. In his 1952 article, Keys recommended “restriction of all fats to the point where 
the total extractable fats in the diet are not over about 25 to 30 per cent of total 
calories.” This general guideline is still in use today. However, after explaining the ability 
of dietary fat to increase blood cholesterol levels, Keys also commented, “there is not 
the slightest evidence for a difference between animal and vegetable fat in this regard.” 
We have advanced our understanding of the effects of different types of dietary fat on 
blood cholesterol levels since then. 
A great deal of attention has recently been focused on dietary sugar intake. Added 
sugars, mostly in the form of high-fructose corn syrup, have been implicated in the 
obesity epidemic, though most studies have failed to dissociate the effects of fructose 
itself from the effects of excess calories from fructose266. The effects of dietary sugar 
have also been studied with specific relation to CVD. Sugar has been acknowledged as 
an independent risk factor for CVD mortality267,268, not only through its association with 
excess calories and weight gain. Although the link between sugar intake and diabetes, a 
disorder of carbohydrate metabolism, is not necessarily direct, consumption of sugar 
may contribute to a dysfunctional cardiometabolic state that promotes atherosclerosis. 
Links between diabetes and CVD were briefly discussed in the risk factors section.  
Dietary reduction of cardiovascular disease 
Compared with the literature on harmful dietary factors, the literature on 
cardioprotective dietary factors is clearer. An excellent review was recently published by 
Mozaffarian and colleagues269, and this section will highlight some key characteristics of 
a healthful diet presented in that review. It is important to consider the outcomes 
examined in each study, and whether these outcomes represent occurrence of hard 
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cardiovascular events or simply risk of cardiovascular events. When helpful, emphasis 
will be placed on study designs and outcomes. 
Dietary patterns 
The strongest evidence on diet and CVD comes from studies on dietary patterns, or 
groups of foods consumed together. The study of dietary patterns instead of individual 
foods has the advantage of being practically applicable, though it also prevents firm 
conclusions from being drawn about the effects of specific foods.  
One of the most widely recognized and scientifically reputable dietary patterns that 
promotes cardiovascular health is the Dietary Approaches to Stop Hypertension (DASH) 
diet270. This diet was developed in National Institutes of Health-funded studies as a 
treatment for hypertension. In the original clinical trial, patients achieved substantial 
blood pressure reductions by consuming a diet rich in fruits, vegetables, whole grains, 
low-fat dairy, nuts, fish, and poultry; red meats and added sugars were limited271. 
Interestingly, the benefits in this first trial were observed without reducing sodium intake. 
Further studies demonstrated a dose-response relationship between amount of dietary 
sodium and blood pressure, with maximum benefits observed at an intake level of 1200 
mg/day272,273. Impressively, the low-sodium DASH diet also eliminates the usual age-
related increase in blood pressure. Although no long-term trials with hard endpoints 
(myocardial infarction, stroke, or death) have been conducted, the DASH investigators 
suggest that such trials are not necessary in light of the strong benefits of the diet on 
established risk markers270.  
A second dietary pattern with strong scientific evidence supporting its cardiovascular 
benefits is the Mediterranean diet. The characteristics of this diet were first identified, 
again by Ancel Keys274, through the study of populations in the Mediterranean region 
with low incidences of cardiovascular events. There are many cultures surrounding the 
Mediterranean Sea, and their diets are heterogeneous275, but the Mediterranean diet 
referred to in most peer-reviewed scientific studies is similar to the DASH diet. It 
contains large amounts of fruits and vegetables, nuts, legumes, fish, and olive oil, with 
moderate consumption of wine, cheese and meats. Olive oil has traditionally contributed 
up to 18% of total calories in southern Italy276. The Mediterranean diet has been shown 
to reduce cardiovascular events and death in prospective cohort studies277 and 
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randomized controlled trials278. It has also improved endothelial function and 
management of metabolic syndrome279, and weight loss280 in other trials.  
In addition to the established benefits of the general Mediterranean dietary pattern, 
specific food components have also been studied. A recent randomized controlled trial, 
the Prevención con Dieta Mediterránea (PREDIMED) trial281, evaluated a 
Mediterranean diet with either added olive oil or mixed nuts. The investigators reported 
a significantly decreased incidence of cardiovascular events in both the olive oil and nut 
groups. Further subgroup analyses showed regression of cIMT in the nut group282, 
reduced atrial fibrillation in the olive oil group283, and reduced blood pressure, lipids, and 
glucose in both intervention groups284. While important, the PREDIMED trial had a 
number of limitations. First, the control group has been criticized. The editorial285 
accompanying the 2013 clinical trial paper281 explains that the control group was 
basically also consuming a Mediterranean diet, and although it was considered a “low 
fat” group, the participants still consumed roughly the same amount of dietary fat as the 
intervention groups. The decision to stop the study early was also questionable. While 
the olive oil and nut groups did technically experience a statistically significant benefit, 
the results were not dramatic. The hazard ratio confidence intervals are close to 
encompassing 1 (which would indicate no effect). There is also evidence that stopping 
clinical trials early may result in artificially high estimates of benefit286,287. Finally, despite 
the title of the article, it is important to note that the diets tested did not actually prevent 
CVD. They merely resulted in a relatively reduced number of cardiovascular events. 
The olive oil group still experienced 96 events, and the nut group 83, compared with 
109 in the control group. For these people, olive oil and nuts did nothing to prevent their 
cardiovascular events.  
A third, related dietary pattern deserves mention. Plant-based vegetarian and vegan 
diets have been promoted by investigators including Dean Ornish, Caldwell Esselstyn, 
and T. Colin Campbell. In several clinical trials, Ornish consistently demonstrated 
reversal of coronary atherosclerosis and reduced incidence of cardiovascular events 
after a plant-based diet and intensive lifestyle intervention288-292. This lifestyle pattern 
has also been beneficial in prostate cancer293-296. Both Esselstyn and Campbell 
advocate a strict, low-fat diet devoid of oils, meats and added sugars. In a small clinical 
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trial, Esselstyn demonstrated decreases in circulating cholesterol levels and reversal of 
coronary atherosclerosis after a low fat, plant-based dietary intervention297,298. While 
Esselstyn’s study lacks the controls, randomization and power of larger clinical trials, 
the results suggest a strong benefit of the dietary intervention. These results have been 
complemented by epidemiological studies of rural Chinese inhabitants consuming low 
fat, plant-based diets, which have demonstrated low circulating cholesterol levels and 
nearly complete absence of CVD in this population299. Though the evidence in support 
of the low fat plant-based dietary pattern is not as strong as for the DASH and 
Mediterranean diets, it is worth considering for the prevention and reversal of CVD.   
Specific foods and food components 
Epidemiological studies have consistently observed an inverse association between 
intake of fruits and vegetables and cardiovascular events and risk factors300-302, with a 
number of studies reporting benefits of tomato intake specifically. Benefits have been 
more consistently observed in women303,304 than in men305,306. Human clinical trials have 
demonstrated increased serum antioxidant enzymes307, reduced LDL oxidation308 and 
reduced blood pressure309 after tomato consumption, with benefits seen in as little as 
one week. Tomatoes are usually consumed as tomato sauce in these trials, which has 
higher carotenoid bioavailability than raw tomatoes310. 
Tomatoes contain a variety of essential nutrients and bioactive compounds311, and 
there has been great interest in the identification of specific bioactive components of 
tomatoes responsible for their salutary effects. Chief among these has been lycopene, 
the carotenoid responsible for red pigmentation in tomatoes. Lycopene has been shown 
to have numerous cardiovascular benefits. Epidemiologically, it has been inversely 
associated with carotid intima-media thickness312, arterial stiffness313 and incident 
CVD314, especially stroke315. Clinical trials have shown similar decreases in LDL 
oxidation with purified lycopene supplementation as with tomato consumption308,316, 
suggesting that lycopene may be predominantly responsible for the cardiovascular 
benefits of tomato consumption. Animal and cell culture studies have corroborated this 
epidemiological and clinical evidence. Lycopene decreases the expression of 
atherogenic adhesion molecules on endothelial cells317, reduces cholesterol synthesis in 
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macrophages318, and when administered at 5 mg/kg body weight for 4 weeks, reduces 
total and LDL cholesterol in rabbits319. Similar results have been shown in rats320. 
In addition to lycopene, tomatoes contain bioactive steroidal alkaloid compounds, or 
“sapogenols”, including tomatine, tomatidine and esculeogenin A. Tomatine was 
originally isolated in 1945, and noted for its antifungal and antibacterial properties321,322. 
It was later discovered that tomatine is metabolized to its aglycone form, tomatidine323. 
Tomatine and its aglycone tomatidine inhibit cancer cell growth324-326, inflammation327 
and muscle atrophy328. A recent study demonstrated that tomatidine inhibits the 
progression of atherosclerosis by reducing the activity of acyl-coenzyme A:cholesterol 
acyltransferase (ACAT). In addition to its health benefits, tomatidine is used as control 
reagent in studies of the Hedgehog signaling pathway because it is structurally similar 
to cyclopamine, a teratogen from the lily Veratrum californicum that interferes with 
Hedgehog signaling50,51,329,330. Esculeogenin A was recently discovered as an additional 
steroidal alkaloid similar to tomatidine that inhibits atherosclerosis through ACAT331. 
Taken together, these results suggest that tomatoes and their bioactive components 
promote cardiovascular health both directly, by promoting proper vascular function, and 
indirectly, by influencing cholesterol metabolism. 
Soy foods have also generated interest as a result of their beneficial effects on the 
cardiovascular system. Soybeans contain many bioactive compounds with salutary 
properties, including isoflavones, sterols, and the soy protein itself. Numerous studies 
have demonstrated the hypocholesterolemic effects of soy protein consumption332,333. 
These benefits are primarily due to incorporation of cholesterol into bile and subsequent 
excretion in feces334. Soy isoflavones also affect HMG-CoA reductase, the rate-limiting 
enzyme in cholesterol biosynthesis.  
Soy germ is a component of whole soybeans that is separated from soy protein 
isolate during processing in an isoflavone-rich “hypocotyledon” fraction. It is typically 
44% protein, 32% fiber and 24% fat by weight. It is currently available as a dietary 
supplement, and its distinct isoflavone profile may confer unique benefits. Although 
there is ample evidence demonstrating the cardiovascular benefits of other soy 
products, only two recent studies (both human clinical trials) have evaluated the effects 
of soy germ. The first enlisted patients with hypercholesterolemia335 (n=31/group). An 
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isoflavone-rich soy germ extract was added to pasta during the manufacturing process. 
The pasta delivered 33 mg isoflavones, which they report as being similar to levels of 
intake in Asian countries, and plasma isoflavones after consumption were in the 200-
250 nmol/L range. In this study, consumption of soy germ significantly reduced arterial 
stiffness, blood pressure, total and LDL cholesterol, and high sensitivity C-reactive 
protein. The authors explain that soy germ isoflavones, particularly equol, may have 
beneficial effects on NO production by the endothelium336. Importantly, this depends on 
equol production from daidzein by intestinal bacteria. In the second clinical trial, soy 
germ was shown to have beneficial cardiometabolic effects in type II diabetics337 (n=9-
11/group). Consumption of the soy germ pasta resulted in remarkable decreases in 
arterial stiffness, blood pressure, oxidized LDL, and homocysteine, combined with an 
increase in plasma GSH levels. No animal studies have tested the cardiovascular 
effects of soy germ. 
Animal models of atherosclerosis 
Animal models have been vital to advancing our understanding of the pathogenesis 
of atherosclerosis. The first animal model to enter widespread use was the cholesterol-
fed rabbit. Studies of atherosclerosis at the beginning of the 20th century in Russia and 
Germany utilized the rabbit as the model of choice. Experiments typically involved 
feeding egg yolks or various types of meat, and then examining the aorta for deposition 
of plaque. A Russian scientist, Anitschkow, realized that cholesterol was the dietary 
factor responsible. He fed rabbits purified cholesterol and hypothesized that the 
atherosclerosis he observed was the result of cholesterol deposition in the artery wall, 
further positing a role for immune cells in the process338. The cholesterol-fed rabbit was 
a favorable model when first introduced due to its physical size, large enough to 
facilitate pathological observation but smaller than monkeys and pigs, and the simplicity 
of the method used to induce atherosclerosis. Its sensitivity to dietary cholesterol 
appears to be due primarily to low rates of excretion339,340. Cholesterol-fed rabbits also 
carry excess blood cholesterol primarily in LDL, similar to humans, with small amounts 
of HDL and variable amounts of VLDL depending on the diet341-343. A second rabbit 
model, the Watanabe heritable hyperlipidemic rabbit, was created when Dr. Watanabe 
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observed a single male rabbit with elevated serum cholesterol levels344. He then used 
conventional animal breeding techniques to create an inbred strain of rabbits with 
elevated blood cholesterol. Subsequent investigations revealed that these rabbits had 
genetic defects in the LDLR, providing a useful model of familial hypercholesterolemia. 
The Watanabe model was later refined to develop more pronounced coronary 
atherosclerosis and myocardial infarction. 
There are disadvantages to working with rabbit models that offset their benefits. 
While atherosclerosis can be induced simply by feeding cholesterol, it also causes 
anorexia and jaundice that interfere with experiments343. The rabbit’s size was originally 
seen as an advantage, but they are much larger and more difficult to handle than the 
rodent models that are commonly used today. Diet and housing costs are also 
considerably higher than those of rodents. Another important factor is the limited 
availability of antibodies and reagents designed for use with rabbit samples. In light of 
these disadvantages, and the ease of genetic modification in mice, rabbits are less 
commonly used today than mouse models. 
Mice are naturally resistant to atherosclerosis, but genetic disruption of lipoprotein 
metabolism has produced useful models. The creation of ApoE-/-345-347 and LDLR-/-348-350 
mice in the early 1990s enabled rapid progress in knowledge of atherosclerotic 
mechanisms, and they remain the two most commonly used mouse models of 
atherosclerosis today. Deletion of ApoE is particularly effective at preventing lipoprotein 
clearance in rodents due to hepatic ApoB mRNA editing by Apobec-1351,352. In humans, 
ApoB mRNA is only edited in the intestine, producing the ApoB48 that is loaded onto 
chylomicrons. The human liver produces full-length ApoB100 that is incorporated into 
LDL and VLDL. In rodents, however, ApoB mRNA editing by Apobec-1 occurs in the 
liver also, resulting in hepatic secretion of lipoproteins decorated with ApoB48. The lack 
of full-length ApoB100 in chylomicron and VLDL remnants makes them critically 
dependent on ApoE for receptor recognition and hepatic clearance from the circulation. 
ApoE is capable of binding to the LDL Receptor, as well as to the LDL receptor related 
protein (LRP). Genetic deletion of ApoE, coupled with the truncated ApoB48, renders 
the murine liver virtually incapable of clearing VLDL and chylomicron remnant 
lipoproteins from the circulation. As a result, circulating lipoprotein levels increase, with 
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VLDL and remnant lipoproteins being the predominant fractions353. The importance of 
ApoE in lipoprotein metabolism is emphasized by the finding that bone marrow transfer 
from wild-type mice into ApoE-/- mice results in production of functional ApoE, 
normalizing lipoprotein metabolism and preventing atherosclerosis354. Although their 
lipoprotein profiles are different from hypercholesterolemic humans, these mice are 
similar to humans in that dietary saturated fat influences circulating cholesterol levels 
more than dietary cholesterol355. They also share many lesion characteristics with 
humans, with the exception that they are not susceptible to lesion rupture356. In this 
regard, hypercholesterolemia and atherosclerosis in ApoE-/- and LDLR-/- mice are 
dramatically increased by consumption of a Western diet, originally developed for use 
with the ApoE-/- mouse by the Breslow group at Rockefeller University in collaboration 
with Harlan Teklad. The Western diet contains 21% milkfat, 34% sucrose, and 0.2% 
cholesterol w/w added to an AIN-76357 or AIN-93358 purified diet formulation. The 
sucrose is converted to fat through the process of de novo lipogenesis, contributing to 
cardiometabolic dysfunction in these animals359. Consumption of a Western diet for 2-4 
weeks typically triples circulating total cholesterol levels in ApoE-/- mice. While ApoE-/- 
mice will develop atherosclerotic lesions on chow, LDLR-/- mice must be fed a Western 
diet to develop lesions in a typical experimental time frame due to the characteristics of 
murine lipoprotein metabolism described above. As with all animal models, these 
models are subject to certain limitations. ApoE has many other physiological roles 
independent from receptor recognition360,361, so its genetic deletion may influence 
experimental results in unforeseen ways.  
Other novel mouse models have been developed. The LDLR-/- apobec-1-/- mouse 
was generated to prevent hepatic ApoB mRNA editing, and carries its increased 
cholesterol exclusively in LDL, providing a model that is more representative of human 
familial hypercholesterolemia352,362. A similar model was also created by transgenic 
addition of ApoB100 onto a C57 Bl/6363 or LDLR-/-364 background. ApoE3-Leiden 
transgenic mice, another model, have a mutated ApoE3 gene inserted into their 
genome. In humans, this mutated APOE3 gene is associated with type III familial 
hypercholesterolemia. Their total cholesterol levels and lipoprotein profile are similar to 
ApoE-/- mice, with most cholesterol contained within VLDL365. This has been called a 
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“humanized” model366, but incorporates a genetic variant that very few people carry and 
displays a different lipoprotein profile than humans, so its advantages are unclear. An 
interesting alternative mouse model of diet-induced atherosclerosis has been 
reported367. This model involves genetic knockout of the scavenger receptor B1, 
coupled with expression of a mutated “hypomorphic” form of ApoE. These mice do not 
display substantial atherosclerosis on a chow diet, but once they are fed an atherogenic 
diet, they rapidly develop extensive occlusive lesions and die in one month.  
A few other animal species are used in atherosclerosis research. Rats do not 
naturally develop atherosclerosis, although some strains are used in hypertension 
research368, and tools for genetic manipulation are beginning to become available369. 
Gerbils have been used in studies of lipoprotein metabolism because their metabolism 
of lipids, and lipophilic compounds like carotenoids, is similar to humans370,371. Gerbils 
do not develop appreciable atherosclerotic lesions372, and genetic modification is not 
commonly performed. Another rodent model is the guinea pig. Guinea pigs are similar 
to rabbits in that cholesterol feeding elicits a dose-dependent increase in plasma LDL, 
whereas dietary fat has less of an effect. They have CETP, LCAT and LPL activity, 
similar rates of hepatic synthesis and catabolism of cholesterol as humans, and minimal 
ApoB mRNA editing in liver373. Disadvantages of the guinea pig model include 
heterogeneous and individualized responses to dietary cholesterol374, inconsistent 
development of atherosclerotic lesions despite hypercholesterolemia375, and lack of 
reagents or assay kits (though some mouse antibodies may show cross-reactivity376). 
The Yucatan mini-pig is an older model that is occasionally used in atherosclerosis 
research377,378. These “mini” pigs can weigh over 100 kg and require special housing 
facilities. Pigs do display atherosclerotic plaques that are vulnerable to rupture, and thus 
may fill a gap left by the more prevalent mouse models379. They have similar blood 
pressure, heart rate, vessel size and plaque morphology to humans. The size of pigs 
and mini pigs, while it presents considerable challenges, may be useful because human 
diagnostic procedures like intravascular ultrasound can be performed in a controlled 
experimental setting380. Recently, a human PCSK9 transgenic mini pig was created381 
that may become a useful translational model of familial hypercholesterolemia and 
atherosclerosis. Primates were frequently used in early studies382, but due to ethical 
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issues and the availability of simpler models, are only used today in select 
instances46,383.  
Methods of atherosclerosis assessment  
This section will focus on established methodologies developed for use with mouse 
models of atherosclerosis. The aortic root and en face methods of atherosclerosis 
assessment will be discussed, as well as methods for measurement of blood 
lipoproteins. 
The aortic root methodology was originally developed by Paigen et al. for assessing 
atherosclerotic plaque development in wild-type Bl/6 mice fed diets with varying 
amounts of fat, cholesterol, and cholate384. While these mice are resistant to 
development of atherosclerotic lesions in other areas of the arterial tree, they do 
develop modest lesions in the aortic root. The technique continued to prove useful after 
development of genetically modified mouse models, and remains the gold-standard385.  
To perform this method, the mouse is euthanized, either with CO2 or by 
exsanguination under anesthesia. Cervical dislocation is the fastest euthanasia method, 
but it impairs perfusion and may result in damage to the aorta because it runs along the 
spine. The mouse is then opened along the midline, the ribcage is cut away on either 
side with blunt scissors, and the heart is perfused with 20-30 mL phosphate buffered 
saline (PBS) through the left ventricle. This works best if the animal is perfused under 
anesthesia, because its heart is still beating and will circulate PBS more effectively. 
Mice can be perfused either with gravity or using an infusion pump. For gravity 
perfusion, a 50 mL syringe is typically mounted 100 cm above the bench top with 
extension tubing connecting it to a catheter. An infusion pump is simpler to set up, and 
uses mechanical force to depress the syringe plunger at a constant rate that is specified 
by the user. It is helpful to cut either the vena cava or right atrium to allow for fluid 
drainage during perfusion. While cutting at the right atrium allows for full circulation of 
fluid, it carries the risk of cutting through the aortic root and damaging the tissue. The 
vena cava is more straightforward to cut. After the perfusion is complete, the mouse can 
optionally be perfused with a fixative such as 10% neutral buffered formalin (NBF) or 
4% paraformaldehyde (PAF). NBF and PAF both fix tissue equally, but PAF is more 
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difficult to work with than NBF. The formaldehyde polymers frequently precipitate, and 
the solution must be boiled to allow the polymers to dissolve.  
Next, the heart is removed with 1 mm of the aorta attached. It is helpful to use a 
dissecting microscope, and to perform a brief dissection to remove the pulmonary 
arteries and veins, and fat on the heart. The auricles (flaps above the atria) should be 
retained for orientation. If further fixation is desired, the heart can be immersed in NBF 
or PAF overnight. Next, the bottom half of the heart is cut away with a scalpel. This step 
is critical. The cut must be parallel to the aortic root. If it is not, the three aortic valve 
leaflets will not be simultaneously visible in the cryosections and quantification may not 
be accurate. The cut will also be roughly parallel to the atria. After the bottom of the 
heart has been removed, the aorta should be standing straight up from the center of the 
heart, and may be pointing to the right slightly (when the heart is viewed from the front). 
This is easier to perform with fixed tissue than fresh tissue, because fixed tissue is more 
rigid, but fixing tissue may affect its ability to bind to charged microscope slides for 
histology (Smith BW, unpublished observations). Fixed hearts can optionally be moved 
to 15-30% sucrose in PBS overnight at 4ºC386, and should sink after being infiltrated by 
the sucrose solution. The sucrose solution protects against freezing artifacts such as ice 
crystals because it has a lower freezing temperature than water. Before freezing in 
optimum cutting temperature compound (OCT), hearts should be washed 3 times for 3 
minutes each in cold PBS. 
The tissue should then be acclimated to the OCT freezing medium in a small weigh 
boat or cryomold for 5-10 minutes at room temperature, with attention given to removal 
of air from inside the aorta. Next, tissues are transferred to a fresh cryomold, covered 
with OCT, and frozen. If retention of lipid in the tissues is not important, they can also be 
paraffin embedded after fixation. Several options are available for freezing tissue. The 
most effective and user-friendly is dry ice-cooled isopentane (2-methylbutane). With this 
method, isopentane is added to a small vessel, preferably stainless steel for efficient 
heat transfer, and surrounded with dry ice. The tissue in OCT is then placed in the 
isopentane for 3 minutes. The key to even freezing is to prevent the isopentane from 
covering the top of the tissue block. This can be accomplished by using deeper OCT 
molds that will not be completely filled after addition of heart tissue, and by only adding 
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a small amount of isopentane to the freezing vessel. If the tissue is fully submerged in 
isopentane, it will freeze more quickly, but the OCT may bubble, ripple and crack. The 
tissue can then be wrapped in parafilm, placed in a sealed plastic bag to prevent drying, 
and stored at -80ºC. Tissue blocks can also be frozen with isopentane cooled in liquid 
nitrogen. This method results in faster freezing than dry ice-cooled isopentane, but is 
more difficult to perform. It is more likely that OCT blocks will expand and crack. Also, 
the isopentane will eventually freeze, so it is difficult to keep it at the correct temperature 
where it is just above freezing. Freezing directly in dry ice, liquid nitrogen, or a -80ºC 
freezer is simpler, but carries a risk of ice crystal formation. Storage at -80ºC is 
preferred long-term, but it is helpful to store tissue blocks at -20ºC overnight prior to 
sectioning. A block that is too cold may develop artifacts when being sectioned. 
Next, serial 10 µm cryosections of the aorta are cut at the aortic valves and mounted 
on charged microscope slides. Ideally, all three valve leaflets will be visible. A set of 6-
12 slides is typically created, with each serial section added to a different slide. Sections 
should be allowed to dry and adhere to the slides for 30-60 minutes. If the tissue has 
not previously been fixed, slides can be dipped in NBF or acetone to fix. 
Once mounted on slides, a variety of stains can be applied depending on the 
measurements desired. The most commonly used stains are hematoxylin and eosin 
(H&E)126,387-396 and Oil Red O54,385,397. The H&E staining procedure dissolves lipids out 
of the tissue, but plaque area can be estimated by examining the tissue morphology 
manually394,395. Oil Red O stains neutral lipids (cholesterol esters and triglycerides) red, 
and the slides are typically counterstained with hematoxylin to provide contrast. 
Because lesions are stained red, software can be used for automated quantification of 
lesion area398. Oil Red O does not always stain lesions effectively. It is also important to 
note that, although neutral lipid staining is a general marker of lesion deposition, it does 
not provide any mechanistic information on the atherosclerotic process such as immune 
cell infiltration, inflammatory cytokine production, fibrous cap development, or 
calcification. Because of this, immunostaining procedures can be helpful. 
Immunostaining of macrophages is commonly performed using Mac-2395,399, MOMA-
2126,137,389,400-405, or F4/80406,407 antibodies. Stains for collagen to indicate development 
of a fibrous lesion, such as Masson’s Trichrome137,211,390,395,408,409 or Movat’s 
  38 
Pentachrome410-412, or stains for calcium to indicate lesion calcification413,414 are also 
used. 
For the en face method385,397, the mouse is perfused as described above, first with 
PBS and then with fixative for 10 minutes. The aorta is delicate, and the inner 
endothelial layer is particularly prone to damage even when the vessel is carefully 
isolated. A brief in situ fixation helps avoid damage. Importantly, if fixation is not desired 
for other organs, they should be collected before perfusing the aorta. Next, the aorta 
should be removed with major branching vessels still attached, cut open longitudinally, 
pinned to a flat black wax surface, and fixed overnight in NBF or PAF. It should then be 
immersed in PBS to wash, and can remain in PBS for up to 12 hours. Next, the aorta is 
briefly rinsed in 70% ethanol and a neutral lipid stain such as Sudan IV is typically 
applied for 5-10 minutes. The aorta is then digitally photographed with a CCD camera 
and polarizing lens to avoid shine and reflections. The images can be analyzed with 
color thresholding as described for Oil Red O above. The aorta can then be rinsed in 
ethanol for destaining and storage. The en face method has the advantage of 
demonstrating total aorta surface lesion coverage, but provides no information on lesion 
depth or morphology. In addition to aortic root and en face preparations, artery cross-
sections are sometimes used to examine specific sections of the coronary367, 
brachiocephalic415, or carotid416 arteries, or the aorta408. If artery cross sections are 
used, care should be taken to preserve the circular shape for lesion quantification. 
Circulating cholesterol levels are usually measured, due to the central role of 
lipoprotein metabolism in atherosclerosis. Two main methods are used: 
chromatography and colorimetric kits. The most informative and well-accepted method 
utilizes fast performance liquid chromatography (FPLC), which separates all lipoprotein 
fractions at once and is considered the most accurate measurement method54,345,401. 
Colorimetric kits are easier to use than FPLC, but only one fraction at a time can be 
determined. 
Lipids from the diet are incorporated into lipoproteins, and it is therefore useful to 
fast animals before measurement of circulating lipid levels. There is a lack of 
information and standardization of fasting procedures in the literature, but they can be 
divided into two major strategies: daytime and overnight fasts (Table 1.1). Daytime fasts 
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are typically 4-6 hours, and overnight fasts are usually 12-16 hours. It is important to 
note that an overnight fast is metabolically stressful to mice, because they typically feed 
at night417. If possible, a daytime fast is preferred. 
 
Fasting time  Model system Lipids measured Comments 
10-120 minutes418 Cells (U2OS) None Effects on the Ulk1/AMPK 
interaction in autophagy in 
≤30 min 
3 hours419 Mouse  None  
4 hours54,420-428 Mouse  Liver: TG 
Blood: TG, LP 
Referred to as daytime 
fast54,425,426 
4-6 hours370 Gerbil  Liver: TG 
Blood: TG, LP 
 
7 hours429 Mouse  Liver: TG 
Blood: TG 
Blood glucose  
“Overnight”430-436 Mouse430-435, rabbit436 Liver: TG 
Blood: TG, LP 
Exact number of hours not 
given 
12 hours437-441 Human Blood: TG437, various LP437 12 hours referred to as 
overnight, typical for humans 
12 hours390,442,443 Mouse390,443, rabbit442 Blood: TG, FFA, LP 12 hours referred to as 
overnight 
12-14 hours444 Mouse  None   
16 hours445-447 Mouse  Liver: TG, cholesterol 
Blood: various LP, TG 
16 hours referred to as 
overnight 
16 hours448  Mouse  None 16 hours referred to as 
overnight 
16 hours449 Mouse  Liver: TG Fasted prior to taking blood 
glucose  
16-20 hours450 Mouse  None   
18 hours372,451 Gerbil372, rabbit451  Blood: TG, LP, CE  
20 hours452 Mouse  Blood: TG, LP 20 hours referred to as 
overnight 
23 hours453,454 Mouse  Blood: FFA Starvation studies 
24 hours455-458 Mouse  Blood: TG, ketones  Fasting metabolism studies 
48 hours459-461 Mouse  Liver: TG459  
Blood: TG, LP459  
None460,461 
Fasting metabolism studies 
2 weeks462 Zebrafish Liver/whole body: TG, FFA, 
cholesterol, CE, ketones 
 
Table 1.1. Experimental fasting and starvation times. Abbreviations: CE, cholesterol 
esters; FFA, free fatty acids; LP, lipoproteins; TG, triglyceride 
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CHAPTER 2: A validated sandwich ELISA for the quantification of von Willebrand 
Factor in rabbit plasma1 
Abstract 
Von Willebrand Factor (vWF) is a multimeric plasma protein important for platelet 
plug formation. As part of its haemostatic role, it is released from endothelial cells during 
vascular stress or injury and is considered an excellent biomarker of endothelial 
function. Currently, there are no validated kits available to measure vWF in rabbits. We 
developed a sensitive and reproducible sandwich enzyme-linked immunosorbent assay 
(ELISA) for detection of vWF in rabbit plasma using commercially available antibodies 
and reagents. Purified human vWF was used as a calibrator standard with a dynamic 
range of 1.56-100 ng/mL. The Minimum Required Dilution for rabbit plasma was 1:100. 
When plasma was spiked with 3.76 or 10 ng/mL vWF, recovery was 108±2% and 
93±2%, respectively. Intra- and inter-assay precision for 8 rabbit plasma samples were 
3% and 4%, respectively. The Minimum Detectable Concentration was 254 pg/mL for 
purified human vWF and 1:10,700 dilution of cholesterol-fed rabbit plasma, and the 
Reliable Detection Limits were 457 pg/mL and 1:5940. Three freeze-thaw cycles 
significantly decreased absorbance readings for purified human vWF and 2 of 3 plasma 
samples assayed. This ELISA provides sensitive and reproducible measurements of 
rabbit plasma vWF, which is an important biomarker for cardiovascular research.  
  
                                            
1This chapter previously appeared in its entirety as Smith BW, Strakova J, King JL, Erdman JW, Jr., 
O'Brien WD, Jr. Validated sandwich ELISA for the quantification of von Willebrand factor in rabbit plasma. 
Biomarker Insights 5:119-127 (2010). The article is open access and the authors retain copyright. 
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Introduction 
Atherosclerosis is a pathological process underlying the majority of clinical 
cardiovascular events1 in which chronic inflammatory mechanisms are culpable in 
initiation and progression2. Vascular endothelial cells express adhesion molecules that 
promote the progression of atherosclerosis3, and there is a great deal of interest in 
discovering biomarkers of endothelial status or inflammation that reflect the activity of 
the various mechanisms at work. These biomarkers can assist clinicians and 
researchers in monitoring the progression of atherosclerosis or predicting disease 
outcomes in research animals and human patients.  
One such biomarker is the multimeric plasma protein von Willebrand Factor (vWF). 
In addition to its well-established haemostatic role4, vWF is currently considered the 
best circulating biomarker of endothelial function5. A growing body of experimental, 
clinical and epidemiological evidence points to high plasma vWF levels as indicative of 
systemic vascular dysfunction6 and predictive of acute cardiovascular events7.  
Our laboratory is interested in evaluating the biological effects of ultrasound, when 
used with ultrasound contrast agents to image the aorta. We developed a cholesterol-
fed rabbit model8 for this purpose. The vWF biomarker would be a useful circulating 
indicator of endothelial status, but there is currently no validated assay kit available to 
determine vWF levels in rabbit plasma. To facilitate accurate and precise measurement 
of this biomarker in pre-clinical studies, we have developed a sandwich enzyme-linked 
immunosorbent assay (ELISA) technique to measure rabbit plasma vWF using 
commercially available antibodies and reagents. The assay was validated by measuring 
parallelism, spike recovery, intra- and inter-assay precision, specificity, sensitivity, and 
freeze-thaw stability of plasma vWF.  
Materials and Methods 
Materials 
The microplate reader (ELx800) was obtained from BioTek (Winooski, VT). Nunc 
Immulon 4HBX Flat Bottom 96-well microplates and adhesive plate seals were obtained 
from Fisher Scientific (Pittsburgh, PA). Tween-20, Thimerosal, Phosphate Buffered 
Saline (PBS), Na2CO3 and NaHCO3 were obtained from Sigma-Aldrich (St. Louis, MO). 
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The vWF protein standard (Purified vWF from citrated human plasma, V2650) was 
obtained from US Biological (Swampscott, MA). Affinity purified goat anti-human vWF 
(GAVWF-AP), biotinylated affinity purified goat anti-human vWF (GAVWF-APBIO), and 
vWF-deficient plasma (VWF-DP) were obtained from Affinity Biologicals (Ancaster, 
Ontario, Canada). Streptavidin-Horseradish Peroxidase (HRP) (016-030-084) and 
Bovine Serum Albumin (BSA) (001-000-162) were obtained from Jackson 
ImmunoResearch (West Grove, PA). 3,3’,5,5’-Tetramethylbenzidine (TMB) substrate 
solution (52-00-03) and TMB Stop Solution (50-85-05) were obtained from KPL 
(Gaithersburg, MD). 
Reagents 
Carbonate Buffer – 20 mM Na2CO3 and 40 mM NaHCO3, pH 9.6, stored at 4ºC. 
Blocking Buffer – 1% w/v BSA in PBS containing 11.9 mM Phosphates (Na2HPO4, 
KH2PO4), 137 mM NaCl, and 2.7 mM KCl, pH 7.4, stored at -20ºC. 
PBST-BSA – 0.1% v/v Tween 20, 1% w/v BSA in PBS containing 11.9 mM 
Phosphates, 137 mM NaCl, and 2.7 mM KCl, pH 7.4, stored at -20ºC. 
Wash Buffer – 0.05% v/v Tween 20 in PBS containing 11.9 mM Phosphates, 137 
mM NaCl, and 2.7 mM KCl, pH 7.4, stored at 4ºC. 
All buffers were preserved with 1 mg/L Thimerosal. 
Rabbit Plasma and Protein Standard 
Four-month-old male New Zealand White rabbits were acquired from Myrtle’s 
Rabbitry (Thompson’s Station, TN). Animals were housed individually in standard 
caging with stainless steel mesh bottom in a 20°C temperature-controlled room with 12 
hour light/dark cycles, and fed either a standard chow diet containing 2% fat, 0% 
cholesterol and 0.4% magnesium (Harlan Teklad, Indianapolis, IN) or an atherogenic 
diet containing 10% fat, 1% cholesterol, and 0.11% magnesium (TestDiet, Richmond, 
IN). Blood samples were collected in heparinized tubes via the lateral saphenous vein 
while under restraint, centrifuged at 1380 x g for 10 minutes and plasma was aliquotted 
and frozen at -70°C. The Institutional Animal Care and Use Committee at the University 
of Illinois at Urbana-Champaign approved all procedures.  
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The vWF protein standard was purified from citrated human plasma negative for 
HIV1, HIV2 and HBsAg. The protein was supplied at a concentration of 0.2 mg/mL in 
buffer containing 25 mM Na Citrate, 100 mM NaCl, 100 mM glycine, pH 6.8, and 
determined by the manufacturer to be ≥95% pure as judged by SDS-PAGE under 
reducing conditions. Upon receipt, the solution was aliquotted and stored at -70ºC 
according to the manufacturer’s instructions. 
Antibody Selection and Optimization 
Several commercially available antibodies were evaluated (Table 2.1). Affinity 
purified goat anti-human vWF and biotinylated affinity purified goat anti-human vWF 
were selected as capture and sandwich antibodies, respectively. Streptavidin-HRP was 
chosen as the detection reagent. Antibody dilutions were optimized using checkerboard 
titration procedures, and the dilutions which returned the strongest signal to noise ratio 
were selected.  
Procedure 
A schematic of the assay procedure can be found in Figure 2.1. Microplate wells 
were coated with 100 µL of affinity purified goat anti-human vWF capture antibody 
diluted 1:5000 in carbonate buffer for a final concentration of 1 µg/mL. Plates were 
covered with adhesive sealing film, placed in a plastic bag with wet paper towels, and 
incubated overnight (≥16h) at 4ºC. Reagents were allowed to equilibrate to room 
temperature (RT) overnight.  
The next day, plates were washed three times with 300 µL of Wash Buffer per well 
on an orbital shaker with gentle agitation for 5 min. The buffer was removed by 
emptying into a sink and blotting on paper towels. Blocking Buffer (300 µL) was then 
added to each well and plates were sealed and blocked for 2 hours at RT with agitation.  
During this time, rabbit plasma samples and the vWF standard were prepared for 
addition to the plate. A standard curve was generated by serially diluting the 0.2 mg/mL 
vWF stock in Blocking Buffer. Working dilutions of 100, 50, 25, 12.5, 6.25, 3.13 and 1.56 
ng/mL were used in the assay. These dilutions span the concentration range of diluted 
plasma samples. Rabbit plasma was diluted 1:100 in Blocking Buffer. Following the 
blocking step, plates were washed three times with Wash Buffer as described above 
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and 100 µL of each standard and sample were added to the plate in duplicate. Blocking 
Buffer alone was used as a blank. Plates were incubated for 2 hours at RT with 
agitation. 
Plates were then emptied into a sink and washed three times with Wash Buffer as 
described above. Biotinylated affinity purified goat anti-human vWF was diluted 
1:40,000 in PBST-BSA to a final concentration of 25 ng/mL and 100 µL were added to 
each well. Plates were sealed and incubated for 1 hour at RT with agitation. After 
emptying the previous solution and washing, Streptavidin-HRP was diluted 1:100,000 in 
PBST-BSA to a final concentration of 5 ng/mL and 100 µL were added to each well. 
Plates were sealed, protected from light and incubated for 1 hour at RT with agitation. 
After removing the Streptavidin-HRP solution and washing, 100 µL of the TMB 
substrate were added to each well. The reaction was stopped after 5 min by addition of 
100 µL TMB Stop Solution per well and allowed to equilibrate for 5 min. The underside 
of the microplate was wiped with 70% ethanol and the plate was read immediately at 
450 nm with wavelength correction at 550 nm using a microplate reader.  
A linear standard curve was generated using the duplicate blanked readings from 
the serially diluted protein standard. Samples were interpolated into the standard curve 
to obtain concentration values. The dynamic range of the standard curve utilized in this 
assay is 1.56-100 ng/mL. The TMB incubation time was optimized to provide a reading 
of 1.5 absorbance units for the most concentrated standard.  
Specificity 
To test for non-specific signal, control wells containing either Blocking Buffer or 
human plasma rendered immunodeficient for vWF were incorporated into each assay. 
In other experiments, wells were also included where rabbit plasma samples were 
assayed in the absence of either the capture or sandwich antibody.  
Minimum Required Dilution 
Minimum Required Dilution (MRD) is identified when establishing parallelism and is 
defined as the minimum sample dilution providing optimal accuracy and precision9. 
Plasma from six cholesterol-fed rabbits was pooled, subjected to dilutions between 
1:6.25 and 1:200 and assayed in quadruplicate. Parallelism was defined as dilution-
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corrected analyte concentrations varying 20% between dilutions10. The minimum 
dilution achieving parallelism was chosen as the MRD. 
Spike Recovery 
Cholesterol-fed rabbit plasma was spiked with purified vWF at concentrations of 3.76 
ng/mL (Low Spike) and 10 ng/mL (High Spike). Plasma, spikes, and spiked plasma 
were each assayed in quadruplicate on the same plate. Recovery was calculated using 
vWF concentration values with the equation: [𝑆𝑎𝑚𝑝𝑙𝑒+𝑆𝑝𝑖𝑘𝑒]−[𝑆𝑎𝑚𝑝𝑙𝑒]
[𝑆𝑝𝑖𝑘𝑒]
× 100. Brackets denote 
a concentration value in ng/mL. Standard deviation (SD) was obtained from the two sets 
of duplicate values. The measured concentration of the spiked sample should be within 
20% of the expected value9.  
Precision 
Eight plasma samples from cholesterol-fed rabbits were selected. Each sample was 
diluted 1:100 in Blocking Buffer and 10 replicates were plated to determine intra-assay 
precision. This experiment was repeated over three different days with parallel aliquots 
to evaluate inter-assay precision. We previously assayed parallel aliquots of the 
samples for plasma total cholesterol (Table 2.4) using an enzymatic colorimetric kit 
(Wako Chemicals, Richmond, VA).  
Sensitivity 
Eighteen serial dilutions of purified vWF were prepared beginning with 400 ng/mL 
and assayed in quadruplicate, along with 24 replicates of the zero concentration buffer 
blank. A similar procedure was followed for rabbit plasma. Plasma from six cholesterol-
fed rabbits was pooled and subjected to serial dilutions from 1:6.25 to 1:102,000.  
Freeze-Thaw Stability of Samples 
Freeze-thaw stability was determined over three freeze-thaw cycles. Three rabbit 
plasma samples were selected. Separate aliquots of each sample were thawed 
between 1-3 times by removal from the -70ºC freezer and thawing on ice for 2 hours. 
They were then returned to the freezer and stored as before. All samples and aliquots 
were diluted 1:100 and assayed on the same plate, with 6 replicates per aliquot, along 
with 6 replicates of purified vWF at 100 ng/mL. Any significant changes in assay 
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response were determined using repeated-measures ANOVA followed by Bonferroni 
adjustment for multiple comparisons. 
Calculations and analysis 
Data are presented as means±SD. All standards and samples were run in duplicate 
unless otherwise noted. Data were analyzed using SigmaPlot 10.0 and PASW Statistics 
18.0 for Windows, and mean differences were considered statistically significant at the 
p<0.05 level.  
Results and Discussion 
ELISA is the most widely used method of screening mammalian plasma for vWF, 
replacing the Laurell techniques previously used11. Several publications have utilized 
the vWF marker specifically in rabbits. De Meyer and coworkers12 utilized 
immunohistochemistry to qualitatively observe deposition of vWF in the vascular intima. 
The group reported lack of an available measurement method for rabbit plasma vWF. 
An earlier publication by Benson et al.13 reported adaptation of an ELISA for 
measurement of plasma vWF in rabbit and other species, but neither demonstrated 
quantitative data for rabbits nor used commercially available antibodies. Benson et al. 
did, however, highlight the important ability to construct a vWF assay without species-
specific antibodies.  
Two subsequent publications attempted to quantify rabbit plasma vWF by sandwich 
ELISA. The first14 merely reported optical density values obtained in each assay, which 
is not useful to other researchers. It is commonly known that optical density values vary 
between assays due to many factors such as activity of the peroxidase conjugate, 
binding of antigen to antibodies, or temperature conditions, and thus it is critical to 
include a standard curve in each assay using purified analyte. A second publication15 
quantified rabbit plasma vWF, and found that the marker correlated well with 
development of atherosclerosis, but provided inadequate detail about the ELISA method 
utilized. Neither of these two assays was validated. Furthermore, cholesterol feeding 
elevates blood cholesterol to extremely high levels, a potential source of interference in 
an immunoassay. We developed and validated an ELISA to improve upon previous 
work. 
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An assay that appears precise but measures the wrong analyte would not be valid. 
We confirmed the specificity of the antibodies used by including positive (the purified 
vWF standard) and negative (vWF deficient plasma) controls. Antibodies demonstrated 
strong affinity for purified vWF. Omission of either the capture or sandwich antibody did 
not result in any signal above that of the buffer blank. Additionally, when vWF-deficient 
human plasma was assayed, no signal above blank was seen (data not shown). 
Parallelism and spike recovery are important considerations when working with 
complex matrices such as blood plasma16. Lipids and other interfering substances in 
plasma can lead to assay variation, but diluting the sample matrix helps minimize these 
effects. Assaying an undiluted sample can also underestimate the amount of analyte 
present, presumably due to saturation of the antibodies. We observed this in our results. 
When rabbit plasma was serially diluted beginning with a 1:6.25 dilution, the MRD was 
1:100 (Table 2.2). Dilution-corrected concentrations increased from 429 ng/mL in the 
1:6.25 dilution to 2440 ng/mL at the 1:100 MRD. Spike recovery analysis is also useful 
in assessing accuracy and sample matrix interference. Theoretically, an identical assay 
response should be seen for a given amount of vWF, whether it is present in plasma or 
purified and diluted in a buffer. In order to demonstrate this, plasma is spiked with vWF 
and the concentration determined. The observed (uncorrected for dilution) vWF 
concentration of the cholesterol-fed rabbit plasma was 16.2 ng/mL. When plasma was 
spiked with 3.76 ng/mL vWF, the measured concentration was 20.3 ng/mL, which 
represents a recovery of 108±2%. When plasma was spiked with 10 ng/mL vWF, the 
measured concentration was 25.5 ng/mL, which represents a recovery of 93±2% (Table 
2.3). 
Measurement reproducibility, or precision, is a crucial aspect of any bioanalytical 
method. Intra-assay precision is the variability between replicates of the same sample in 
an assay, and inter-assay precision is the variability over multiple days. CV was used as 
a measure of precision and defined as (Mean/Standard Deviation)*10017. 
Recommended CV for immunoassays is 20%16,18. Our average intra-assay CV of 3% 
is well within this guideline (Table 2.4). Measurement of the same 8 plasma samples on 
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three different days yielded an inter-assay CV=4% (Table 2.4). Thus, this assay 
provides precise and reproducible measurements of plasma vWF.  
These data also illustrate the excellent selectivity of the assay. Selectivity is 
commonly defined as the ability of the antibodies to bind consistent amounts of protein 
in the presence of other interfering agents, such as lipids and plasma matrix 
components. The antibodies bind both purified human vWF and rabbit vWF in plasma 
with equally high precision, despite potential interference from an average total 
cholesterol level of 935 mg/dL in the 8 rabbit plasma samples used (Table 2.4). It is 
recommended to establish and confirm selectivity of an immunoassay in disease 
states16, however this is rarely done. Our assay is effective in atherosclerotic, 
hyperlipidemic animals.  
Statistical measures used to evaluate assay sensitivity include Minimum Detectable 
Concentration (MDC) and Reliable Detection Limit (RDL). The MDC is the concentration 
at which there is a high probability of a response significantly lower than the blank. The 
RDL, conversely, is the lowest concentration of analyte that produces a response 
significantly greater than the blank19. A 4-parameter logistic regression curve was fit to 
the data20 and 95% Confidence Intervals (CIs) of the curve were calculated. Graphically, 
the MDC is the intersection of the 4-parameter logistic curve with an asymptote drawn 
horizontally from the upper 95% CI of the 4-PL curve at zero concentration. The RDL 
lies at the intersection of the lower 95% CI of the 4-PL curve of the standards data with 
an asymptote drawn horizontally from the upper 95% CI of the 4-PL curve at zero 
concentration. The MDC and RDL were 254 and 457 pg/mL for the vWF standard and 
1:10,700 and 1:5940 for rabbit plasma (Figure 2.2). This assay is versatile and could 
easily be adapted to assay protein levels in the single-digit picogram range simply by 
increasing the Streptavidin-HRP concentration. 
The sensitivity of an ELISA is largely dependent on the antibodies used. High 
sensitivity requires two well-paired antibodies. Theoretical support for the use of these 
antibodies in screening rabbit plasma is provided by previous work which demonstrated 
87% homology between human and rabbit vWF cDNA sequences, including 100% 
homology in the region corresponding to the first 116 amino acids of the N-terminal 
domain of the mature vWF subunit21. The aforementioned multispecies ELISA13 
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provided additional evidence of the high degree of homology of vWF molecules from 
many vertebrate species, and the resultant cross-reactivity of many anti-vWF 
antibodies.  
Protein stability over multiple thaw cycles is an important practical consideration 
when handling biological specimens. Freeze-thaw cycles commonly reduce protein 
stability, and our results suggest that vWF is degraded after multiple freeze-thaw cycles. 
Decreases reached statistical significance for most samples, with mean absorbances 7-
17% lower after three freeze-thaws (Table 2.5). Absorbance readings for Samples 2 
and 3 were significantly different between 1 and 3 freeze-thaw cycles (p<0.001). 
Absorbance readings for the vWF standard at 100 ng/mL were significantly decreased 
after 3 freeze-thaw cycles compared with 1 (p<0.01) and 2 (p<0.05) freeze-thaw cycles. 
Sample 2 showed a 7% decrease in mean absorbance after 3 freeze-thaws, Sample 3 a 
17% decrease, and the 100 ng/mL vWF standard a 9% decrease. While the decrease 
for Sample 1 was not statistically significant, the mean absorbance was 15% lower after 
3 freeze-thaw cycles. It is advisable to aliquot all specimens prior to freezing for the first 
time to avoid these complications. 
In conclusion, we have described an accurate, precise and sensitive method to 
analyze rabbit plasma for vWF that has been formally validated in accordance with 
current recommendations. To our knowledge, this is the only currently available 
validated ELISA for rabbit vWF and may prove useful in the ongoing search for suitable 
biomarkers of atherogenesis and endothelial damage. 
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Figures and Tables 
 
Figure 2.1. Schematic illustrating the sandwich ELISA procedure described in the 
Procedure subsection of Materials and Methods. 
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Figure 2.2. Sensitivity. (A), 18 serial dilutions of purified vWF were prepared beginning 
with 400 ng/mL and assayed in quadruplicate, along with 24 replicates of the zero 
concentration buffer blank. (B), Rabbit plasma was subjected to serial dilutions 
beginning at 1:6.25 and assayed in quadruplicate. 4-parameter logistic regression 
curves with 95% Confidence Intervals were fit to the data. Bars are SD. MDC, Minimum 
Detectable Concentration. RDL, Reliable Detection Limit. 
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Table 2.1. vWF antibody selection. Several antibodies were evaluated for effectiveness 
in detecting rabbit vWF. Some antibodies detected neither rabbit plasma vWF nor 
purified human vWF (the putative antigen) in this experimental setup. When the Abcam 
goat anti-human vWF antibody was used in the sandwich configuration, a donkey anti-
goat IgG antibody (Novus NB7357) was used as the detection reagent. When the 











6.25 429 2 - 
12.5 794 6 185 
25 1360 2 171 
50 2080 7 154 
100 2440 5 117 
200 2420 12 99 
Table 2.2. Minimum Required Dilution. Plasma from six cholesterol-fed 
rabbits was pooled, diluted starting at 1:6.25 and assayed in 
quadruplicate. The MRD is the first dilution to fall within 20% of the 
previous dilution’s concentration. 
 
Sample 
Observed Concentration,  
ng/mL 
Recovery, Mean±SD, % 
Rabbit Plasma 16.2  








Table 2.3. Spike Recovery. Rabbit plasma was spiked with purified 
human vWF at concentrations of 3.76 ng/mL (Low Spike) and 10 
ng/mL (High Spike). Plasma, spikes, and spiked plasma were each 
assayed in quadruplicate on the same plate. A concentration within 
20% of expected was considered acceptable recovery. 
  













Rabbit 1 1100 1730 42 3 2 
Rabbit 2 868 2430 66 4 3 
Rabbit 3 897 3240 153 3 5 
Rabbit 4 950 2290 153 3 7 
Rabbit 5 906 3280 127 2 4 
Rabbit 6 691 2600 68 2 3 
Rabbit 7 1000 2200 130 2 6 
Rabbit 8 1070 2720 77 4 3 
Average 935 2560 102 3 4 
Table 2.4. Precision. Eight plasma samples from cholesterol-fed rabbits were 
selected. Each sample was diluted 1:100 in Blocking Buffer and run with 10 
replicates. The experiment was repeated over three different days with parallel 
aliquots to determine inter-assay precision. Intra-assay CV and vWF values 











100 ng/mL standard 100 89     83** 
Rabbit 1 2350 77   59* 
Rabbit 2 3030 91 83 
Rabbit 3 1910 75   45* 
Table 2.5. Freeze-thaw stability of vWF in rabbit plasma. Aliquots of rabbit 
plasma and purified vWF were frozen and thawed between 1-3 times and 
assayed with six replicates on the same plate. Data were analyzed by 
repeated-measures ANOVA followed by Bonferroni adjustment for multiple 
comparisons.  *p<0.001 vs. 1 freeze-thaw cycle, **p<0.01 vs. 1 freeze-thaw 
cycle and p<0.05 vs. 2 freeze-thaw cycles. 
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CHAPTER 3: Contrast ultrasound imaging of the aorta alters vascular morphology 
and circulating von Willebrand Factor in hypercholesterolemic rabbits2 
Abstract 
Objective – Ultrasound contrast agents (UCAs) are intravenously infused 
microbubbles that add definition to ultrasonic images. UCAs continue to show clinical 
promise in cardiovascular imaging, but their biological effects are not known with 
confidence. We utilized a cholesterol-fed rabbit model to evaluate these effects when 
used in conjunction with ultrasound (US) to image the descending aorta.  
Methods – Male New Zealand White rabbits (n=41) were weaned onto an 
atherogenic diet containing 1% cholesterol, 10% fat and 0.11% magnesium. At 21 days, 
rabbits were exposed to contrast ultrasound at one of four pressure levels using either 
the UCA Definity® or saline control (n=5 per group). Blood samples were collected and 
analyzed for lipids and von Willebrand Factor (vWF), a marker of endothelial function. 
Animals were euthanized at 42 days and tissues were collected for histological analysis.  
Results – After adjustment for pre-exposure vWF, high-level US (in situ [at the aorta] 
peak rarefactional pressure of 1.4 or 2.1 MPa) resulted in significantly lower vWF one 
hour post-exposure (p=0.0127, padj < 0.0762). This difference disappeared within 24 
hours. Atheroma thickness in the descending aorta was lower in animals receiving UCA 
as compared to animals receiving saline.  
Conclusions – Contrast ultrasound affected the descending aorta as evidenced by 
two separate outcome measures. These results may be a first step in elucidating a 
previously unknown biological effect of UCAs. Further research is warranted to 
characterize the effects of this procedure. [Supported by NIH R37EB002641] 
 
  
                                            
2This chapter previously appeared in its entirety as Smith BW, Simpson DG, Sarwate S, Miller RJ, Blue 
JP, Jr., Haak A, O’Brien WD, Jr., Erdman JW, Jr. Contrast ultrasound imaging of the aorta alters vascular 
morphology and circulating von Willebrand Factor in hypercholesterolemic rabbits. Journal of Ultrasound 
in Medicine 31:711-720 (2012). Reprinted with permission from the American Institute of Ultrasound in 
Medicine. 
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Introduction 
Ultrasound contrast agents (UCAs) are microbubbles encapsulating inert gases that 
serve to enhance the echogenicity of blood for cardiovascular imaging applications1. 
The interaction of ultrasound (US) with circulating UCAs introduces the potential for 
unique biological effects. These bioeffects must be fully characterized and assessed 
before recommendations can be made regarding the appropriate uses of UCAs, and 
progress is urgently needed. The importance of medical imaging for early diagnosis is 
underscored by the fact that 2300 Americans die each day of cardiovascular disease 
(CVD) by current estimates2. 
Many in vitro and in vivo bioeffects of UCAs have been noted, including hemolysis3, 
capillary rupture4, endothelial cell damage5, and elevations in Troponin T, a biomarker 
of cardiac damage6. Previous studies in our lab have demonstrated UCA-induced 
arterial endothelial and vascular smooth muscle injury7 and cardiac arrhythmias8. These 
results suggest that the interactions of US with UCAs in the cardiovascular system may 
have important consequences, especially if exposure to contrast US hastens the onset 
or increases the severity of atherosclerosis in patients at risk. 
To this end, we utilized a cholesterol-fed rabbit model to evaluate the biological 
effects of the UCA Definity® when used in conjunction with US to image the descending 
aorta. In order to assess these bioeffects, we chose to focus on the biomarker von 
Willebrand Factor (vWF). vWF is a multimeric protein produced and stored within 
endothelial cells, and secreted both across the basolateral endothelial membrane into 
the vascular intima9 and across the apical membrane into the vessel lumen, where it 
circulates in the blood10. vWF has a physiological role in platelet plug formation during 
thrombosis11. In addition to its physiological function, elevated vWF is a biomarker of 
endothelial damage12 and clinical predictor of adverse cardiovascular events13. vWF is 
positively associated with risk for CVD and cardiac death in epidemiological studies14,15, 
and vWF has been shown to increase experimentally in hypercholesterolemic rabbits16. 
We hypothesized that plasma vWF would increase when rabbits consumed a 
cholesterol-containing diet, and that any further increase after US exposure would 
indicate endothelial damage due to the contrast US procedure.    
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Materials and Methods 
Animals and Experimental Design 
The experimental design is presented in Figure 3.1. After acclimation and 
consumption of a standard chow diet (2031 Teklad Global High Fiber Rabbit Diet, 
Harlan, Indianapolis, IN), male New Zealand White rabbits (n=41, Myrtle’s Rabbitry, 
Thompson’s Station, TN) were randomized to experimental groups and weaned onto an 
atherogenic diet (5TZB Test Diet®, Richmond, IN) containing 1% cholesterol, 10% fat 
and 0.11% magnesium over a 10-day period as previously described17. The diet was 
optimized to elevate serum cholesterol and initiate the atherosclerotic process while 
minimizing side effects such as jaundice and anorexia. Weight and age (±SD) of the 41 
rabbits at the beginning of the study (immediately prior to initiation of the atherogenic 
diet) were 3.3±0.2 kg and 21.8±1.0 wk. Rabbits were exposed to ultrasound with or 
without UCA at day 21 and euthanized at day 42. The Institutional Animal Care and Use 
Committee at the University of Illinois at Urbana-Champaign approved all procedures.  
Serial blood samples were collected from each rabbit at baseline (prior to initiation of 
the atherogenic diet), 2 weeks, 1 week, and 1 hour pre exposure, and 1 hour, 24 hours, 
48 hours, 1 week, 2 weeks and 3 weeks post exposure. Blood samples were collected 
with heparinized syringes into heparinized tubes via the lateral saphenous vein while 
under restraint, centrifuged at 1380 x g for 10 minutes, and the plasma was aliquotted 
and frozen at -70°C.  
Exposimetry 
On day 21, 20 of the rabbits were infused with saline only and 21 were infused with 
saline+UCA (0.5 mL of Definity® in 19.5 mL of saline). Infusion rate was 1 mL/min.  The 
ultrasound exposure conditions for all 41 rabbits were: 3.2 MHz, 2-min exposure 
duration at each of the 4 exposure sites, 10-Hz pulse repetition frequency, 1.6-μs pulse 
duration at four separate in situ [at the aorta] peak rarefactional pressures, pr(in situ): 0 
(sham), 0.72, 1.4 and 2.1 MPa. 
The exposimetry and calibration procedures have been described previously in 
detail18-23. Ultrasonic exposures were conducted using a focused f/3, 19-mm-diameter 
lithium niobate ultrasonic transducer (Valpey Fisher, Hopkinton, MA USA). Water-based 
(degassed, 22ºC) pulse-echo ultrasonic field distribution measurements were performed 
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according to established procedures22,24 and yielded a center frequency of 3.2 MHz, a 
fractional bandwidth of 11%, a focal length of 38 mm, a -6-dB focal beamwidth of 1.6 
mm, and a -6-dB depth of focus of 27 mm. 
An automated procedure, based on established standards25 was used to routinely 
calibrate the ultrasound fields22. Briefly, the source transducer’s drive voltage was 
supplied by a high-power pulse source (RAM5000, Ritec, Inc., Warwick, RI USA).  A 
calibrated PVDF membrane hydrophone (Marconi Model Y-34-6543, Chelmsford, UK) 
was mounted to the computer-controlled micropositioning system (Daedal, Inc., 
Harrisburg, PA USA). The hydrophone’s signal was digitized with an oscilloscope (500 
MS/s, LeCroy Model 9354TM, Chestnut Ridge, NY USA), the output of which was fed to 
the same computer (Dell Pentium II, Dell Corporation, Round Rock, TX USA) that 
controlled the positioning system. Off-line processing (MATLAB®, The Mathworks, 
Natick, MA USA) yielded the water-based peak rarefactional pressure pr(in vitro). The 
Mechanical Index (MI) was also determined from the measurement procedure25: the 
MI = pr.3/√fc where pr.3 is the derated (0.3 dB/cm-MHz) peak rarefactional pressure (in 
MPa) and fc is the center frequency (in MHz). The MI is reported because it is a 
regulated quantity26 of diagnostic US systems, and its value is available to system 
operators. Thus, there is value to provide the MI for each of our exposure settings in 
order to give general guidance to manufacturers and operators as to the levels we are 
using in this study. All four pr(in situ) levels were below the FDA upper limit for diagnostic 
US of MI=1.9 (see Table 3.1)26. 
Independent calibrations were performed at least weekly on the 3.2-MHz focused 
transducer during the 7-week duration of the US exposure component of the 
experiment. Relative standard deviation (
standard deviation
mean
) of pr(in vitro) was 1.6% (n = 10). 
The pulse duration was also measured19 at each calibration and its mean value (relative 
standard deviation) was 1.2 (0.6%) µs.  
The calibration procedures were performed in degassed water, which minimally 
attenuates the US signal. In contrast, when US is used to image tissues in a live animal, 
the signal is attenuated as it passes through intervening tissue en route to its focus. 
Thus, estimation of the actual in situ (at the aorta) peak rarefactional pressure, pr(in situ), 
requires that attenuation be taken into account. A study was conducted to estimate the 
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attenuation slope (AS, dB/cm-MHz) along the same in vivo tissue path as that of the 
single-element exposure path using the RF data from the Sonix RP (Ultrasonix Medical 
Corporation, Richmond, BC) with the reference phantom technique27. Three RF data 
sets were acquired at different locations and times. The first data set was acquired just 
before US exposure and UCA injection (Dataset I). Two minutes after injecting the UCA 
or saline the second data set was recorded (Dataset II). Then, a 1 cm section of the 
descending aorta near the renal artery was exposed at 4 sites, 2 above the bifurcation 
to the renal artery and 2 below, with 2 mm between exposure sites. At the location of 
the last US exposed site, a third data set was acquired (Dataset III). The in situ location 
of Dataset III was about 6 mm away from Datasets I and II. A reference dataset from a 
characterized physical phantom (AS = 0.67 dB/cm-MHz) was recorded using the same 
system settings. The AS was processed using the technique described by Yao et al.27 
and was then divided between saline-only and UCA rabbits to yield for the 3 
datasets/locations (mean ± standard deviation; dB/cm-MHz): ASSAI = 0.80±0.097 & 
ASUCAI = 0.86±0.16; ASSAII = 0.78±0.094 & ASUCAII = 0.86±0.16; ASSAIII = 0.78±0.079 & 
ASUCAIII = 0.85±0.24. Note the AS difference in Dataset I (saline-only vs. UCA; 0.080 vs. 
0.086) even though this data set was acquired under the same rabbit conditions, that is, 
prior to injection of either saline or UCA. Further note that AS for saline-only remains 
about the same for all 3 datasets (0.80, 0.78, 0.78) as does AS for UCA (0.86, 0.86, 
0.85). Overall AS means were 0.79±0.089 for saline-only and 0.85±0.18 for UCA, 
yielding the individual pr(in situ) values listed for each exposure condition in Table 3.1. For 
practical purposes by noting how close the individual ASs are between the saline-only 
and UCA rabbits (relative to their individual standard deviations), an overall AS value of 
0.82±0.15 dB/cm-MHz was used to estimate pr(in situ) at 3.2 MHz for a propagation 
distance of 4 cm, the pr(in situ). Therefore, the results reported and analyzed herein are 
the pr(in situ) values relative to the overall AS value of 0.82 dB/cm-MHz (Table 3.1). 
Histology  
All rabbits were anesthetized with ketamine hydrochloride and xylazine and then 
euthanized with CO2. The rabbit was placed in dorsal recumbency and a ventral midline 
incision made to expose the abdominal and thoracic cavities. The ribs were cut along 
the left lateral aspect of the sternum and manually spread open to allow visualization of 
  92 
the heart. A hemostat was clamped at the origin of the descending aorta. All tissues 
cranial to this site required to free the aorta were transected with scissors. The aorta, 
with heart attached, was slowly and carefully removed to the bifurcation of the aorta into 
common iliac arteries. Precautions were taken to gently remove the aorta in order to 
keep the endothelium intact. Surrounding fat was carefully removed and the aorta was 
opened along one lateral aspect adjacent to the renal artery bifurcation. The liver was 
removed en masse and weighed. A small section of the liver was immediately frozen at 
-20°C for analysis of lipid content. Two sections of the aorta (the entire arch and a 2 cm 
section surrounding the renal artery at the site of US exposure) and a representative 
section of the left liver lobe were then placed in 10% formalin for 24-72 hrs. for 
subsequent pathological evaluation.  
After formalin fixation, sections of each tissue were trimmed off, placed in 
embedding cassettes, and subsequently processed, embedded in paraffin and cut to 3-
µm thickness. Sections were stained with hematoxylin and eosin. The aortic arch was 
cut transversely into 3-4 sections and placed in one cassette. The 2 cm section of the 
aorta (1 cm on either side of the renal artery) was cut longitudinally in 3 sections. Three 
edges were painted with tissue ink for orientation purposes and placed in one cassette. 
The representative section of the liver (including the central hepatic vein) was trimmed 
down to 1 x 1 cm and placed in one cassette. One microscope slide was created from 
each cassette, resulting in 3 microscope slides per animal.  
An atherosclerosis score was defined between 0 and 5 using the American Heart 
Association classification scheme for human atherosclerotic lesions28. Score 0 = 
Absence of atherosclerosis; Score 1 = Presence of isolated foam cells; Score 2 = Lipid 
accumulation mainly within the foam cells; Score 3 = Lipid accumulation within the foam 
cells and small pools of extracellular lipid; Score 4 = Intracellular lipid, lipid pools and 
core of extracellular lipid; and Score 5 = Lipid core and fibrotic layer, or multiple lipid 
cores and fibrotic layer, or mainly calcified or fibrotic plaque. The atheroma thickness 
was measured using an ocular micrometer (Olympus America Inc., Center Valley, PA). 
The condition of the vascular endothelium was also assessed and categorized as 
mostly, partially or minimally intact. The pathologist (author SS) assigned an 
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atherosclerosis score, measured the atheroma thickness and evaluated the 
endothelium for each tissue sample while blinded to exposure conditions.  
Plasma von Willebrand Factor 
Measurement of vWF was performed as previously described29 with some 
modifications. Briefly, a mouse anti-human monoclonal antibody to the N-terminal 
trypsin and plasmin sensitive region of vWF (Abcam, Cambridge, MA) was diluted in 
carbonate buffer (pH 9.6), and 96-well microtiter plates were coated with 100 μL per 
well overnight at 4ºC. The next day, the coating solution was emptied and the plate was 
washed three times with 0.5% Tween-20 in phosphate-buffered saline (PBS). Wells 
were then blocked with 0.2% bovine serum albumin (BSA) in PBS for 2 hours on an 
orbital shaker. After removing the block solution and washing, a vWF standard from 
human plasma (Calbiochem, La Jolla, CA) was serially diluted and added to the plate. 
Rabbit plasma samples were diluted 1:100 in 0.05% BSA in PBS. The standard and all 
samples were plated in duplicate and incubated for 2 hours on an orbital shaker. The 
plate was emptied and washed again, after which a goat anti-human vWF polyclonal 
antibody (Abcam, Cambridge, MA) diluted in 0.05% BSA in PBS was added as the 
sandwich antibody for 1 hour. After emptying and washing the plate, a donkey anti-goat 
horseradish peroxidase-conjugated polyclonal antibody was diluted in 0.05% BSA in 
PBS and added to the plate for 1 hour. The chromogenic substrate o-phenylenediamine 
dihydrochloride (OPD) was combined with 0.05 M phosphate-citrate buffer (pH 5.0) and 
30% H2O2. After washing, 100 μL of the OPD solution was added to the plate for 30 
minutes. The reaction was stopped by addition of 0.5 N H2SO4 and the plate was read 
at 490 nm. A linear standard curve was generated using the duplicate blanked readings 
from the serially diluted protein standard. Sample readings were interpolated into the 
standard curve to obtain concentration values. Average intra- and inter-assay 
coefficients of variation (CV) for rabbit plasma samples were 2.9% and 18.7%. Inter-
assay precision was determined by incorporating a control rabbit plasma in each assay. 
This control was a large amount of plasma obtained in a single blood draw from an 
animal on chow diet, and was separated into many aliquots to validate inter-assay 
precision. 
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Plasma and Liver Lipids 
Plasma low-density lipoprotein (LDL), high-density lipoprotein (HDL) and total 
cholesterol were analyzed using enzymatic colorimetric kits (Wako Chemicals, 
Richmond, VA). Human control sera (Wako) were included in each assay for quality 
control. Average intra-assay CV of control sera in each assay were 12% for the LDL 
assay, 4.0% for HDL and 4.7% for total cholesterol. Average intra-assay CV for rabbit 
plasma samples were 14% for the LDL assay, 4.0% for HDL and 5.1% for total 
cholesterol.  
Liver lipids were extracted using a modification of the Folch method30. A 0.5 g 
section of liver was placed in a 1:1 mixture of chloroform and methanol, homogenized 
and gravity filtered. The filtrate was immersed in 0.29% NaCl solution, vortexed briefly 
and centrifuged. The supernatant was then discarded and the remainder was washed 
with 0.29% NaCl, transferred to a weighed test tube, evaporated, placed in a desiccator 
for ≥48 hrs., and weighed to determine total lipids.  
Statistical Analysis 
Effects of UCA and pr(in situ) on vWF expression were evaluated via analysis of 
covariance31 for each of the post-exposure time points, with covariate adjustment for the 
vWF level 1 hour prior to exposure.  UCA was encoded as 0=“saline only” or 1=“saline + 
Definity®”. The differences among the four levels of ultrasound were encoded as 
variables US1, US2 and US3 according to the orthogonal contrast matrix in Table 3.2. 
US1 is the contrast between  -1=low (pr(in situ) of 0 or 0.72 MPa) and 1=high (pr(in situ) of 1.4 
or 2.1 MPa) acoustic pressures, US2 is the contrast between 0 and 0.72 MPa, and US3 
is the contrast between 1.4 and 2.1 MPa acoustic pressure. The ANOCOVA model for 
time point t was of the form: 
 
  vWFt = b0t + b1t*UCA + b2t*US1 + b3t*US2 + b4t*US3 + b5t*vWFpre + noise 
 
with the above encoding, where vWFt is the vWF level at time t, vWFpre is the pre-
exposure level, b0t is the regression coefficient for the intercept for time point t, b1t is the  
coefficient for ultrasound contrast agent (UCA) at time t, b2t – b4t are the coefficients for 
US1, US2 and US3, respectively, at time t, and b5t is the coefficient for the effect at time t 
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of the pre-exposure level of vWF.  The model was run for time points t = 1 hr, 24 hrs, 48 
hrs, 7 days, 14 days, and 21 days post-exposure. For each of the 6 time points the 
coefficients were estimated by least squares multiple linear regression. The statistical 
computations were performed using R32. A conservative Bonferroni adjustment was 
employed to account for repeated effect testing across six time points. 
Results 
Plasma cholesterol levels began very low and increased rapidly after rabbits began 
consuming the cholesterol diet (Figure 3.2). At baseline, total cholesterol averaged 39 
mg/dL, with approximately 27 mg/dL in LDL and 12 mg/dL in HDL. After consuming the 
cholesterol diet for 3 weeks, total cholesterol averaged 995 mg/dL, with 537 mg/dL in 
LDL and 15 mg/dL in HDL. Liver lipids for all rabbits averaged 137±32 mg lipid/g liver 
(mean±SD).  
High-level US (1.4 or 2.1 MPa) resulted in significantly lower vWF one hour post-
exposure (p=0.0127) than low-level US (0 or 0.72 MPa) (Figure 3.3). Conservative 
Bonferroni adjustment for multiple time points gives an upper bound of padj< 0.0762 for 
the overall significance of this difference. The other two US variables (contrasts 
between 0 and 0.72 MPa, and between 1.4 and 2.1 MPa) were not significant (p>0.1), 
thus supporting a reduction in the model for ultrasound effects to the contrast between 
low and high levels. Figure 3.4 demonstrates the correlation between vWF levels one 
hour post exposure and one hour before exposure for low and high levels of ultrasound. 
The superimposed lines are the least squares lines for low and high levels of 
ultrasound, obtained from the fitted analysis of covariance model. The difference 
between the superimposed lines shows the US effect at one hour post-exposure. This 
difference disappeared within 24 hours. UCA was not a statistically significant factor in 
this analysis.  
Animals receiving the Definity® UCA displayed lower atheroma thickness in the 
descending aorta as compared to animals receiving saline at the same ultrasound 
pressure level (Figure 3.5). The average atheroma thickness (mean±SEM) was 46±9 
μm for Saline at 0 MPa, 55±16 μm for Definity® at 0 MPa, 86±16 μm for Saline at 0.72 
MPa, 48±13 μm for Definity® at 0.72 MPa, 98±37 μm for Saline at 1.4 MPa, 45±18 μm 
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for Definity® at 1.4 MPa, 104±31 μm for Saline at 2.1 MPa, and 62±18 μm for Definity® 
at 2.1 MPa. 
Atherosclerosis scores were assigned by a pathologist blinded to the exposure 
conditions and are represented in Figure 3.5. The average atherosclerosis scores 
(mean±SEM) were 2.8±0.20 for Saline at 0 MPa, 2.6±0.40 for Definity® at 0 MPa, 
2.4±0.25 for Saline at 0.72 MPa, 2.2±0.37 for Definity® at 0.72 MPa, 3.0±0.55 for Saline 
at 1.4 MPa, 2.2±0.37 for Definity® at 1.4 MPa, 2.6±0.40 for Saline at 2.1 MPa, and 
2.5±0.37 for Definity® at 2.1 MPa. Evaluation of the vascular endothelium is presented 
in Table 3.3. 
Histological evaluation of tissues excised from the rabbits at 42 days revealed 
profound diet-induced atherosclerotic changes. Analysis of the abdominal aorta 
revealed atherosclerotic damage including atheroma, extracellular lipids, foam cells, 
calcification and vacuolar changes. Of the 41 animals on the study, atheroma was noted 
in all animals, extracellular lipids in 24 animals, foam cells were noted in all 41 animals, 
calcification in 1 animal and vacuolar changes in 6 animals. Analysis of the aortic arch 
revealed similar findings. Atheroma was noted in all 41 animals, extracellular lipids in 35 
animals, foam cells in all animals, calcification in 7 animals and fibrosis in 5 animals.  
Damage to the liver included steatosis of hepatocytes in 40 animals, steatosis of Kupffer 
cells in 39 animals, steatohepatitis in 3 animals, and autolysis in 2 animals.  
Discussion 
Ultrasound has developed into an extremely versatile imaging modality both 
experimentally and diagnostically.  As with any diagnostic technology, the balance of its 
risks and benefits must be weighed before a decision can be made regarding its safe 
use. While UCAs are valuable diagnostically, concerns have been raised regarding their 
safety. In addition to the numerous bioeffects observed experimentally, the FDA issued 
an advisory in 2007 indicating that cardiopulmonary complications and death have been 
observed in patients soon after the administration of some approved UCAs, including 
Definity®1. The further development and use of UCAs is pending additional in vivo data 
regarding their safety. 
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Our objective was to determine if the interaction of US with UCAs in the vasculature 
impacts the onset or severity of atherosclerosis. In this study, we undertook a risk-
based assessment of US bioeffects in a cholesterol-fed rabbit model. Plasma 
cholesterol levels increased dramatically (Figure 3.2), rising above 1500 mg/dL in some 
animals. Elevated plasma cholesterol is a substantial stress on the vascular system, 
and we assayed for vWF to determine the extent of this stress. The vWF biomarker 
could also potentially provide information about any additional stress of the US+UCA 
interaction on the vascular system. As we expected, vWF increased as a result of the 
vascular stress induced by the atherogenic diet and elevated cholesterol.  
However, we also observed a decrease in plasma vWF after US exposure in 
animals exposed to 1.4 or 2.1 MPa US as compared to those exposed to 0 or 0.72 
MPa, after adjustment for pre-exposure vWF levels (Figure 3.3). The decrease was 
observed when blood was drawn after exposure, although the pre- and post-exposure 
time points were less than two hours apart. This raised questions about any potential 
effect of ultrasound exposure on plasma vWF. After 24 hours, vWF returned to levels 
primarily determined by consumption of the atherogenic diet and continued a gradual 
decrease until the completion of the study, possibly due to progressive endothelial 
dysfunction33.  
Interestingly, both decreased vWF and lower atheroma thickness were observed in 
the US+UCA groups. These results suggest an impact of US+UCA on vascular integrity. 
There is a substantial body of literature documenting the potential of US to damage 
tissue, including US-induced lesions and hemorrhage in lung tissue34 observed in our 
lab. In the experiments described here, we may be seeing US-induced damage to the 
aorta, including the intima and endothelial monolayer. If that is so, some of the 
circulating vWF may be recruited to the site of damage in accordance with its coagulant 
role11 to form a platelet plug before the vessel is re-endothelialized. It is unknown how 
plasma vWF levels change after such an event, preventing us from determining if the 
decrease represents an injury due to US+UCA exposure.  
The post-exposure decrease in vWF is probably not due to reduced secretion by 
endothelial cells. Clearance time of unused plasma vWF in rabbits is 240 min35, so a 
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decrease in vWF would probably not reflect reduced secretion during the time frame of 
US exposure.  
Animals receiving UCA also displayed lower atheroma thickness in the descending 
aorta as compared to animals receiving saline only at three weeks post exposure. 
These results may suggest that at the time of US exposure the rabbits receiving UCA 
experienced disruption of atheromas located at the site of exposure, while the saline-
only groups did not experience this. Thus, the artery walls in the UCA groups would 
represent only 3 weeks growth and repair following US+UCA exposure whereas the 
saline-only groups represent continual thickening throughout the study. The intima is the 
main driver of atheroma thickness36, so US would presumably have affected the 
vascular intima.  
We cannot rule out the possibility that less atheroma could simply be an artifact of 
tissue processing by the investigators or histotechnologist. However, tissue processing 
and histological evaluation were blinded and any changes in tissue morphology due to 
processing would not account for the results observed selectively in the US+UCA 
groups. We did not observe consistent long-term changes in the vascular endothelium 
across treatment groups upon pathological evaluation of the vascular endothelium at 42 
days, but any damage to the endothelium would presumably have been repaired by 
then37. Ultrasonic disruption of an atheroma could potentially lead to thrombosis and 
myocardial infarction, and our results could be a first step in uncovering a previously 
unknown bioeffect of UCAs. We should also consider the alternative possibility that this 
is a beneficial effect. The exposure-response relationship for the US+saline animals 
shown in Figure 3.5 could infer that US promotes deposition of atherogenic materials 
and consequent plaque growth, but coadministration of UCA protects against this effect. 
Atheroma thickness for 0 MPa US was very similar among animals receiving UCA or 
saline only, but the groups displayed a diverging trend upon introduction of US. Other 
beneficial therapeutic uses of UCAs have been explored, including thrombolysis in 
myocardial infarction38 and gene or drug delivery39. Our findings may lead to additional 
exploration of the beneficial effects of UCAs in diagnostic and therapeutic applications. 
While our results are preliminary, they highlight the need for further research 
investigating US-UCA interactions in vivo. 
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Cholesterol, liver lipid levels and histology underscore the impact of the atherogenic 
diet. The rabbit is a representative model of commonly identified changes in human 
atherosclerotic arteries. We were able to use a human classification scheme to evaluate 
the pathology of atherosclerotic lesions in the rabbits, providing further justification for 
the model. We thus chose the rabbit as a straightforward and representative model for 
these experiments. We decided that all of the rabbits would be on only the atherogenic 
diet, allowing for an exposure-dependent effect if present, but with the largest possible 
number of animals per group. 
In conclusion, we have described a risk-based assessment of contrast US bioeffects 
in a cholesterol-fed rabbit model. The contrast US procedure affected the vasculature 
as reflected by transient changes in plasma vWF and long-term differences in atheroma 
thickness. Future research is warranted to fully characterize the effects of this 
procedure, with the long-term goal of defining the specific conditions at which this 
procedure is safe for routine clinical use. 
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Figures and Tables 
 
Figure 3.1. Study design with 41 four-month-old male New Zealand White rabbits. 
Rabbits (n=5-6 randomly assigned per group) were gradually introduced to an 
atherogenic diet consisting of 1% cholesterol, 10% fat, 0.11% Mg over 10 days and 
continued to consume the diet for 11 more days. On day 21, rabbits underwent the 
contrast US procedure using either the UCA Definity® in saline vehicle or saline alone at 
4 different US pressure levels. Rabbits were euthanized at 42 days and tissues were 
collected for histology. US, ultrasound; UCA, ultrasound contrast agent. 
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Figure 3.2. Time course plot for plasma cholesterol. Plasma LDL, HDL and total 
cholesterol were analyzed using enzymatic colorimetric kits (Wako Chemicals, 
Richmond, VA). Human control sera (Wako) were included in each assay for quality 
control. Serial blood samples were collected from each rabbit at the timepoints 
indicated. “21 pre” and “21 post” denote 1 hour pre and post exposure, respectively. 
Bars are SEM, n=4-41 per timepoint.  
 
Figure 3.3. Time course plots for plasma von Willebrand Factor (vWF) over the course 
of the entire study (A) and near exposure time (B, enlargement of the boxed area in 
graph A and displaying a linear time course on the x-axis). vWF was assayed using a 
sandwich ELISA procedure. Serial blood samples were collected from each rabbit at the 
timepoints indicated. “Low” US indicates ultrasound exposure at 0 or 0.72 MPa, “High” 
US indicates 1.4 or 2.1 MPa. These pressure levels were combined for the purposes of 
statistical analysis. *significantly different from high US (p=0.0127, padj < 0.0762). Bars 
are SEM, n=10-11 per group. US, ultrasound; UCA, ultrasound contrast agent.  
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Figure 3.4. Scatter plot of vWF levels one hour post exposure versus one hour pre-
exposure for low and high levels of ultrasound exposure with fitted ANOCOVA lines for 
each group. The difference between the superimposed lines is the US effect at one hour 
post exposure. 
Figure 3.5. Atherosclerosis score and atheroma thickness as a function of the in situ 
peak rarefactional pressure amplitude (PRPA). A 2 cm section of the abdominal aorta 
was excised from the area surrounding the renal artery and placed in 10% formalin for 
24-72 hr. An atherosclerosis score was defined between 0 and 5 using the American 
Heart Association classification scheme for human atherosclerotic lesions. Score 0 = 
Absence of atherosclerosis; Score 1 = Presence of isolated foam cells; Score 2 = Lipid 
accumulation mainly within the foam cells; Score 3 = Lipid accumulation within the foam 
cells and small pools of extracellular lipid; Score 4 = Intracellular lipid, lipid pools and 
core of extracellular lipid; and Score 5 = Lipid core and fibrotic layer, or multiple lipid 
cores and fibrotic layer, or mainly calcific or mainly fibrotic. The pathologist assigned an 
atherosclerosis score and measured the atheroma thickness for each tissue sample 
while blinded to exposure conditions. Animals are grouped based on US exposure level 
and UCA. Bars are SEM, n=5-6 per group. US, ultrasound; UCA, ultrasound contrast 
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Rabbit Group pr(in vitro) (MPa) AS (dB/cm-MHz) pr(in situ) (MPa) MI 
Saline-only 0 0.79±0.089 0  
Saline-only 2.4 0.79±0.089 0.75±0.092  
Saline-only 4.7 0.79±0.089 1.5±0.18  
Saline-only 7.1 0.79±0.089 2.2±0.27  
UCA 0 0.85±0.18 0  
UCA 2.4 0.85±0.18 0.69±0.16  
UCA 4.7 0.85±0.18 1.3±0.31  
UCA 7.1 0.85±0.18 2.0±0.47  
Overall 0 0.82±0.15 0 0 
Overall 2.4 0.82±0.15 0.72±0.14 0.64±0.011 
Overall 4.7 0.82±0.15 1.4±0.28 1.3±0.041 
Overall 7.1 0.82±0.15 2.1±0.42 1.8±0.060 
Table 3.1. Ultrasound exposimetry for the four exposure groups. 
 
pr(in situ) (MPa) Ultrasound Encoding Variable 
 US1 US2 US3 
0 -1 -1 0 
0.72 -1 1 0 
1.4 1 0 -1 
2.1 1 0 1 
 
Table 3.2. Orthogonal contrast matrix for encoding four levels of ultrasound acoustic 
pressure in the analysis of covariance model.  
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CHAPTER 4: Contrast ultrasound imaging does not affect Hsp70 expression in 
cholesterol-fed rabbit aorta 
Abstract 
Objective – Diagnostic ultrasound imaging is enhanced by the use of circulating 
microbubble contrast agents (UCAs), but the interactions between ultrasound, UCAs, 
and vascular tissue are not fully understood. We hypothesized that ultrasound with UCA 
would stress the vascular tissue and increase levels of Hsp70, a cellular stress protein.  
Methods – Male New Zealand White rabbits (n=32) were fed a standard chow diet 
(n=4) or a 1% cholesterol, 10% fat and 0.11% magnesium diet (n=28). At 21 days, 24 
rabbits on cholesterol diet were either exposed to ultrasound (3.2 MHz f/3 transducer, 
2.1 MPa, Mechanical Index=1.17, 10 Hz pulse repetition frequency, 1.6 µs pulse 
duration, 2 min exposure duration at 4 sites along the aorta) with the UCA Definity® (1x 
concentration, 1 mL/min) or sham exposed with a saline vehicle injection (n=12 per 
group). Four rabbits on cholesterol diet and four on chow diet served as cage controls, 
and were not exposed to ultrasound or restrained for blood sample collection. Animals 
were euthanized 24 hours after exposure and aortas quickly isolated and frozen in liquid 
nitrogen. Aorta lysates from the area of ultrasound exposure were analyzed for Hsp70 
protein level by Western blot. Blood plasma was analyzed for cholesterol, Hsp70, and 
von Willebrand Factor (vWF), a marker of endothelial function.  
Results – Plasma total cholesterol levels increased to an average of 705 mg/dL. 
Ultrasound did not affect plasma vWF, plasma Hsp70, or aorta Hsp70. Restraint 
increased Hsp70 (p<0.001 by ANOVA). 
Conclusions – Restraint, but not ultrasound with UCA or cholesterol feeding, 
significantly increased Hsp70. 
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Introduction 
Cardiovascular disease (CVD) remains the leading cause of death in the United 
States and worldwide1. Atherosclerosis, the deposition and development of lipid-rich 
arterial plaques, is the pathogenic process underlying most cardiovascular events2,3. 
Evidence suggests atherosclerosis is reversible in its early stages4, but it develops 
asymptomatically, and is frequently undetected until it results in heart attacks and 
strokes. Early detection is thus a critical frontier in reducing deaths from CVD. 
Ultrasound imaging is a flexible, inexpensive, widely used, and real-time imaging 
modality that can be used for early detection and diagnosis of CVD5-8. Diagnostic 
ultrasound imaging is improved by the use of microbubble ultrasound contrast agents 
(UCAs), which are injected intravenously prior to imaging. The interaction of ultrasound 
with UCAs in the circulation causes them to oscillate or collapse, and aids in delineation 
of tissue. In some cardiac imaging situations, ultrasound alone is unable to provide a 
clear image, but the addition of UCAs can improve images to diagnostic quality9.  
Although the clinical benefits of UCAs are established, the effects of the ultrasound-
UCA interaction on cardiac and arterial tissue are not well understood. Contrast 
ultrasound imaging of the cardiovascular system is not typically performed in 
asymptomatic patients without risk factors. Rather, most patients will have some degree 
of pathology present10. Rabbits were fed a cholesterol diet to reflect this scenario, 
increasing the translational relevance of the model. We performed contrast ultrasound 
imaging of the aorta in cholesterol-fed rabbits, and hypothesized that the interaction of 
ultrasound with UCAs in the blood would stress the vascular tissue and increase levels 
of Heat shock protein 70 (Hsp70), a cellular stress protein. 
Materials and Methods 
Animals and Experimental Design 
The University of Illinois Institutional Animal Care and Use Committee approved all 
live animal procedures. Twenty-eight male NZW rabbits (Myrtle’s Rabbitry, Thompson’s 
Station, TN; and Covance, Princeton, NJ) consumed a 1% cholesterol, 10% fat, 0.11% 
magnesium diet (5TZB; TestDiet, Richmond, IN) for three weeks as previously 
described11 (Figure 4.1). An additional 4 rabbits consumed a chow diet (2031 Global 
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High Fiber Rabbit Diet; Harlan Teklad, Madison, WI), throughout the study. Animals 
were provided 140 g/day of feed. After three weeks, 24 animals on cholesterol diet were 
randomized to receive either an ultrasound exposure at 2.1 MPa with the UCA Definity® 
(n=12) or a sham exposure with the saline UCA vehicle (n=12). Blood samples were 
obtained from the lateral saphenous vein weekly, as well as 1 hour prior to, 1 hour after, 
and 24 hours after ultrasound exposure. Animals were then euthanized 24 hours after 
ultrasound exposure to allow adequate time for induction of Hsp7012,13. Aorta tissue 
from the site of ultrasound exposure (5 mm length, 10-20 mg) was rapidly isolated, 
rinsed with cold PBS to remove blood, frozen in liquid nitrogen, and stored at -50ºC.  
Exposimetry 
The ultrasound procedures have been previously described in significant detail using 
a calibrated polyvinylidene fluoride (PVDF) membrane hydrophone (Y-34–3598 
EW295, GEC Marconi, Chelmsford, UK) with a 0.5-mm-diameter active element 
11,14. Ultrasound exposures were performed using a 3.2-MHz f/3, 19-mm-diameter 
lithium-niobate single-element transducer with intravenous infusion of Definity® UCA 
(2.6% Definity® in saline, 1 mL/min, 15-20 min total infusion time). A separate 
ultrasound system was used to guide and position the single-element transducer for 
exposures (Ultrasonix Medical Corporation, Richmond, British Columbia, Canada). The 
transducer was regularly calibrated in degassed water. To account for in vivo 
attenuation of the ultrasound signal, we also calculated the attenuation slope and in situ 
derated peak rarefactional pressure amplitude using the radio frequency dataset. The in 
situ peak rarefactional pressure amplitude in this study was 2.1 MPa, corresponding to 
a Mechanical Index of 1.17, with 10 Hz pulse repetition frequency, 1.6 µs pulse 
duration, and 2 minute exposure duration at each of 4 sites along the abdominal aorta 
(exposure 1, 2 mm cranial to the cranial edge of renal artery; exposure 2, 2 mm caudal 
to exposure 1; exposure 3, 2 mm caudal to exposure 2; exposure 4, 2 mm caudal to 
exposure 3).  
Western Blotting 
Aorta tissue was homogenized in 4ºC Radioimmunoprecipitation Assay (RIPA) 
buffer with protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) using a glass tissue 
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grinder (Pyrex; Corning, Tewksbury, MA) followed by a handheld motorized 
homogenizer (Polytron PT1200E; Kinematica Inc., Bohemia, NY). Lysates were kept on 
ice with agitation for 30 min, centrifuged for 10 min at 10,000 x g and 4ºC, aliquotted, 
and frozen at -50ºC. Protein concentrations were determined in triplicate with a Bradford 
assay (Bio-Rad, Hercules, CA). Lysates were then diluted 1:1 in Laemmli sample buffer 
with 5% β-mercaptoethanol (Bio-Rad), heated at 95ºC for 5 minutes, and centrifuged at 
3000 x g for 1 minute. Equal amounts of total protein (20 μg per sample) were loaded 
onto 10% Tris-Glycine gels (Mini-Protean TGX; Bio-Rad), and electrophoresis was 
performed for 35 minutes at 200 V (Mini-Protean Tetra Cell with PowerPac HC power 
supply; Bio-Rad). Proteins were then transferred onto nitrocellulose membranes with a 
semi-dry transfer cell (Bio-Rad) for 30 minutes at 15 V. Total protein transfer was 
verified by staining with 0.1% Ponceau S (Sigma-Aldrich) for 5 min, and the stain was 
then removed by washing membranes in 0.1 M NaOH for 30 seconds, followed by a 
brief rinse in deionized water. Western blotting was performed with the Fast Western kit 
(Pierce Biotechnology, Rockford, IL) according to the manufacturer’s instructions, using 
a mouse monoclonal anti-Hsp70 antibody (clone C92F3A-5; Enzo Life Sciences Inc., 
Farmingdale, NY) with mouse monoclonal anti-β-actin (clone AC-15; Novus Biologicals, 
Littleton, CO) as a loading control. Purified Hsp70 and Hsc70 (Enzo) were included as 
positive and negative controls, respectively. Membranes were imaged using a 
ChemiDoc XRS system with Quantity One software (Bio-Rad). Data are expressed as 
density of the Hsp70 band divided by density of the β-actin band after local background 
subtraction.  
Blood Analysis 
Plasma total cholesterol, LDL, HDL, and triglyceride levels were determined in 
triplicate using enzymatic colorimetric kits (Wako Chemicals, Richmond, VA) with 
human control sera (Wako) included in each assay to evaluate precision. Coefficient of 
Variation (CV) was used as a measure of precision. The intra-assay CVs for control 
sera were 5.0% for total cholesterol, 8.1% for LDL, 5.3% for HDL, and 6.6% for 
triglycerides. The inter-assay CVs for control sera were 8.2% for total cholesterol, 8.0% 
for LDL, 23% for HDL, and 16% for triglycerides. The intra-assay CVs for rabbit plasma 
samples were 4.1% for total cholesterol, 5.7% for LDL, 3.7% for HDL, and 4.5% for 
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triglycerides. Measurement of plasma vWF was performed by ELISA as previously 
described15. The intra-assay CV for rabbit plasma vWF was 2.3%. Plasma Hsp70 was 
measured in duplicate by ELISA (Enzo) according to the manufacturer’s instructions. 
Average intra-assay CV for the Hsp70 ELISA was 2.7%, and average inter-assay CV 
was 42%. 
Statistical Analysis 
Feed intakes, body weights, blood cholesterol, and Hsp70 data were evaluated with 
an analysis of variance (ANOVA) or analysis of covariance (ANOCOVA) approach in 
the general linear mixed models procedure of SAS 9.3 as previously described16. 
Plasma and aorta Hsp70 were also evaluated for correlation using simple linear 
regression in SAS. vWF data were analyzed in R as previously described11. Repeated 
measures analyses incorporated baseline values as a covariate random effect when the 
term contributed significantly to the statistical model. Datasets that did not meet the 
assumption of normality (Shapiro-Wilk W>0.9 or Spearman rank-order correlation 
p<0.05) were log-transformed. Bonferroni adjustments for multiple comparisons were 
made when necessary, and statistical significance was declared at p<0.05.  
Results 
Feed intake and body weights 
Chow-fed animals consumed all 140 g/day they were provided throughout the study. 
Feed intake decreased significantly over time in cholesterol diet groups. By week 3, 
feed intake decreased significantly in cholesterol-fed animals to 88 g/day compared with 
140 g/day for those fed chow (p<0.05). Body weights averaged 3.0 kg at baseline and 
3.3 kg after 3 weeks, and did not differ among diet groups (p=0.16, adjusted for baseline 
body weight). Ultrasound did not affect feed intake (p=0.35) or body weight (p=0.97). 
Contrast ultrasound does not affect circulating cholesterol or vWF 
Plasma total cholesterol initially averaged 25 mg/dL and quickly escalated after 
introduction of the cholesterol diet, reaching an average of 705 mg/dL by the end of the 
study (p<0.0001, Figure 4.2a). No difference in plasma cholesterol levels was observed 
between animals receiving ultrasound with contrast agent and animals receiving the 
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sham treatment (p=0.57). Plasma LDL increased in parallel with total cholesterol, 
reaching 468 mg/dL after 3 weeks. LDL decreased after the experimental procedure at 
3 weeks in both sham and ultrasound-exposed animals (p<0.001), and returned to pre-
treatment levels 24 hours later. HDL levels remained unchanged throughout the study, 
and averaged 41 mg/dL. Plasma triglyceride levels increased from 37.2 mg/dL to 130 
mg/dL after consumption of the cholesterol diet (p<0.0001), but were not altered by the 
ultrasound procedure. Plasma vWF levels also increased from 166 mg/dL to 2840 
mg/dL during cholesterol feeding, but did not change significantly 1 hour (p=0.72) or 24 
hours (p=0.27) post-ultrasound compared with animals receiving the sham treatment 
(Figure 4.2b). 
Contrast ultrasound does not affect aorta or plasma Hsp70 protein levels 
Rabbits that had been restrained for serial blood sample collection had significantly 
higher aorta Hsp70 than control rabbits that had not been restrained, regardless of diet 
(p<0.001, Figure 4.3). Ultrasound with UCA did not significantly affect aorta Hsp70 
levels. Plasma Hsp70 was significantly lower at 22 days than prior to experimental 
procedures on day 21, regardless of ultrasound treatment group (p<0.01, Figure 4.4a), 
but was otherwise not significantly altered throughout the study. No correlation was 
observed between tissue and plasma Hsp70 levels 24 hours post-ultrasound exposure 
(F0.05 (1,9)=0.9, r2=0.083, p=0.36 for sham+saline; F0.05 (1,9)=0.04, r2=0.005, p=0.84 for 
ultrasound+UCA; Figure 4.4b). One animal had plasma Hsp70 levels an average of 10 
standard deviations above the mean throughout the study (including at baseline), and 
was therefore excluded from the dataset during analysis. 
Discussion 
When exposed to ultrasound, microbubbles dynamically expand and contract17 in 
response to the temporal varying acoustic pressure amplitude. Ultrasound induces 
oscillation of UCAs at lower pressure levels, and collapse at higher pressures. The 
biophysical interaction of ultrasound with circulating microbubbles increases the 
echogenicity of blood and results in improved contrast between blood and tissue. For 
this reason, UCAs have proven useful in enhancement of clinical ultrasound images. 
The ultrasound-UCA interaction is useful for imaging, but may cause other biological 
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effects. Although clinical trials and meta-analyses have recently dispelled concerns over 
the safety of UCAs in human patients18-23, there is a large experimental research 
literature that has not been controverted. Ultrasound and UCAs have induced capillary 
rupture and hemorrhage24-26, cardiac damage27 and arrhythmias28, and impaired 
vascular endothelial function29 in animal studies. Ultrasound has been shown to 
mechanically disturb cell membranes, inducing temporary permeability in a 
phenomenon known as sonoporation30-35. Based on these studies, we hypothesized 
that the interaction of ultrasound with UCAs would stress the vasculature at the site of 
ultrasound exposure, resulting in increased levels of the stress protein Hsp70. 
Fundamentally, proteins are chains of amino acids joined by peptide bonds. These 
amino acid chains (primary structures) must fold into specific three-dimensional 
conformations (tertiary structures) to achieve their catalytic activity. A protein’s tertiary 
structure is determined by its primary amino acid sequence in vitro36, but in the complex 
in vivo cellular environment, proteins require assistance from a quality control system of 
molecular chaperones to ensure proper folding37. These chaperones mediate not only 
proper initial folding of proteins, but also re-folding during times of cellular stress, 
including oxidative stress, exposure to ethanol and other toxins, pH or osmotic changes, 
UV radiation, and elevated temperatures37,38. All living organisms respond to elevated 
temperatures and other forms of cellular stress by producing a class of chaperones 
known as heat shock proteins39, with Hsp70 being one of the most robustly produced in 
times of cellular stress. The induction of heat shock proteins is primarily controlled at the 
translational level40-42. For this reason, we chose to measure protein levels of Hsp70 
instead of mRNA. Translated heat shock protein products appear within minutes of heat 
shock in cultured cells43. The reported half-life of Hsp70 varies by model system and 
experimental conditions44-49, but was recently estimated to be 18 hours by quantitative 
proteomic profiling of U937 cells after heat shock50. Although Hsp70 has been detected 
within minutes in cell culture studies, measurable induction of the heat shock response 
takes longer in a physiological context. We selected our euthanasia timepoint 24 hours 
after ultrasound to allow for induction of Hsp70 protein expression in rabbit aorta12,13.  
Hsp70, and several other heat shock proteins, are involved in the cardiovascular 
system and CVD51. Cells in the heart and blood vessels respond to stress by increasing 
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production of Hsp70. Intracellular Hsp27, 70 and 90 protect against the stresses of 
atherosclerosis, but circulating soluble Hsp60 can activate both the innate and adaptive 
immune systems52,53. Heat shock increases the ability to withstand subsequent heat 
shock and environmental stress. As evidence of this thermotolerance, prior heat shock 
reduces myocardial infarct size in animal models12,54,55. Thermotolerance is most 
effectively induced when the animals are heat shocked 24 hours prior to infarction, 
providing further support for our selection of euthanasia time. Mechanical stress is 
another activator of the heat shock response, and the studies of sonoporation 
referenced above have demonstrated ultrasound-induced mechanical effects on cell 
membranes, providing an additional rationale for the inclusion of Hsp70 as a cellular 
stress marker. 
Several other studies have evaluated the effects of ultrasound on heat shock 
proteins. Hsp70 and other heat shock proteins have been used as biomarkers in studies 
of high-intensity focused ultrasound (HIFU), an application that is emerging as a 
potential treatment for cancer. HIFU technology delivers concentrated ultrasonic energy 
to tumors, causing an elevation in temperature sufficient to kill the tumor cells while 
leaving surrounding tissue intact. Studies of cultured cancer cells56, mice57,58, and 
human breast cancer patients59 have demonstrated increases in Hsp60 and Hsp70 after 
HIFU. It is important to note that HIFU uses ultrasound exposure conditions that are 
more intense than clinical contrast ultrasound exposures. Another study used contrast 
ultrasound to monitor radiofrequency thermal ablation of rabbit liver tissue60. They noted 
a qualitative increase in Hsp70 protein expression after radiofrequency ablation, and 
interestingly also a modest increase in Hsp70 with contrast ultrasound alone. This study 
used a different UCA, Sonazoid, at unknown concentration in a bolus infusion. The 
authors posit that this biological effect was due to the interaction of ultrasound with 
UCAs. The effect of ultrasound on Hsp70 has also been investigated in rat muscle. 
While acute ultrasound exposure did not induce Hsp7061, a series of four exposures did 
result in increased production of Hsp7062. These two studies used a 1 MHz transducer 
without UCA, and measured Hsp70 by Western blot using an antibody similar to the one 
used in the current study. The rabbit and rat studies described above also chose a 24 
hours post-exposure timepoint for collection of tissue samples. Importantly, none of 
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these studies have focused on the cardiovascular system, the primary target of contrast 
ultrasound imaging, using clinically relevant contrast ultrasound exposure conditions.  
Blood collection from the lateral saphenous vein requires restraint of the animals. 
We included unrestrained control groups of cholesterol and chow-fed animals to 
account for the effect of restraint, and found that restrained animals had significantly 
higher aortic Hsp70 protein levels, regardless of diet (Figure 4.3). Previous work has 
shown that restraint stress can induce aortic Hsp70 protein expression in rats63, and we 
have now demonstrated this effect in rabbits. However, we cannot rule out the 
possibility that anesthetics may have contributed to the elevated Hsp70 levels seen in 
these rabbits. Anesthesia has been shown to increase Hsp70 protein levels in rats64. 
We also observed a decrease in LDL after the experimental procedure at 3 weeks, 
independent of ultrasound treatment. Anesthetics have been shown to affect blood 
cholesterol levels65,66, and it is possible that the LDL fraction was particularly affected. In 
addition to plasma lipids and Hsp70, we also measured plasma vWF (Figure 4.2b). 
vWF is a clotting protein produced and secreted by endothelial cells, and it serves as a 
marker of endothelial function67,68. We included vWF in order to identify any acute 
effects of contrast ultrasound on the vascular endothelium. The lack of effect of imaging 
on vWF suggests that the endothelium was not disturbed by the procedure. 
In conclusion, this was an assessment of contrast ultrasound imaging focused on 
vascular stress, with aorta Hsp70 protein levels as the key indicator. Hsp70 was 
expressed in vascular tissue, but no additional vascular stress was observed as a result 
of the imaging procedures.  
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Figures and Tables 
 
Figure 4.1. Study design with 32 New Zealand White (NZW) rabbits. After 3 weeks on 
either chow diet or the 1% cholesterol, 10% fat, 0.11% Magnesium diet, rabbits (n=24) 
underwent ultrasound imaging at 2.1 MPa with intravenous administration of the 
Definity® UCA, or a sham procedure. Serial saphenous vein blood samples were 
collected from these animals under restraint. An additional 4 rabbits on cholesterol diet 
and the 4 on chow served as cage controls. Rabbits were euthanized 24 hours after the 
ultrasound procedure (day 22), and aorta tissue was collected for analysis. UCA, 
ultrasound contrast agent. 
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Figure 4.2. Plasma cholesterol and von Willebrand Factor (vWF). A, plasma total 
cholesterol was measured by enzymatic colorimetric kit. B, vWF was measured by 
ELISA. 
 
  124 
Figure 4.3. Aorta tissue Hsp70 analysis on day 22. Aorta tissue from the site of 
exposure was carefully dissected from the surrounding tissue and frozen in liquid 
nitrogen. Tissue lysates were analyzed for Hsp70 by Western blot, with -actin as a 
loading control. Western blot lanes shown are representative of the mean of each 
group, and the lanes are separated to indicate that they are derived from separate blots. 
Bars are SEM. Labels +/- indicate presence/ absence of the treatment. 
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Figure 4.4. Plasma Hsp70. A, Plasma Hsp70 was measured by ELISA. B, no 
correlation between plasma and tissue Hsp70 levels. Bars are SEM. Hsp70, Heat shock 
protein 70. 
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CHAPTER 5: Contrast ultrasound imaging of the aorta does not affect progression of 
atherosclerosis or cardiovascular biomarkers in ApoE-/- mice 
Abstract 
Objective – Ultrasound Contrast Agents (UCAs) enhance cardiovascular ultrasound 
imaging. Adverse biological effects have occurred after administration of UCAs, and 
more research is needed for a comprehensive understanding of the risks involved. We 
used the ApoE-/- mouse model of atherosclerosis to characterize the effects of 
ultrasound and UCAs on atherosclerosis and plasma biomarkers.  
Methods – Male ApoE-/- mice (8 weeks old, n=24) were intravenously infused with 
UCA (2x1010 Definity® microbubbles/hr) and exposed to 2.8 MHz center frequency 
ultrasound (10 Hz pulse repetition frequency, 1.4 µs pulse duration, 2 min exposure 
duration, two sites) at one of three peak rarefactional pressure amplitudes (0, 1.9 or 3.8 
MPa PRPA), and then consumed either a chow or Western diet for 4 weeks (n=4 per 
group). Blood plasma samples were collected before ultrasound exposure and at 2 and 
4 weeks post-exposure, and assayed for total cholesterol and von Willebrand Factor 
(vWF). A pathologist measured atheroma thickness in formalin-fixed, hematoxylin & 
eosin-stained transverse aorta sections and scored them for severity of atherosclerosis. 
Results – Plasma total cholesterol initially averaged 286 mg/dL in the Western diet 
group and increased to 861 mg/dL after 4 weeks on the diet (p<0.0001). Total 
cholesterol did not increase significantly in the chow diet group. Plasma vWF increased 
after two weeks on the Western diet (p<0.0001). Atheroma thickness was greater in 
animals consuming the Western diet than in chow-fed animals (p<0.05). Ultrasound had 
no significant effect on plasma total cholesterol, plasma vWF or atheroma thickness. 
Conclusions – Contrast ultrasound did not increase the severity of atherosclerosis or 
alter cardiovascular biomarkers in the ApoE-/- mouse model. 
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Introduction 
Ultrasound Contrast Agents (UCAs) are used to enhance ultrasound imaging of the 
cardiovascular system. UCAs are administered intravenously as a solution of micron-
sized bubbles, consisting of an inert gas encased in a shell of phospholipid or albumin. 
When ultrasound is applied to the heart or blood vessels, the ultrasonic waves interact 
with UCAs in the circulation, causing the bubbles to oscillate or collapse. The interaction 
of ultrasound with UCAs opacifies the blood, allowing for improved imaging of cardiac 
structure and function1, arterial stenosis2, vascularization of atherosclerotic plaques3, 
and other aspects of the cardiovascular system. When used for cardiac left-ventricular 
opacification, UCAs can enhance the visual quality of ultrasound scans in patients that 
are difficult to image, and improve diagnostic accuracy4,5. 
While UCAs have clear clinical utility in detection and diagnosis of cardiovascular 
disease, concerns have been raised over their safety. There have been reports of 
adverse cardiovascular events after ultrasound with UCA administration in animal 
models and humans. In experimental studies from our research group and others, 
UCAs have been shown to induce cardiac arrhythmias6, hemorrhage7-9, impair 
endothelium-dependent vasodilation10, and alter atheroma thickness and the circulating 
biomarker von Willebrand Factor11. Reports of cardiopulmonary complications and 
deaths in human clinical patients associated with UCA administration added to these 
concerns, and patients with pre-existing cardiovascular disease appeared to be at 
increased risk12. As a result, the U.S. Food & Drug Administration (FDA) mandated 
warning labels for two commercially available UCAs, Definity® (Lantheus Medical 
Imaging, North Billerica, MA) and Optison™ (GE Healthcare, Princeton, NJ) in 2007.  
The reported adverse events highlight the importance of further research in this 
area. The biological effects of contrast ultrasound may be a function of ultrasound 
pressure level or UCA concentration, so it is necessary to test for adverse events using 
a variety of scenarios and experimental models. In this study, we used the ApoE-/-
 mouse model of atherosclerosis to determine thresholds for arterial damage at several 
different ultrasound pressure levels, with concomitant UCA administration. We fed 
groups of mice either a standard chow diet or a high fat, high sugar, cholesterol-
containing Western diet to modulate the progression of atherosclerosis after a single 
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contrast ultrasound exposure. We hypothesized that contrast ultrasound would induce 
vascular injury and accelerate the progression of atherosclerosis, that this effect would 
be pressure-dependent, and that the threshold for effects of contrast ultrasound on 
biomarkers would be lower than FDA limits established for clinical ultrasound imaging. 
Materials and Methods 
Animals and Experimental Design 
The University of Illinois Institutional Animal Care and Use Committee approved all 
live animal procedures. Male ApoE-/- mice (8 weeks old, fed chow prior to study diets, 
n=24; Jackson Labs, Bar Harbor, ME) were randomized to experimental groups and 
exposed to ultrasound at one of three pressure levels with intravenous infusion of UCA 
as described in Exposimetry, with n=8 mice per group. The mice then consumed either 
a chow diet (7012; Harlan Teklad, Madison, WI) with 3.1 kcal/g, or a Western diet 
containing 21% milkfat, 34% sucrose, 0.2% cholesterol w/w, and 4.7 kcal/g (TD.10885; 
Harlan Teklad), for 4 weeks after ultrasound exposure (n=4 per group). Mice were 
individually housed, fed ad libitum with fresh diet provided twice per week, and given ad 
libitum access to water. Serial blood samples were collected at baseline, 2 weeks post-
exposure and 4 weeks post-exposure. Blood samples were collected from the 
submandibular region by puncture with a 5 mm lancet (Goldenrod; MEDIpoint Inc., 
Mineola, NY) into an EDTA-coated capillary tube (Microvette; Sarstedt AG & Co., 
Nümbrecht, Germany), centrifuged at 2500 x g and 4ºC for 10 minutes, aliquotted and 
frozen at -70ºC. Mice were euthanized 4 weeks post-exposure and tissues were 
collected for analysis (Figure 5.1).  
All mice were anesthetized with isoflurane and euthanized by cervical dislocation. 
After euthanasia, mice were placed in dorsal recumbency and a ventral midline incision 
was made to expose the abdominal and thoracic cavities. The aorta was perfused with 
0.8 mL 10% neutral-buffered formalin (NBF) through the left ventricle of the heart and 
allowed to fix for 30 minutes. An additional 0.2 mL NBF was added to the outer surface 
of the aorta. Next, under magnification, microscissors and fine-point forceps were used 
to remove the fat surrounding the three aortic arch branches (brachiocephalic, left 
common carotid, left subclavian). The length of the aorta was removed from its origin at 
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the left ventricle to a few millimeters distal to its bifurcation into the common iliac 
arteries. The aorta was freed from surrounding vessels by making cuts at each of the 
three branches of the arch, the origin of the aorta at the heart, and distal to the aortic 
bifurcation into the common iliac arteries.  
After removal, the entire aorta was sectioned transversely. The first two cuts were 
made midway between the 1st and 2nd and 2nd and 3rd aortic branches off the arch. The 
third cut was made 2 mm distal to the second cut. All subsequent sections were made 
2.5 mm from the previous section. The average length of aorta removed was 3.5 cm, 
with 15 sections per aorta. All sections were placed in a single embedding cassette with 
the distal cut side down in order from the cranial to the caudal end of the aorta, fixed in 
10% NBF for 24 hours, and embedded in paraffin.  
Exposimetry 
Ultrasound exposures were performed with a focused f/2, 19 mm diameter lithium 
niobate single-element transducer (Valpey Fisher, Hopkinton, MA USA) driven by a 
high-power pulse source (RAM5000; Ritec, Inc., Warwick, RI USA). Ultrasonic field 
distribution measurements were performed in 22ºC degassed water according to 
established procedures13,14 and yielded a center frequency of 2.8 MHz, fractional 
bandwidth of 11%, focal length of 26 mm, -6 dB focal beamwidth of 0.98 mm, and -6 dB 
depth of focus of 11 mm. Weekly calibrations were performed as previously described11. 
A custom transducer holder was machined from aluminum and designed to incorporate 
both a high-frequency array transducer (MS-400; VisualSonics, Inc., Toronto, Canada) 
for image guidance and the single-element transducer described above for exposures. 
The transducers were angled to focus on the same anatomical location at a depth of 14 
mm inside the animal.  
Male ApoE-/- mice (8 weeks old, n=24) were anesthetized with 5% isoflurane with 2 
L/min supplemental O2 for induction of anesthesia, and then maintained at 2% 
isoflurane (adjusting the isoflurane level as necessary to keep the animal properly 
anesthetized) with 2 L/min O2 via facemask. Heart and respiratory rates were monitored 
throughout the experiment. The average heart rate was 368 beats per minute and the 
average respiratory rate was 29 breaths per minute. Hair was removed from the ventral 
side of the animal with clippers (Wahl, Sterling, IL) followed by a depilatory agent (Veet; 
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Reckitt Benckiser, Parsippany, NJ). A high frequency ultrasound system (Vevo 2100; 
VisualSonics, Inc., Toronto, Canada) was used to image the aorta and position the 
single-element transducer for ultrasound exposures. Once transducers were positioned, 
mice were intravenously infused with UCA (2.6% Definity® in saline, 1.8 mL/hour, 2x1010 
microbubbles/hour, 10 min. total infusion time) through a lateral tail vein with a 27g x ½” 
butterfly catheter (Surflo; Terumo, Somerset, NJ) attached to a 1 mL syringe (BD, 
Franklin Lakes, NJ) and an infusion pump (KD Scientific, Inc., Holliston, MA). When the 
UCA infusion was started, the aorta was exposed to 2.8-MHz center frequency 
ultrasound (10 Hz pulse repetition frequency, 1.4 µs pulse duration, 2 min exposure 
duration) at one of three peak rarefactional pressure amplitudes (0, 1.9 or 3.8 MPa 
PRPA). The 1.9 MPa PRPA matched Definity®’s 90% collapse threshold15. The 
Mechanical Index (MI) was also determined as part of the routine calibration 
procedure16, and yielded 0, 1.1 and 2.3, respectively. The purpose for providing the MI 
is because it is a regulated quantity17 of diagnostic ultrasound systems, and its 
magnitude is available to system operators. Ultrasound exposures were performed at 
two sites on the aorta: the arch near the branch to the left common carotid artery, and 
the abdominal region immediately caudal to the diaphragm. After the second exposure, 
the UCA infusion was stopped and mice were allowed to recover from anesthesia. 
Histology 
Aorta sections were cut from paraffin blocks at 3 µm thickness, mounted on 
microscope slides, and stained with hematoxylin and eosin. One microscope slide, with 
3 sections of the paraffin block, was created for each animal. A board-certified 
pathologist blinded to the exposure conditions measured the thickest atheroma in the 
aorta using an ocular micrometer (Olympus America Inc., Center Valley, PA) and 
assigned an atherosclerosis score between 0 and 5 using the American Heart 
Association classification scheme for human atherosclerotic lesions18. Score 0 = 
Absence of atherosclerosis; Score 1 = Presence of isolated foam cells; Score 2 = Lipid 
accumulation mainly within the foam cells; Score 3 = Lipid accumulation within the foam 
cells and small pools of extracellular lipid; Score 4 = Intracellular lipid, lipid pools and 
core of extracellular lipid; and Score 5 = Lipid core and fibrotic layer, or multiple lipid 
cores and fibrotic layer, or mainly calcified or fibrotic plaque. 
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Blood Analysis 
Plasma total cholesterol was measured using an enzymatic colorimetric kit (Wako 
Chemicals, Richmond, VA) with samples plated in triplicate. Human control sera (Wako) 
were included in each assay to evaluate the reproducibility of measurement. Intra-assay 
precision was defined as the variability among replicates of the same sample within an 
assay, and inter-assay precision as the variability among replicates of the same sample 
over multiple assays. Coefficient of Variation (CV) was used as a measure of precision19  
and defined as 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛
𝑀𝑒𝑎𝑛
×  100. The intra-assay CV for control sera was 3.5%, 
and the inter-assay CV was 9.2%. The intra-assay CV for mouse plasma samples was 
2.3%. 
vWF was measured using a sandwich enzyme-linked immunosorbent assay (ELISA) 
as previously described20 with the following modifications: to adapt the assay for mouse 
plasma instead of rabbit plasma, a standard curve from 25-0.39 ng/mL was used 
instead of 100-3.13 ng/mL, and mouse plasma was diluted 1:25 for analysis instead of 
1:100. Samples were plated in duplicate. The same antibodies and reagents were used 
for mouse and rabbit plasma, as a BLAST search21 demonstrates 83% sequence 
alignment between human (accession: CCQ25771.1) and mouse (accession: 
AAN07781.2) vWF, and 81% between mouse and rabbit (accession: DAA34807.1) 
vWF. For mouse plasma samples, the intra-assay CV was 3.2%, and the inter-assay 
CV was 13%.  
Statistical Analysis 
Statistical analysis was performed in SAS 9.3 (SAS Institute, Inc., Cary, NC) for 
Windows, and graphs were created in SigmaPlot 12.3 for Windows. Atheroma thickness 
data were analyzed by analysis of variance (ANOVA) within the general linear mixed 
models procedure of SAS 9.3. Feed intake, body weights, plasma total cholesterol, and 
plasma vWF data were analyzed by repeated measures analysis of covariance 
(ANOCOVA), using baseline values as covariates, also within the general linear mixed 
models procedure of SAS 9.3. The covariance structure of repeated measures data was 
assessed graphically and quantitatively, and an appropriate covariance model was fit. 
Non-parametric atherosclerosis score data were analyzed using a two-sample Wilcoxon 
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rank sum test with diet as the treatment variable. Each model was first run with all fixed 
effects and covariates of interest (diet, time point, PRPA, and baseline values) 
incorporated, and then reduced to eliminate non-significant variables. When a 
significant result was reported for a fixed variable with more than two categories, 
multiple comparisons were made using estimate statements based on the least squares 
means, followed by Bonferroni adjustment for multiplicity. Data met the necessary 
assumptions of each test. The threshold for statistical significance was set at p<0.05. 
Results 
Contrast ultrasound does not affect feed intake or body weight 
Animals on chow diet consumed more feed by weight, but less kilocalories (kcal), 
than animals on the Western diet (4.1 g/day feed intake for chow animals vs. 3.3 g/day 
for Western diet animals, p<0.0005; 12.8 kcal/day feed intake for chow animals vs. 15.4 
kcal/day for Western diet animals, p<0.005). Animals on chow diet weighed less than 
animals on the Western diet (24.6 g final body weight for chow animals vs. 26.5 g for 
Western diet animals, p<0.005). Ultrasound did not significantly affect feed intake or 
body weight. 
Contrast ultrasound does not affect plasma cholesterol or von Willebrand Factor 
Total cholesterol initially averaged 283 mg/dL and did not increase significantly in 
the chow diet group (Figure 5.2a). While cholesterol levels in chow-fed animals 
remained stable, animals in the Western diet groups experienced a rapid and significant 
elevation to an average of 726 mg/dL after 2 weeks on the diet (p<0.0001 by repeated 
measures ANOCOVA), and levels remained significantly elevated after that, averaging 
861 mg/dL after 4 weeks. Ultrasound (p=0.25), diet*ultrasound (p=0.89), and 
diet*ultrasound*timepoint (p=0.37) were not significant variables in the statistical model, 
and so were removed.  
Plasma vWF initially averaged 112 ng/mL in all animals (Figure 5.2b). Consumption 
of the Western diet for two weeks significantly elevated vWF to an average of 257 
ng/mL as compared to 78 ng/mL for animals continuing to consume chow (p<0.0001 by 
repeated measures ANOCOVA). Levels were highly variable at 4 weeks and no 
significant differences between diets or ultrasound groups were seen.  
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Contrast ultrasound does not affect aorta atheroma thickness or atherosclerosis score 
Atheroma thickness was significantly greater in animals consuming the Western diet 
than in chow-fed animals, with an average±SEM of 0.031±0.010 mm for chow and 
0.073±0.014 mm for Western at 0 MPa, 0.020±0.007 mm for chow and 0.039±0.012 
mm for Western at 1.9 MPa, and 0.025±0.014 mm for chow and 0.036±0.010 mm for 
Western at 3.8 MPa (p<0.05 by ANOVA, n=3-4/group, Figure 5.3b). Ultrasound 
(p=0.11) and diet*ultrasound (p=0.40) were not significant variables in the statistical 
model, and so were removed. If the diet*ultrasound variable was retained, the 
ultrasound variable would approach statistical significance within the Western diet group 
only (p<0.08), and there would be a significant difference between Western and chow at 
0 PRPA (p<0.05), but not 1.9 (p=0.24) or 3.8 (p=0.50) PRPA. A regression analysis of 
the atheroma thickness data, within either the Western diet group or the chow diet 
group, and treating both the atheroma thickness and the ultrasound PRPA as 
continuous variables, does not identify any significant trends among PRPA groups (F0.05 
(1, 9)=2.51, r2=0.22, p=0.15 for Western; F0.05 (1, 9)=0.08, r2=0.009, p=0.78 for chow). 
Atherosclerosis score was also significantly greater for Western diet-fed animals 
than chow-fed animals, with an average±SEM of 2.25±0.0.946 for chow and 3.33±0.882 
for Western at 0 MPa, 1.25±0.479 for chow and 2.00±0.408 for Western at 1.9 MPa, 
and 1.00±0.577 for chow and 2.50±0.866 for Western at 3.8 MPa (one-sided p<0.05 by 
Wilcoxon rank sum test, n=3-4/group, Figure 5.3c). Ultrasound was not a significant 
variable overall (p=0.45), within the chow diet group alone (p=0.62), or within the 
Western diet group alone (p=0.25) for atherosclerosis score.  
Discussion 
Concerns over the safety of UCAs began after reports of adverse cardiopulmonary 
events and deaths following their administration. Based on these reports, the FDA 
required revised labeling for Definity® and Optison™ in 2007, adding a “black box” label 
warning of adverse events and requiring a 30 minute monitoring period for all patients 
injected with UCAs. However, a small number of adverse events were reported during a 
span of several years in which millions of patients were safely imaged, so the estimated 
incidence of adverse events was far lower than for many established medical 
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procedures22. The few deaths that did occur were likely due to underlying disease 
conditions rather than UCAs23. A large body of literature has emerged to demonstrate 
the safety of UCAs12,24-27, and a recent meta-analysis28 of over 5 million patients 
concluded that the use of UCAs in ultrasound imaging is safe and not associated with 
an increased risk of myocardial infarction or death. After these reports of UCA safety 
accumulated, the FDA relaxed its warnings on Definity® in October 2011 and Optison™ 
in August 2012, noting that serious complications are uncommon and removing the 30 
minute monitoring period post-UCA injection. The present study adds support for the 
safety of UCAs and suggests that UCAs can be utilized even in patients with 
atherosclerosis. 
In addition to their growing safety record, UCAs show promise in therapeutic 
applications. UCAs have been used to enhance gene and drug delivery29,30, reduce 
infarct size and improve ventricular remodeling after cardiac ischemia31, and induce 
angiogenesis to improve tissue perfusion32-37. These innovative functions of UCAs, in 
conjunction with their safety record, make a strong case for their continued use in the 
laboratory and clinic.  
We selected the ApoE-/- mouse as a model of atherosclerosis for our investigations, 
a well-established mouse model38 that recapitulates many aspects of human 
atherosclerosis39. ApoE is an apolipoprotein important for cholesterol metabolism, 
particularly in rodents40. Deletion of ApoE results in impaired hepatic clearance of 
lipoproteins from the circulation. As a result, lipoproteins accumulate in the blood, 
reaching nearly 900 mg/dL in this study, and infiltrate arterial tissue to promote 
atherosclerosis. The ApoE-/- mouse provides several advantages over the cholesterol-
fed rabbit model also used by our research group41,42. They are easier to handle, and 
readily consume the atherosclerotic diet. As in our previous study11, we measured the 
biomarker von Willebrand Factor (vWF), a protein produced and secreted by vascular 
endothelial cells. Alterations in plasma vWF levels reflect endothelial dysfunction43 and 
predict risk of cardiovascular events44. The ApoE-/- mouse, validated assays and 
histological techniques comprise a sensitive model system to test for biological effects 
of contrast ultrasound. 
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Our findings in this study were different than those observed in the cholesterol-fed 
rabbit model11. The lack of concordance between the two studies may be due to 
methodological and/or physiological differences. First, we are working with a different 
animal model, and mice may simply respond differently to ultrasound and UCAs than 
rabbits. The increased heart, respiratory and metabolic rates of mice may decrease the 
half-life of UCAs. In this study, we did not collect blood samples immediately before and 
after exposure. We also measured plaque thickness by examining the entire aortic arch 
and descending aorta, instead of just the specific ultrasound exposure site, which may 
explain why we did not observe alterations in aorta plaque thickness. Small sample 
sizes may also have limited our statistical power. Further studies are needed to 
determine whether differences in results between the two studies are due to differences 
in experimental methods or animal physiology. 
In conclusion, contrast ultrasound did not affect clinically relevant cardiovascular 
biomarkers or progression of atherosclerosis in ApoE-/- mice. This study represents an 
important step in understanding the biological effects of UCAs, and adds to a growing 
body of literature demonstrating their safety in cardiovascular ultrasound imaging. The 
focus of this research area has begun to shift away from the potential of UCAs to cause 
cardiovascular harm, and on to improving cardiovascular health and diagnosis, and it 
has become clear that the benefits of UCAs outweigh the potential risks in almost all 
current applications. 
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Figures and Tables 
 
Figure 5.1. Study design. Baseline blood samples were obtained from 24 male ApoE-/- 
mice. The mice then received contrast agent and were exposed to ultrasound at 0, 1.9, 
or 3.8 MPa in situ peak rarefactional pressure amplitude (PRPA), with n=8 per group. 
Half of the mice continued to consume chow diet, and half were switched to the 
Western diet. Subsequent blood samples were obtained at 2 and 4 weeks. Mice were 
euthanized at 4 weeks, and aortas were obtained for analysis. 
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Figure 5.2. Plasma cholesterol (a) and von Willebrand Factor (vWF, b). Plasma total 
cholesterol was analyzed using an enzymatic colorimetric kit (Wako Chemicals, 
Richmond, VA). Human control sera (Wako) were included in each assay for quality 
control. Plasma vWF was determined using an in-house validated sandwich ELISA. 
Bars are SEM, n=3-4 per group per time point. 
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Figure 5.3. Aorta histology. The aortic arch and descending aorta were fixed briefly in 
situ with 10% neutral buffered formalin (NBF), then carefully excised and fixed in 10% 
NBF for an additional 24 hours, embedded in paraffin, sectioned, and stained with H&E 
(a). A pathologist blinded to the exposure conditions measured atheroma thickness with 
an ocular micrometer (b), and assigned an atherosclerosis score between 0 and 5 using 
the American Heart Association classification scheme for human atherosclerotic lesions 
(c). Bars are SEM, n=3-4 per group, *p<0.05. PRPA, in situ peak rarefactional pressure 
amplitude. 
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CHAPTER 6: Ultrasound with microbubble contrast agents does not damage skeletal 
muscle tissue or capillaries in rats 
Abstract 
This study was designed to evaluate the biological effects of ultrasound and 
microbubble contrast agents at the tissue-capillary interface, with particular emphasis 
on the microbubble concentration-dependence of these effects. Eighteen 11-13 week 
old female Sprague-Dawley rats were divided into 6 groups, with 3 per group. One 
gracilis muscle per animal was exposed to ultrasound, with the opposite leg serving as 
a sham control. Animals were euthanized 24 hours post-exposure, and gracilis muscle 
samples from the site of ultrasound exposure were obtained using a punch biopsy. 
Formalin-fixed, H&E-stained gracilis muscle sections were evaluated for myofibrillar 
damage, myocyte necrosis, inflammatory cell infiltrate, hemorrhage, fibrosis, change in 
fiber size, and presence of centrally located nuclei (which would presumably indicate 
satellite cell fusion). No adverse biological effects of ultrasound were observed. 
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Introduction 
Ultrasound imaging is ubiquitous in medical practice, and is favored for its low cost, 
safety and real-time image generation. Ultrasound Contrast Agents (UCAs) are gas-
containing microbubbles that were originally developed to improve ultrasound imaging 
of the heart. In addition to their canonical role in image contrast enhancement, the 
interaction of ultrasound with UCAs has numerous effects on biological tissue, with 
capillaries seeming particularly susceptible1. One of the more intriguing effects has 
been an induction of angiogenesis, growth of new capillaries, especially in previously 
ischemic tissues. The angiogenic effect was first observed in the gracilis muscle of rats2, 
and has important implications for the treatment of ischemic conditions like heart 
attacks, strokes, and peripheral vascular disease. Findings from our research group 
have extended the initial findings by providing information on vascular endothelial 
growth factor (VEGF) expression and vascular permeability in the gracilis muscle3-5. 
Although numerous studies have demonstrated capillary damage in animal models after 
administration of ultrasound with UCAs1,6,7, recent evidence5 suggests that the 
angiogenic effect might be due to an interaction between UCAs and the vascular 
endothelium, without capillary damage. We used our previously established rat model 
and its associated methods to investigate ultrasound and contrast agent bioeffects at 
the gracilis muscle tissue-capillary interface, with a more direct focus on muscle 
damage. This study evaluated both the UCA concentration-dependence and ultrasound 
pressure-dependence of acute muscle damage. 
Materials and Methods 
Animals and Exposimetry 
Female Sprague-Dawley rats (n=18, 11-13 weeks old, average body weight of 229 
g) were exposed to ultrasound at four concentrations of UCA (0x, 1x, 5x, 10x) and four 
pressure levels: 0, 0.7, 1.3 and 1.9 MPa (corresponding to Mechanical Indices of 0, 0.7, 
1.3 and 1.9, respectively), with n=3 per group (Table 6.1). The experimental procedures 
were performed as previously described3-5, with minor modifications. Briefly, rats were 
anesthetized with inhaled isoflurane and placed on a heat pad to maintain body 
temperature. Hair was then removed from the area of the gracilis muscle with clippers 
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(Wahl, Sterling, IL) followed by a depilatory agent (Veet; Reckitt Benckiser, Parsippany, 
NJ) to maximize sound transmission. The tail was cleaned with soap and warm water in 
preparation for tail vein infusion of UCA. Rats were then secured in dorsal recumbency 
with a custom-built holder. The site to be exposed was marked, first with a yellow 
highlighter, and then with a black permanent marker. Mineral oil was then applied to the 
skin. The bottom of a plastic bucket was removed and covered with plastic wrap 
(Freeze-tite®; Polyvinyl Films, Inc., Sutton, MA) secured by a rubber band. Degassed 
water was added to the bucket and heated to 37ºC to avoid vasoconstriction when 
contacting the animal. The bucket was then lowered until the plastic wrap contacted the 
skin over the gracilis muscle, and the ultrasound transducer was placed in a custom-
built holder and lowered into the bucket. 
The UCA solution was then prepared. Definity® (Lantheus Medical Imaging, North 
Billerica, MA) was agitated in a vial mixer for 45 seconds according to the 
manufacturer’s recommendation. UCA doses were adjusted for the rat as described5 
and mixed with saline in a syringe (BD, Franklin Lakes, NJ) at three different 
concentrations: 1x (6.7% Definity®, 5 x 108 microbubbles/mL), 5x (17% Definity®, 2 x 109 
microbubbles/mL), and 10x (50% Definity®, 5 x 109 microbubbles/mL). Saline alone was 
infused for control animals. A butterfly catheter (Surflo; Terumo, Somerset, NJ) was 
inserted into a lateral tail vein, with success verified by aspiration of blood from the vein. 
First, 0.5 mL UCA solution was manually infused over a 30 second time period to 
introduce UCA into the circulation. Next, the syringe was placed in an infusion pump 
(KD Scientific, Inc., Holliston, MA) set to 0.067 mL/min. The UCA infusion and 
ultrasound exposure were started simultaneously.  
Ultrasound exposures were performed using a 1 MHz focused f/3 single-element 
transducer, with 10 Hz pulse repetition frequency, 10 µs pulse duration, and 5 min 
exposure duration on each leg. Weekly transducer calibrations were performed in 22ºC 
degassed water according to established procedures8,9. One gracilis muscle per animal 
was exposed to ultrasound, with the opposite leg serving as a sham control. In order to 
blind the researcher handling the animals to the exposure conditions during the 
experiment and subsequent tissue collection, a separate researcher operated the 
ultrasound equipment and randomly selected the leg to be exposed. The UCA solution 
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was infused continuously from the beginning of the exposure of the first leg until the 
exposure of the second leg was completed (15 minutes total).  
Animals were euthanized 24 hours post-exposure, and gracilis muscle samples from 
the site of ultrasound exposure were obtained using a 6 mm punch biopsy. Rats 
typically removed the black dot marking the exposure site, but the highlighter was 
visualized using a handheld black light (UVL-23R; UVP, Upland, CA). Biopsy samples 
were fixed in 10% neutral buffered formalin for 2-6 hours, embedded in paraffin, cut into 
3 μm sections, and mounted on slides for evaluation. 
Histology 
Formalin-fixed, H&E-stained gracilis muscle sections were evaluated for myofibrillar 
damage, myocyte necrosis, inflammatory cell infiltrate, hemorrhage, fibrosis, change in 
fiber size, and presence of centrally located nuclei (a marker of satellite cell fusion) by a 
board-certified pathologist. 
Results and Discussion 
Ultrasound-mediated destruction of microbubbles has biological effects that range 
from detrimental to therapeutic. Our objective in this study was to characterize the 
effects of ultrasound and UCAs on skeletal muscle tissue and capillaries. We performed 
ultrasound imaging at four different pressure levels, with intravenous administration of 
the UCA Definity at four different doses. The investigators who originally characterized 
the pro-angiogenic effect of ultrasound-mediated microbubble destruction2 reported that 
1 MHz ultrasound was effective at rupturing capillaries, while higher frequencies were 
not. We based our use of a 1 MHz transducer on this information in order to maximize 
the potential for biological effects. Despite rigorously performed methods, we did not 
observe histological evidence of damage after the experimental procedure (Figure 6.1), 
supporting our previous hypothesis5 of a non-destructive ultrasound-UCA-endothelium 
interaction. 
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Figures and Tables 
Figure 6.1. Gracilis muscle histology. Gracilis muscle samples were collected by punch 
biopsy 24 hours after administration of ultrasound and UCA, fixed in 10% neutral 
buffered formalin for 2-6 hours, paraffin-embedded, cut into 3 μm sections, mounted on 
slides, and stained with hematoxylin and eosin. Images were captured at 40x 
magnification and scale bars are 50 μm. Minor tissue folding artifacts that appear in 
some images are a result of histological processing and do not indicate tissue damage. 
PRPA, derated peak rarefactional pressure amplitude; UCA, ultrasound contrast agent.  
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  PRPA 




1x (3)     3 
5x (3)     3 
10x (3) 3 3 3 
 
Table 6.1. Experimental design with 18 female Sprague-Dawley rats. Numbers in 
parentheses represent samples from sham-exposed gracilis muscles.  
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CHAPTER 7: Tomatoes and soy germ for reduction of atherosclerosis in ApoE-/- mice 
Abstract 
Dietary patterns with cardiovascular benefits have been established, but the relative 
contributions of individual foods and food components, alone or in combination, remain 
unclear. Male ApoE-/- mice were fed either a purified AIN-93G control diet, a Western 
diet, or a Western diet with 10% tomato powder, 2% soy germ, or the combination, for 
four weeks, with ten animals per group. Plasma total cholesterol and triglycerides were 
measured with enzymatic colorimetric kits, and serum amyloid A (SAA) was measured 
by ELISA. Liver lipids were extracted with chloroform:methanol, and triglycerides, free 
and esterified cholesterol measured with enzymatic colorimetric kits. Expression of 
Cyp27a1, Cyp7a1, Abcg5, and Abcg8 in the liver was determined by quantitative 
polymerase chain reaction. Sections of the aortic root and aorta were cut and stained 
with H&E to assess extent of atherosclerotic lesions. Western diet animals had greater 
liver and adipose weights, plasma cholesterol and SAA, liver lipids, and atherosclerosis 
than AIN-93G animals. Tomato diets further increased plasma cholesterol, but also 
increased expression of the Abcg5/8 transporters involved in cholesterol efflux. Addition 
of soy germ alone to the Western diet attenuated Western-diet induced increases in 
plasma cholesterol, liver lipids and gonadal adipose weight. Tomato and soy germ did 
not decrease atherosclerosis as measured by H&E-stained sections of the aortic root, 
aortic arch and descending aorta. The results of this study do not support the use of 
either tomatoes or soy germ for reduction of atherosclerosis, but suggest beneficial 
effects of soy germ on lipid metabolism. 
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Introduction 
Cardiovascular Disease (CVD) claims nearly 800,000 lives per year in the United 
States1, and remains the leading cause of death despite significant medical advances. 
A condition known as atherosclerosis drives the development of CVD. Atherosclerosis is 
a complex pathological process characterized by entrance of cholesterol-containing 
lipoprotein particles into the arterial wall, with subsequent inflammation and formation of 
lipid-rich plaques2. Atherosclerosis progresses silently throughout life, manifesting itself 
during adulthood in heart attacks and strokes. Diet has been acknowledged as an 
important determinant of CVD risk3. In epidemiological studies, adherence to a healthy 
diet rich in fruits, vegetables, nuts and whole grains has been shown to reduce risk of 
CVD by up to 80%4 and reduce mortality if CVD is already present5. Although the 
benefits of fruit and vegetable consumption are clear, effective combinations of specific 
nutritional components remain to be identified. Evidence points to potential 
cardiovascular benefits of tomatoes6,7 and soy germ8,9, but there is a need for controlled 
animal studies to evaluate their effects on atherosclerosis. We hypothesized that 
tomatoes and soy germ would decrease atherosclerosis and lipid bioaccumulation in 
ApoE-/- mice.  
Materials and Methods 
Experimental Diets 
Tomato powder (Drum Dried -20; FutureCeuticals, Momence, IL) and soy germ 
(SoyLife Complex Regular; Frutarom, Londerzeel, Belgium) were added to a Western 
diet (TD.10885; Harlan Teklad, Madison, WI). Composition of the experimental diets is 
given in Table 7.1. Diets were balanced for total energy, protein, fat, digestible 
carbohydrates and fiber. To prevent degradation of the heat-labile carotenoids, diets 
were pelleted without heat and air-dried overnight. Carotenoids were extracted from 
diets with hexane and quantified by HPLC using a 150x4.6 mm YMC C30 column (3 µm 
particle size) with a modified Yeum gradient method10 as previously described11. 
Animals  
The University of Illinois Institutional Animal Care and Use Committee approved all 
live animal procedures. Male ApoE-/- mice (n=50, Figure 7.1) were allowed to acclimate 
  151 
to the animal facility for ≥2 days, and baseline blood samples were collected from the 
submandibular region by puncture with a 5 mm lancet (Goldenrod; MEDIpoint Inc., 
Mineola, NY) into an EDTA-coated capillary tube (Microvette; Sarstedt AG & Co., 
Nümbrecht, Germany), centrifuged at 2500 x g and 4ºC for 10 minutes, aliquotted and 
frozen at -50ºC. Mice were then randomized to one of five experimental diets: AIN-93G 
control (AIN), Western diet (WD), Western diet with 2% soy germ (WDSG), Western diet 
with 10% tomato powder (WDTP), or Western diet with 10% tomato powder and 2% soy 
germ (WDTPSG), with ten mice per diet, and fed three times per week (35-40 g total, 
adequate for ad libitum intake) for four weeks. Mice were individually housed and given 
ad libitum access to water. Feed intake was measured each time the animals were fed 
and body weights were measured weekly. After four weeks, mice were fasted overnight 
(10-14 hours), and blood samples were collected from the submandibular region. Mice 
were then euthanized with CO2 and perfused with 20 mL cold PBS. Liver and gonadal 
adipose were removed, sectioned, frozen by immersion in liquid nitrogen, and stored at 
-50ºC. A portion of the liver was added to 5 mL RNA preservation solution (RNAlater; 
QIAGEN, Valencia, CA) for 24 hours at 4ºC, then blotted dry and stored at -50ºC. The 
heart was excised with 1 mm aorta attached. The bottom half was removed with careful 
attention to the orientation of the aorta, immersed in OCT inside a 12x12x20 mm 
tapered cryomold (Electron Microscopy Sciences, Hatfield, PA), frozen in 2-
methylbutane surrounded with dry ice, wrapped in parafilm, and stored at -50ºC. The 
rest of the aorta was dissected into 14-15 pieces, fixed in NBF, sectioned and stained 
with H&E as previously described (Chapter 5). 
Blood Analysis 
Total cholesterol and triglycerides were measured using enzymatic colorimetric kits 
(Wako Chemicals, Richmond, VA) with samples plated in triplicate and human control 
sera (Wako) included in each assay to evaluate the reproducibility of measurement. 
Intra-assay and inter-assay coefficients of variation for mouse plasma samples were 
2.3% and 2.4% for total cholesterol, and 2.7% and 4.0% for triglycerides. Intra-assay 
and inter-assay coefficients of variation for control sera were 2.4 and 2.9% for total 
cholesterol and 1.3% and 3.4% for triglycerides. Serum Amyloid A (SAA) was measured 
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by ELISA (Life Technologies). The antibodies in the assay react with murine SAA1 and 
SAA2. Intra-assay and inter-assay precision were 5.2% and 7.7%. 
Liver Lipid Analysis 
Total lipids were extracted from an average of 0.42 g liver with chloroform:methanol 
and quantified by weight as previously described12,13. Lipids were then re-suspended in 
the cholesterol assay buffer by vortexing and homogenization, and assayed for 
triglycerides and free/esterified cholesterol with enzymatic colorimetric kits (BioVision, 
Milpitas, CA). 
Gene Expression Analysis 
Total RNA was isolated from liver tissue using TRIzol (Life Technologies, Grand 
Island, NY) and the RNeasy kit (QIAGEN). RNA purity was determined by 
spectrophotometry at 260 nm, 280 nm, and 230 nm (BioSpectrometer Basic with 
µcuvette G1.0 1mm; Eppendorf, Hamburg, Germany). RNA integrity was determined by 
agarose gel electrophoresis, with ethidium bromide (Sigma-Aldrich, St. Louis, MO) used 
as a fluorescent agent to visualize RNA. An average of 11.0 mg liver tissue yielded 544 
ng/µL RNA, with average 260/280 of 1.9 and 260/230 of 2.2. Complementary DNA was 
synthesized from RNA using the High-Capacity cDNA Reverse Transcription kit (Life 
Technologies), with reactions performed in a thermal cycler (Eppendorf). Quantitative 
polymerase chain reaction was carried out in an ABI Prism 7900HT sequence detection 
system (Applied Biosystems, Foster City, CA) using Taqman probes (Life Technologies; 
assay IDs: Mm00470430_m1 for Cyp27a1, Mm00484150_m1 for Cyp7a1, 
Mm00446241_m1 for Abcg5, Mm00445980_m1 for Abcg8, Mm02342430_g1 for Ppia) 
in duplex, with the reference gene peptidylprolyl isomerase A (Ppia) in a primer-limited 
formulation, and the QuantiNova probe kit (QIAGEN). Gene expression was normalized 
to Ppia and the AIN-93G control group using the ΔΔCT method14. 
Histology 
Serial 10 µm cryosections of the aortic root15 were cut from OCT-embedded samples 
at -20ºC using a cryostat (Leica Microsystems, Nussloch, Germany) and mounted on 
charged microscope slides (Superfrost Plus Gold; Fisher Scientific, Pittsburgh, PA). A 
set of six microscope slides was created for each sample, with six sections per slide. 
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Sections were allowed to dry and adhere to the slides for 30-60 min, fixed in NBF for 5 
min, dipped in water for 1 min, allowed to dry for 60 min, and stored at -20ºC until 
staining. Slides were then stained with H&E. Images were captured using an Olympus 
BX51 microscope with DP25 camera. Six serial sections with all three valve leaflets 
visible were quantified by manually tracing lesion area using the DP2 program 
(Olympus America Inc., Center Valley, PA). Only foam cell lesions underneath the valve 
leaflets were included. To quantify the extent of atherosclerotic lesions in the rest of the 
aorta (from 1 mm distal to the aortic root to the renal bifurcation), lesion area was 
determined for each of the 14-15 pieces and summed for total lesion area. The arch 
lesion area was based on sections of the first three pieces. 
Statistical Analysis 
Statistical analysis was performed in SAS 9.3 (SAS Institute, Inc., Cary, NC) for 
Windows, and graphs were created in SigmaPlot 12.3 for Windows. Differences among 
means were determined using analysis of variance (ANOVA) and analysis of covariance 
(ANOCOVA) in the general linear mixed models procedure, with repeated measures 
testing for serial measurements. Covariance structures were compared graphically and 
quantitatively, and an appropriate covariance model was fit. Normality was assessed 
with the Shapiro-Wilk W test in the univariate procedure. Data that did not meet the 
necessary assumptions were transformed. Each model was first run with all fixed effects 
and covariates of interest, and then reduced to eliminate non-significant variables. 
When a significant result was reported for a fixed variable with more than two 
categories, specific comparisons were made using estimate statements based on the 
least squares means, and significance values were adjusted for multiple comparisons 
with the Tukey-Kramer or Bonferroni methods. Regression analyses were conducted in 
the regression procedure. Regression models were evaluated for normality (Shapiro-
Wilk W), heterogeneity of residual variances (statistically by Spearman rank-order 
correlation between absolute values of residuals and predicted values, and graphically 
by plotting residuals vs. predicted values), serial correlation (Durbin-Watson D statistic), 
and influential observations (Cook’s D statistic). 
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Results 
Animals and Diets 
The diet pelleting process did not impact carotenoid levels or isomerization (Figure 
7.2). The pelleted diet appears to have more lycopene than the other diets, but this 
difference was not statistically significant (p=0.24 by ANOVA). A portion of the pellet 
with slightly more tomato powder may have been used for extraction.  
All mice gained weight progressively during the study (p<0.0001 by ANOCOVA with 
baseline body weight as covariate, Figure 7.3A). After two weeks, mice in the WDSG, 
WDTP, and WDTPSG groups were significantly heavier than AIN mice (p<0.01 after 
Bonferroni adjustment). These differences persisted after three and four weeks, with 
WDTPSG animals also having greater body weights than WD animals (p<0.05). 
Western diet-fed animals had greater liver weight than AIN-93G control animals (p<0.01 
by ANOVA, Figure 7.3B), and no differences were seen among Western diet groups. 
Animals in the WD (p<0.05 by ANOVA), WDTP (p<0.0001), and WDTPSG (p<0.0001) 
groups had greater gonadal adipose weights than AIN animals. Animals in the WDSG 
group experienced an attenuated increase in gonadal adipose tissue, with no significant 
difference from AIN (p=0.21) or WD (p=0.69), but significantly less adipose than WDTP 
and WDTPSG (p<0.05). 
Animals consumed 3-4 g feed (12-18 kcal) per day (Figure 7.3C-D). Animals in 
Western diet groups consumed significantly more kcal per day than the 12.7 kcal/day 
average for animals fed AIN-93G (14.3 kcal/day and p<0.05 for WD, p<0.0001 for 
WDSG (16.4 kcal/day), WDTP (15.8 kcal/day), and WDTPSG (17.7 kcal/day) by 
repeated-measures ANOVA; all feed intake p values adjusted with a Tukey test). 
WDSG (p<0.05) and WDTPSG (p<0.0005) animals consumed more feed than WD 
animals, but WDTP animals did not (p=0.27). Among the tomato and soy groups, 
WDTPSG animals consumed more than WDTP (p<0.05) but not WDSG (p=0.35). Feed 
intake was greater overall in week 4 than week 1 (p<0.05). The diet*timepoint 
interaction variable was not significant (p=0.69), preventing more detailed sub-
comparisons.  
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Blood Analysis 
There were no differences in plasma total cholesterol at baseline (p=0.23 by 
repeated-measures ANOVA; Figure 7.4A). After 4 weeks on experimental diets, plasma 
cholesterol levels increased significantly within all groups (p=0.001 for AIN, p<0.0001 
for all Western diet groups by repeated-measures ANOVA), and were significantly 
higher in all Western-diet groups than AIN-93G (p<0.0001). The WDTP and WDTPSG 
groups had significantly higher plasma cholesterol than the Western diet group 
(p<0.0001). The WDSG group did not have significantly higher cholesterol levels than 
the WD group (p=0.47), despite consuming significantly more feed each day. Total 
cholesterol and feed intake were correlated in linear regression analysis 
(F0.05(1,47)=26.82, r2=0.36, p<0.0001). Plasma triglycerides did not differ among groups 
at 0 or 4 weeks, or within groups over time (Figure 7.4B). 
SAA levels were not different among groups at the beginning of the study (p=0.54 by 
repeated-measures ANOVA, Figure 7.4C). SAA increased within all groups after four 
weeks compared with initial levels (p<0.0001). At 4 weeks, Western diet groups had 
significantly higher SAA than the AIN-93G group (p<0.0001), but no differences were 
seen among the Western diet groups. Data were log-transformed to meet the 
assumption of normality. 
Liver Lipids and Gene Expression 
Total liver lipids were greater in Western diet animals than in AIN-93G animals (83.8 
vs. 162 mg/g liver, p<0.01 by ANOVA with Tukey-Kramer adjustment for multiple 
comparisons, Figure 7.5A). WDTP (167 mg/g, p<0.001) and WDTPSG (185 mg/g, 
p<0.001), but not WDSG animals (126 mg/g, p=0.12), also had significantly higher liver 
lipids than AIN animals. Similarly, liver free cholesterol was elevated in WD (p<0.05 by 
ANOVA with Tukey-Kramer adjustment for multiple comparisons), WDTP (p<0.01), and 
WDTPSG (p<0.05) groups, but this increase was attenuated in the WDSG group 
(p=0.24, Figure 7.5B). Liver total and esterified cholesterol were increased in Western 
diet groups (p<0.05), with no differences among the groups (Figure 7.5C-D). No 
differences were seen among groups in liver triglycerides (p=0.67, Figure 7.5E). 
Relative Cyp27a1 expression levels were unchanged across experimental groups 
(p=0.37, Figure 7.5F). Cyp7a1 expression levels were affected by diet (p<0.05 for 
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overall diet effect by ANOVA), with levels reduced by half in the WD and WDTPSG 
groups, though differences among diets were too small to be statistically significant after 
adjustment for multiple comparisons. Abcg5 and Abcg8 levels were increased in the 
WDTP group relative to AIN and WD (p<0.05 by ANOVA with Tukey-Kramer adjustment 
for multiple comparisons), but were unchanged in the other Western diet groups. 
Histology 
Aortic root lesion areas were 35,500 µm2 for AIN, 92,400 µm2 for WD, 98,700 µm2 
for WDSG, 101,000 µm2 for WDTP, and 129,000 µm2 for WDTPSG. When normalized 
to the total inner area of the aortic root, all Western diet groups had significantly greater 
percent lesion area than AIN, but were not different from each other (3.7% lesion area 
for AIN, 10.4% and p<0.05 for WD, 10.7% and p<0.005 for WDSG, 12.5% and p=0.05 
for WDTP, 13.9% and p<0.05 for WDTPSG; by ANOVA with Bonferroni adjustment for 
multiple comparisons; Figure 7.6A). Lesion area in the rest of the aorta was 
significantly greater than AIN controls in the WDSG (p<0.01), WDTP (p<0.01), and 
WDTPSG (p<0.05) groups, but not different among Western diet groups (Figure 7.6B). 
Data were log-transformed to meet the assumption of normality. No differences were 
seen among groups in aortic arch lesion area. Linear regression analyses revealed 
weak but significant correlations between lesion area in the aortic root and the rest of 
the aorta (F0.05(1,32)=11.42, r2=0.26, p<0.005 for raw aortic root values; 
F0.05(1,32)=11.00, r2=0.26, p<0.005 for normalized aortic root values), between plasma 
total cholesterol and aortic root lesion area (F0.05(1,32)=8.79, r2=0.22, p<0.01 for raw 
values; F0.05(1,32)=15.39, r2=0.32, p<0.001 for normalized aortic root values; aortic root 
lesion area dependent variables were log-transformed to correct heterogeneity of 
residual variances), and between plasma total cholesterol and aorta lesion area 
(F0.05(1,42)=14.98, r2=0.26, p<0.001; the aorta lesion area dependent variable was log-
transformed to correct non-normality and heterogeneity of residual variances). Feed 
intake did not contribute significantly to the normalized aortic root lesion area statistical 
model (p=0.13), nor was it correlated with normalized aortic root lesion area 
(F0.05(1,32)=3.37, r2=0.10, p=0.08). 
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Discussion 
This study evaluated the ability of dietary tomato and soy germ to reduce 
atherosclerosis in ApoE-/- mice. While it would be interesting to study the impact of 
either tomato powder or soy germ individually, evaluation of both in combination is a 
particularly novel aspect of this study. Tomatoes were selected based on previous 
literature suggesting their beneficial cardiovascular effects. Consumption of lycopene, a 
bioactive carotenoid pigment found in tomatoes, has been shown to improve endothelial 
function in a randomized controlled trial16, and an inverse relationship between serum 
lycopene concentration and arterial stiffness has also been noted17. Whole tomatoes 
contain many other phytochemicals and micronutrients that can benefit cardiovascular 
health18, so tomatoes can be provided in the diet as a more practical approach than 
lycopene supplementation. Additionally, previous work has demonstrated greater health 
benefit to consuming whole tomatoes instead of lycopene supplements19. Although 
some studies have suggested cardiovascular benefits of tomatoes, most experts agree 
that the literature is not conclusive and that more research is needed7,20-22. Soy germ is 
a component of whole soybeans that is separated from soy protein isolate during 
processing in an isoflavone-rich “hypocotyledon” fraction. It was selected as an 
additional dietary ingredient based on clinical trial data8,9, as well as prior literature on 
the hypocholesterolemic effects of other soy products23,24. While soy germ has not been 
previously tested for its effects on atherosclerosis, numerous studies have suggested 
antiatherosclerotic effects of soy isoflavones25, including reduced monocyte 
activation26,27, and increased excretion of dietary cholesterol24. These effects may be 
dependent on direct activation of ERα by isoflavones28, and other studies have shown 
that isoflavones without soy protein reduce atherosclerosis in cholesterol-fed rabbits29 
and ApoE-/- mice30. It has also been suggested that the effects of soy isoflavones are 
mediated through increases in LDLR activity31. The amounts of tomato powder and soy 
germ chosen for this study result in bioaccumulation of tomato and soy bioactive 
components and metabolites, and correspond to realistically achievable levels of 
consumption in humans. Tomato powder consumption (10% w/w) by the mice in this 
study is comparable to 1 cup tomato sauce, ½ cup tomato paste, or 6 cups raw 
tomatoes per day in humans32-34. Soy germ consumption (2% w/w) results in similar 
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serum isoflavone concentrations to men consuming soy foods or isoflavone 
supplements34,35.  
All Western diet-fed animals had higher plasma total cholesterol levels than AIN-93G 
diet animals, which was expected, and helps to serve as a positive control. Cholesterol 
levels in WDTP and WDTPSG-fed animals were higher still, contrary to our hypothesis, 
but the WDSG group did not experience this increase despite consuming significantly 
more feed than WD animals. Similarly, Western diet animals experienced a doubling of 
total liver lipids and increased gonadal adipose weights, but the WDSG group had 
attenuated increases. Gonadal adipose is a major adipose depot, comprising about 
30% of dissectable adipose in Bl/6 mice36,37.  
The attenuated increases in plasma cholesterol, liver lipid accumulation and adipose 
weight in WDSG animals led us to hypothesize that soy germ was affecting cholesterol 
excretion. The primary route of cholesterol disposal from the liver is by secretion into 
bile, either as bile acids or free cholesterol38. We measured gene expression of Cyp7a1 
and Cyp27a1, two enzymes involved in bile acid synthesis, and Abcg5/8, which form a 
heterodimer to efflux cholesterol from the liver into bile. Soy germ did not significantly 
impact expression of these genes. The regulation of bile acid metabolic enzymes such 
as CYP7A1 may occur at post-transcriptional levels, including mRNA stability and 
enzyme activity39. There was a modest, yet significant, induction of Abcg5/8 
transcription in the WDTP group. This suggests tomato may be able to influence 
cholesterol efflux, though not enough to overcome the hyperlipidemia of the Western 
diet-fed ApoE-/- mouse model.  
Circulating triglycerides in ApoE-/- mice are only moderately higher than in WT 
mice40-42, and in this study, did not increase further in Western diet-fed animals. Why do 
ApoE-/- mice on Western diet have elevated liver lipids, elevated blood cholesterol 
(primarily in VLDL and remnants, which typically carry some triglyceride), but not 
elevated blood triglycerides, as compared to ApoE-/- mice fed the purified AIN-93G 
control diet? Triglycerides in circulating lipoproteins are removed in extrahepatic tissues 
by lipoprotein lipase, which is present on capillary endothelial cells43, and at the liver by 
hepatic lipase. While ApoE-/- mice have defective hepatic lipoprotein uptake, they do not 
have defective lipolysis, so the triglycerides may be hydrolyzed to free fatty acids and 
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taken up by liver and other tissues, producing atherogenic remnant lipoproteins40,44. 
Once these dietary fatty acids reach the liver, they may be used to esterify cholesterol 
for export in lipoproteins45. Contributions to hepatic lipid content, which was elevated in 
Western-diet fed animals, are made by dietary fat intake, by de novo lipogenesis in 
response to dietary fructose46, and by re-esterification of adipose-derived circulating 
free fatty acids.  
We chose to measure SAA as a circulating biomarker of systemic inflammation. 
There are several isoforms of SAA, each with their own characteristics. SAA 1 and 2 are 
similar isoforms that are responsive to dietary interventions. High fat and cholesterol 
feeding increase circulating SAA147,48, while green and yellow vegetables decrease 
SAA1/249. SAA1/2 levels are similar in healthy humans and mice50. SAA3 is another 
isoform secreted by macrophages51 and adipocytes52 that does not contribute to serum 
levels of SAA152. SAA3 is a pseudogene in humans but is an actual acute phase protein 
in mice. Based on this information, SAA1/2 were the most appropriate isoforms to 
measure. We observed an increase in SAA over time, particularly in Western diet 
groups. Bacterial infection increases circulating SAA to 350 µg/mL in C57 Bl/6 mice53, 
suggesting that the 60-100 µg/mL seen in Western diet animals in this study is 
indicative of low-grade systemic inflammation. The lack of effect of tomato and soy on 
SAA suggests the dietary intervention was not able to abrogate mild systemic 
inflammation in this mouse model. 
Consumption of tomato or soy did not reduce atherosclerotic lesion area in the aortic 
root or the rest of the aorta. The aortic root was the most appropriate region to evaluate 
for this study, because it is one of the first sites to develop atherosclerotic lesions, and 
the animals in this study were at an early stage of atherosclerosis54. The two gold-
standard methods for atherosclerosis assessment are aortic root frozen sections, and 
en face preparations of the aorta15,55. The aortic root method generates a tissue cross-
section for evaluation of lesion morphology and composition, but does not demonstrate 
lesion area in the entire aortic tree. The en face method allows quantitative 
determination of aorta surface area lesion coverage, but does not provide information 
on lesion depth or morphology. The two methods can thus be seen as providing 
complementary information. The method of measuring lesion area in serial cross-
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sections of the aortic arch and descending aorta used in this study addressed limitations 
of the en face method by allowing measurement of lesion cross-sectional area 
throughout the aorta. Some studies have shown plasma total cholesterol levels to be 
correlated with en face lesion area42,56, but others have reported that they are not well-
correlated41. Studies also report that aortic root lesion area is correlated with lesion area 
in the whole aorta measured by the en face method42,55,57, but this may depend on the 
stage of atherosclerosis, as lesions appear earliest in the aortic root54,55. The weak 
correlations observed in this study may be due to the early stage of atherosclerosis, 
when aortic root lesions are most prominent.  
In summary, we did not observe a decrease in atherosclerosis in ApoE-/- mice with 
tomato or soy added to a Western diet. The effects of 2% soy germ alone on cholesterol 
and lipid metabolism suggest beneficial effects that can be investigated in future work. 
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Figures and Tables 
 
Figure 7.1. Experimental design. Male ApoE-/- mice were fed their respective diets for 
four weeks, and tissues were then collected and analyzed.  
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Figure 7.2. Lycopene profiles of experimental diets. A, lycopene content was measured 
by HPLC. B, lycopene isomer profiles in tomato powder and experimental diets. For the 
“3 day” diet samples, 12 grams of diet were left in a mouse cage in the animal facility 
with bedding (no water bottle or animal) for 3 days. Powdered diet was left in plastic 
feed bowls, and pellets were left in the hopper on top. Each bar shows the mean+SEM 
of triplicate measurements. B, lycopene isomer profiles of experimental diets. WD, 















pellet 3 day 
78 22 
WD+TP+SG 
powder 3 day 
80 20 
A B 
  167 
 
Figure 7.3. Feed intake, body and tissue weights. Feed intake was measured three 
times per week, body weights measured weekly, and liver and gonadal adipose weights 
were measured at euthanasia. Means not sharing a letter are significantly different. 
Errors bars are SEM. 
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Figure 7.4. Plasma biomarkers. Plasma total cholesterol and triglycerides were 
measured with enzymatic colorimetric kits, and serum amyloid A was measured by 
ELISA. Means not sharing a letter are significantly different. Errors bars are SEM. 
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Figure 7.5. Liver lipids and gene expression. A, liver lipids were extracted with 
chloroform:methanol and total lipids determined by weight. B-E, triglycerides and 
free/esterified cholesterol were measured in the lipid extracts with enzymatic 
colorimetric kits. F, gene expression was measured by quantitative real-time 
polymerase chain reaction and normalized with the ΔΔCT method. Means not sharing a 
letter are significantly different. Errors bars are SEM. 
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Figure 7.6. Atherosclerosis in the aorta. A, dot density plot of atherosclerotic lesion area 
in the aortic root. Frozen sections of the aortic root were cut from OCT-embedded tissue 
samples and stained with H&E. Lesion area was manually traced in six serial sections 
per animal, normalized to the total inner area of the aortic root, and averaged to provide 
a value for each animal. Each dot represents the normalized lesion area for one animal, 
group means are represented by red lines, and means not sharing a letter are 
significantly different. Symbols with white fill are the representative samples shown in C. 
B, dot density plot of atherosclerotic lesion area in the aorta. Aortas from the arch to the 
renal bifurcation were divided into 14-15 pieces, fixed in 10% neutral buffered formalin, 
and embedded in paraffin. Cross-sections of each piece of the aorta were stained with 
H&E, and lesion area was manually traced. Each dot represents the total lesion area for 
one animal. C, Representative H&E stained aortic root sections. Scale bars are 200 µm.  
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Ingredient (g/kg) AIN-93G WD WDSG WDTP WDTPSG 
Casein 200 195 184.9 180.6 170.5 
L-Cystine 3 3 3 3 3 
Corn Starch 397.5 55.46 55.46 43.26 43.26 
Maltodextrin 132 60 60 60 60 
Sucrose 100 340 340 298.8 298.8 
Soybean Oil 70 20 15.2 15.14 10.34 
Cellulose 50 50 44.9 22.66 17.58 
Mineral Mix 35 43 43 43 43 
Vitamin Mix 10 19 19 19 19 
Choline Bitartrate 2.5 3 3 3 3 
TBHQ 0.014 0.04 0.04 0.04 0.04 
Anhydrous Milkfat 0 210 210 210 210 
Cholesterol 0 1.5 1.5 1.5 1.5 
Tomato Powder 0 0 0 100 100 
Soy germ 0 0 20 0 20 
Total 1000 1000 1000 1000 1000 
Fat (% w/w) 7.2 23.2 23.2 23.2 23.2 
Protein (% w/w) 17.4 17.0 17.0 17.0 17.0 
CHO (% w/w) 58.3 44.7 44.7 44.7 44.7 
kcal/g 3.68 4.55 4.55 4.55 4.55 
Fat (% kcal) 17.6 45.8 45.8 45.8 45.8 
Protein (% kcal) 18.9 14.9 14.9 14.9 14.9 
CHO (% kcal) 63.4 39.3 39.3 39.3 39.3 
 
Table 7.1. Composition of experimental diets. WD, Western diet; WDSG, Western diet 
with 2% soy germ; WDTP, Western diet with 10% tomato powder; WDTPSG, Western 
diet with 10% tomato powder and 2% soy germ.  
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CHAPTER 8: Summary and future directions 
This final chapter will provide an overview of the dissertation, which has described a 
body of work focused on two areas: the biological effects of ultrasound and ultrasound 
contrast agents, and nutritional interventions to reduce atherosclerosis. The first chapter 
provided a survey of the literature on these two topics, beginning with lipoprotein 
metabolism and atherosclerosis, continuing with sections on cardiovascular risk factors, 
cardiovascular imaging, and cardiovascular effects of the diet, and concluding with 
descriptions of animal models and techniques used in atherosclerosis research. 
Several chapters of the dissertation (Chapters 3-6) report investigations of the 
biological effects of ultrasound when used with ultrasound contrast agents to image 
blood vessels. This contrast ultrasound imaging procedure is clinically useful for 
cardiovascular disease diagnosis, but the interaction of ultrasound with the circulating 
contrast agents may affect the arteries being imaged in unique ways that are not well 
understood. It is important to characterize these biological effects to ensure that 
contrast ultrasound does not accelerate the deposition of plaque in the arteries being 
imaged. Contrast ultrasound exposures were performed on rabbits and mice, and 
histological and biochemical techniques were utilized to assess biological effects. As a 
step toward evaluation of these biological effects, an assay for measurement of von 
Willebrand Factor (vWF), a blood biomarker of endothelial function, was developed for 
rabbit samples (Chapter 2). The ELISA format was chosen for this purpose, as it is 
quantitative and relatively user-friendly. Although there were no commercially available 
antibodies directed against rabbit vWF, a pair of anti-human vWF antibodies were 
selected based on the sequence homology between human and rabbit vWF. The assay 
was then validated according to expert recommendations. All steps of the assay were 
carefully evaluated, its repeatability and precision were established. The validation 
process included demonstrations of Minimum Required Dilution (the dilution of plasma 
necessary to avoid matrix interference), spike recovery, intra- and inter-assay precision, 
antibody specificity, sensitivity, and freeze-thaw stability of plasma vWF. This assay was 
used in Chapter 3, in a study where blood samples were obtained from rabbits before 
and after ultrasound exposure to evaluate effects of contrast ultrasound on the vascular 
endothelium. Ultrasound-exposed rabbits had decreased vWF one hour after ultrasound 
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exposure (independent of contrast agent). This effect could potentially indicate 
disruption of the endothelium by ultrasound. Plaque thickness was also lower in animals 
receiving contrast agent with ultrasound than in animals receiving ultrasound alone. 
This could possibly be a protective effect, whereby contrast agent protects against 
ultrasound-induced accelerations in plaque deposition. It was interesting that the vWF 
effect was independent of contrast agent. If contrast agent protects the vascular tissue 
from ultrasound-induced stress, the effects of contrast ultrasound on vWF would likely 
be contrast agent-dependent. This work uncovered novel vascular effects of the 
ultrasound-contrast agent interaction. 
Next, another rabbit study was conducted (Chapter 4). The goal of this study was to 
assess the effect of contrast ultrasound on a new biomarker, Hsp70. Hsp70 is a cellular 
chaperone induced in times of cellular stress to aid in management of damaged 
proteins. It was hypothesized that additional stress resulting from the ultrasound 
procedure would be reflected in elevated Hsp70 protein levels. Groups of rabbits 
consumed either the cholesterol diet or a chow diet, with some cholesterol-fed rabbits 
exposed to ultrasound with contrast agent. Hsp70 protein levels were quantified in aorta 
tissue at the site of ultrasound exposure by Western blot. Neither ultrasound with 
contrast agent nor cholesterol diet affected Hsp70 levels. However, physical restraint of 
the animals was also evaluated, and was associated with significantly higher Hsp70.  
The cholesterol-fed rabbit model has some benefits but also many drawbacks. The 
aorta is large and easy to target with ultrasound, and rabbits’ blood cholesterol profile is 
similar to humans. However, rabbits are large, expensive and unwieldy, leading to small 
sample sizes and requiring a major investment of laboratory personnel and resources, 
and they develop jaundice and anorexia when fed the cholesterol diet. In light of these 
concerns, there was interest in switching to a different animal model that would be a 
more consistent and effective model of atherosclerosis and that would be easier to work 
with, allowing for increased sample sizes. The ApoE-/- mouse, a well-established and 
widely used model, addressed these needs. The mice are easy to handle and also 
maintain their food consumption when fed a high-fat, high-cholesterol, high-sucrose diet 
known as the Western diet. In addition to the animal model, histological techniques also 
needed to be improved. In the past, the aorta tissue was frequently damaged during 
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isolation, making histological evaluation difficult. Methodological improvements were 
made that allowed isolation of the aorta intact for pathological evaluation. This model 
was then used to assess the biological effects of contrast ultrasound in Chapter 5. No 
effects of contrast ultrasound on tissue morphology or circulating biomarkers were seen. 
A study was conducted to evaluate ultrasound bioeffects in another context, the 
gracilis muscle tissue and capillaries of rats (Chapter 6). In this study, 18 female 
Sprague-Dawley rats were divided among 4 concentrations of ultrasound contrast agent 
and 4 ultrasound pressure levels. The gracilis muscle was exposed to ultrasound, and 
contrast agent was infused through the tail vein. One day after ultrasound, animals were 
euthanized and tissues were collected for analysis. Histological sections of the gracilis 
muscle were evaluated by a pathologist. The histological measures were designed to 
identify structural and morphological damage across a spectrum of severity. Although 
the methods were well-executed, no effects of ultrasound or contrast agent on gracilis 
muscle damage were seen. There may have been biological effects of the procedure, 
but they may have been too subtle to capture at the level of gross morphology. 
Molecular techniques like immunohistochemistry may uncover effects of contrast 
ultrasound at the cellular level. Another possible explanation for the lack of effect is that 
there simply were not any adverse effects of the procedure. Our pressure levels were 
designed to be clinically relevant, but an increased ultrasound pressure level might 
induce damage.  
In summary, we have not been able to demonstrate consistent patterns of adverse 
events caused by contrast ultrasound imaging. When we began our investigations into 
the biological effects of contrast ultrasound, concerns were raised after reports of 
cardiopulmonary complications and deaths in patients who had undergone contrast 
ultrasound. The FDA responded by mandating warning labels for ultrasound contrast 
agents, noting the potential for serious complications and requiring a 30 minute 
monitoring period after contrast ultrasound. Over the next several years, a number of 
clinical trials were conducted, and a meta-analysis of over 5 million patients showed that 
the use of ultrasound contrast agents did not increase the risk of adverse events. The 
few adverse events that were initially noted were probably due to pre-existing vascular 
disease, and not caused by ultrasound contrast agents. The FDA then relaxed its 
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warnings, noting that serious complications are uncommon and removing the 30 minute 
monitoring period post-injection. Although the human clinical literature has produced 
convincing evidence for the safety of microbubble contrast agents, the preclinical animal 
literature in this area is weighted heavily toward demonstrating harmful effects of 
ultrasound and ultrasound contrast agents. This may partly be due to inherent 
publication bias, whereby negative studies are not published. Our studies showing lack 
of adverse effects of contrast ultrasound help to harmonize the preclinical and clinical 
literature. It is possible that the effects of contrast ultrasound manifest as subtle 
molecular changes. Future studies could utilize immunohistochemistry and other 
molecular techniques to probe these changes. 
Chapter 7 describes a more nutrition-focused project aimed at evaluating dietary 
tomatoes and soy germ, added alone or in combination to a high fat, high sugar, 
cholesterol-containing Western diet, for reduction of atherosclerosis in ApoE-/- mice. It is 
important to note that addition of tomatoes and soy to a Western diet for ApoE-/- mice 
can be used as a dietary approach to attenuate or slow atherosclerosis. Development of 
atherosclerosis is inevitable in these mice due to their genetic modification, but the rate 
of progression of atherosclerosis might be modified. Addition of soy germ alone to the 
Western diet attenuated Western-diet induced increases in plasma cholesterol, liver 
lipids and adipose, while addition of tomatoes alone increased expression of the 
Abcg5/8 transporters involved in cholesterol efflux. Overall, however, tomato and soy 
did not decrease atherosclerosis as assessed by histopathology. This is probably not 
due to the amounts of tomato and soy added to the diets, because the dose levels used 
have been previously shown to result in tissue and blood accumulation of their 
biologically active components. The lack of effect of the dietary intervention on 
atherosclerosis is likely due to a combination of factors, with two explanations being 
most likely. First, the dietary intervention may not have been long enough. We selected 
an earlier timepoint in light of the relatively modest effect sizes of most dietary 
interventions, but it may be that differences among groups would become more 
pronounced over a longer period of time. Second, the extreme phenotype of the 
Western diet-fed ApoE-/- mouse may have masked any beneficial effects. While soy and 
its products have established cardiovascular benefits, the cardiovascular effects of 
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tomatoes are currently unclear. This study does not support the use of either tomatoes 
or soy germ for reduction of atherosclerosis, but suggests that soy germ may have 
positive metabolic effects. Future studies could feed the diets for a longer period of time. 
The addition of tomatoes and soy germ to an AIN-93G diet instead of a Western diet 
should also be considered. This would lead to a more mild atherosclerotic phenotype 
that could be more amenable to dietary interventions. 
